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Abstract

SLEEP DISTURBANCES AND DEPRESSION: THE ROLE OF GENES AND TRAUMA
Mackenzie Jean Lind, B. S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017
Advisor: Ananda B. Amstadter, Ph.D.
Associate Professor, Departments of Psychiatry, Psychology, and Human and Molecular
Genetics, Virginia Institute for Psychiatric and Behavioral Genetics

Sleep disturbances and insomnia are prevalent, with around 33% of adults indicating that
they experience at least one main symptom of insomnia, and bidirectional relationships exist
with common psychopathology, particularly major depressive disorder (MDD). However,
genetic and environmental (e.g., traumatic event exposure) contributions to the etiology of these
phenotypes are not yet well understood. A genetically informative sample of approximately
12,000 Han Chinese women aged 30-60 (50% with recurrent MDD) was used to address several
gaps within the sleep literature. Sleep disturbances were assessed in all individuals using a
general item addressing sleeplessness (GS). A sleep within depression sum score (SDS) was also
created in MDD cases, combining information from the GS and two insomnia items within
MDD. A total of 11 traumatic events were assessed and additional information on childhood
sexual abuse (CSA) was also obtained. First, factor analyses were conducted to determine trauma
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factor structure. The best-fit solution included 3 factors: interpersonal, child interpersonal, and
non-assaultive, and composite variables were constructed accordingly. A series of hierarchical
regressions were run to examine differential effects of trauma type and timing on sleeplessness.
All traumatic events predicted sleeplessness at similar magnitudes, although population models
indicated that childhood interpersonal trauma may be particularly potent. An association between
CSA and sleeplessness was also replicated. A series of genetic analyses demonstrated that the
single nucleotide polymorphism-based heritability of sleep phenotypes did not differ
significantly from zero. Further, association analyses did not identify any genome-wide
significant loci. However, using a liberal false discovery rate threshold of 0.5, two genes of
interest, KCNK9 and ALDH1A2, emerged for the SDS. Polygenic risk score (PRS) analyses
demonstrated genetic overlap between the SDS in MDD cases and GS in MDD controls, with
PRSs explaining 0.2-0.3% of the variance. A final combined model of both genetic and
environmental risk indicated that both PRS and traumatic events were significant predictors of
sleeplessness. While genetic results should be interpreted with caution given the lack of
heritability, additional research into the genetic and environmental contributions to insomnia,
utilizing more standardized phenotypes and properly ascertained samples, is clearly warranted.

x

Chapter 1: Introduction

Disturbed sleep is a widespread problem in today’s society, but the etiologic
contributions to this important phenotype are not well understood. Known influences are both
environmental (e.g., trauma exposure) and biologic (e.g., genetic) in nature, and studies
demonstrate overlap in etiologic sources between sleep difficulties and common internalizing
disorders, such as major depressive disorder (MDD). However, questions remain as to how the
type (e.g., interpersonal violence versus non-interpersonal violence) and timing (i.e., childhood
versus adult onset) of traumatic events influence sleep disturbances. The genetic architecture of
insomnia and related phenotypes (e.g., sleep disturbances), including overlap with MDD, is also
not well understood. Thus, the purpose of this dissertation is to deepen our understanding of how
both traumatic event exposure and molecular genetic contributions influence sleep disturbances.
The following section begins with an overview of the prevalence and correlates of
insomnia/sleep disturbances and related psychopathology, with a focus on MDD. Following, the
epidemiology of traumatic events, an environmental risk factor associated with both poor sleep
and MDD, is reviewed with specific attention to trauma type and timing in relation to these
phenotypes. Next, a review of studies that examine genetic contributions to insomnia is provided,
starting with behavioral genetics (i.e., twin and family studies) and moving on to molecular
genetics (candidate gene and genome-wide association studies [GWAS]). Throughout the
genetics section, the insomnia literature is compared to that of MDD, with a specific focus on
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studies of overlap between these phenotypes. Finally, recent innovations in statistical genetics
methods will be discussed, followed by an outline of the aims for this dissertation.

I. Prevalence and correlates of disturbed sleep/insomnia and MDD
Epidemiology of disturbed sleep/insomnia. Insomnia, defined in the Diagnostic and
Statistical Manual, 5th edition (DSM-5) as sleep complaints, which include difficulty falling
asleep, difficulty maintaining sleep, or early morning awakenings, for at least three nights a
week, persisting for a minimum of three months, and causing “significant distress” to the
individual1 and its symptoms are an emerging health concern. Although definitions of insomnia
vary within epidemiologic studies (insomnia diagnosis, insomnia symptom(s), subjective sleep
quality),2 disturbed sleep is a widespread problem: General population studies in Western
countries indicate that approximately one third of adults endorse a minimum of one of the main
nighttime insomnia symptoms (e.g., difficulty falling or staying asleep), with difficulty
maintaining sleep typically reported the most often.2,3 Although sleep disturbances are a
widespread problem globally, rates of endorsement do appear to differ by country. An
epidemiologic study of the same three insomnia symptoms in China found much lower rates than
Western countries, with only 9% of individuals endorsing at least one symptom,4 and lower rates
have also been reported in Nigeria (12%).5 The first published meta-analysis of insomnia in
China identified a point prevalence of 15%, across a wide variety of definitions.6 Further, the
prevalence of lifetime insomnia disorder itself, when measured through DSM or International
Classification of Disease (ICD) definitions, is thought to be closer to 6-10%.2 A recent
epidemiologic study comparing insomnia diagnoses between the US and Hong Kong found that
estimates were similar across multiple definitions.7 The epidemiology literature consistently
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shows that both age and sex influence insomnia prevalence. Older adults are more likely to
report insomnia/sleep disturbances than younger adults (prevalence increasing to 20-48% for
older populations)8-12 and women are more likely to report insomnia than men (risk ratio 1.41).13
Sleep and physical health outcomes. Disturbed sleep and insomnia are related to a
multitude of negative physical, occupational, and mental health outcomes. In terms of physical
health, insomnia has associations with diabetes, hypertension, metabolic syndrome,
cardiovascular disease, and neuropsychiatric disease, among other chronic health conditions.2,14
While many of these studies vary in terms of phenotype used, severity of insomnia, and inclusion
of sleep duration, results converge to suggest that disturbed sleep is associated with common
health problems. Similar results are also reported in studies from China, which indicate that poor
sleep quality or insomnia is also related to higher incidence of diabetes,15 hypertension,16
dyslipidemia (in women),17 heart attack and stroke,18 metabolic syndrome,19,20 and even levels of
objective measures of metabolic function such as cholesterol and insulin resistance.21 More
globally, there is some evidence that insomnia is related to increased mortality, an association
that may be stronger for men.14,22-25 Finally, there are also important occupational health
implications, with studies showing that insomnia results in higher odds of accidents and errors
and is costly to the workplace.26-28 Taken together, these associations between insomnia and
health outcomes, although often cross-sectional in nature, highlight the importance of
understanding risk factors related to disturbed sleep.
Sleep and psychopathology. In addition to being associated with physical health
conditions, disturbed sleep is related to psychiatric phenotypes, particularly internalizing
disorders (e.g., MDD, anxiety),29-32 with approximately 40% of individuals with insomnia
endorsing another psychiatric disorder.3,29,31 MDD is the most common comorbid psychiatric
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condition with insomnia.33 The relationship between disturbed sleep/insomnia and psychiatric
disorders is complex. The high rates of comorbidity could be explained by the overlap in
symptoms, as insomnia is embedded within the DSM criteria for MDD, generalized anxiety
disorder (GAD), and posttraumatic stress disorder (PTSD),1 manifesting as a key symptom of
each disorder.32,34 Sleep disturbances are prevalent within these disorders, particularly for MDD,
where insomnia is thought to be a core symptom35 and up to 90% of individuals with MDD
report sleep problems.32 Further, experiencing insomnia may be indicative of more severe MDD
(e.g., 36,37). There is also evidence that the relationship between sleep disturbances and
psychopathology is bi-directional,32,34,38 as individuals with insomnia are at a higher risk for
developing new-onset psychopathology.29,30 Two meta-analyses support this conclusion for
MDD more specifically,39,40 as both reported that individuals with insomnia are at least twice as
likely to develop MDD as compared to those without the disorder. Longitudinal studies of
combat veterans reinforce these relationships, showing that sleep disturbances predict future
MDD and PTSD symptoms (e.g., 41,42). Overall, robust relationships between sleep and
psychopathology, particularly MDD, underscore the importance of studying these comorbid
conditions together.
Epidemiology of MDD. MDD, the most common internalizing disorder, affects
approximately 16% of individuals in the US43 and 3.3% in China44 across their lifetimes. This
difference in prevalence could be attributed to under-reporting in China, due to cultural
differences (e.g., 45,46,47), although note that many risk factors for MDD, such as stressful life
events (SLEs) and childhood sexual abuse (CSA) have been shown to be the same across
countries.48 Like insomnia, MDD is more common in women than men,49,50 with 8-17% of
women and 4-9% of men in Western countries50 and 4% of women and 3% of men in China44
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reporting lifetime MDD. The disorder is also extremely costly; MDD is one of the most common
causes of disability worldwide51 and global burden of disease data consistently shows that MDD
is one of the leading causes of years lost to disability across many countries.52,53 There are also
associations between MDD and many of the same physical health outcomes as insomnia (e.g.,
diabetes,54-58 cardiovascular disease59-62), and it is comorbid with many other psychiatric
disorders (e.g.,49,63,64). Thus, given the high prevalence and overlapping negative consequences
of both insomnia and MDD, it is important to examine etiologic factors, both genetic and
environmental (e.g., exposure to a traumatic event) in nature, that influence these common and
comorbid outcomes. Trauma exposure is an important environmental risk factor to consider, as it
is common65 and has robust associations with both MDD (e.g., 66) and sleep disturbances (e.g.,
67

), which will be outlined below.

II. Environmental influences (i.e., trauma exposure)
a. Trauma epidemiology
Prevalence of traumatic events and sex differences. Exposure to traumatic events is
common worldwide. The World Mental Health Survey Consortium (WMHSC) recently
published data collected in 24 countries on lifetime exposure to a wide range of traumatic events.
The overall prevalence of at least one traumatic event was more than 70%. More specifically,
82.7% of participants assessed in the United States endorsed at least one trauma, which was
among the highest prevalence rates. In contrast, most prevalence rates in European countries
were below 80%, with the exception being Ukraine (84.6%). Rates were also considerably lower
in Asian populations, with 52.5% of individuals in China and 60.7% in Japan indicating that they
had experienced at least one of the 29 types of traumatic events. The traumatic event most
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commonly endorsed across the full, worldwide sample was unexpected death of a loved one, and
the authors note that the pattern of events that were the most common (i.e., top five) was
consistent across countries.65 Overall, traumatic event exposure is more common in men.68 For
example, rates of lifetime trauma exposure were significantly different across the sexes in the
National Comorbidity Survey (NCS; 60.7% for males; 51.2 % for females).69 Men also
experienced, on average, more traumatic events than women in a community sample.70 However,
there are important sex differences across specific traumatic events that will be discussed in later
sections.
Trauma and physical health outcomes. There are a wide range of post-trauma sequelae
that are associated with both mental (e.g., MDD, PTSD; 69,71,72) and physical health,73,74 making
trauma exposure a significant global public health issue. A number of specific physical health
outcomes have been examined in the context of traumatic event exposure. In a large crosssectional study of 14 countries, lifetime exposure to at least one traumatic event was shown to
increase risk for onset of physical health conditions, even after controlling for psychopathology.
In general, odds ratios increased as the number of event types increased, indicating a larger effect
for multiple traumas. The pattern of results was similar for most individual physical health
phenotypes (e.g., arthritis, heart disease, diabetes), and did not typically differ across countries.75
Additionally, a study of six health outcomes in a community sample of African Americans found
that individuals who endorsed eight or more traumatic events reported an age of onset for a
physical health condition that was on average 15 years earlier than for those who did not endorse
this high level of trauma,76 emphasizing the potential deleterious relationship between trauma
exposure and physical health.
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Trauma and psychopathology. The development of psychiatric disorders is also common
following traumatic event exposure. Epidemiologic data from adults in the United States
participating in the Mental Health Surveillance Study indicates that individuals who had been
exposed to at least one lifetime traumatic event were more likely to report any mental illness than
those who had not been exposed (prevalence rates were 23.2% vs. 14.3%).77 Although PTSD, a
stress-related disorder requiring traumatic event exposure and encompassing symptoms of reexperiencing the event, avoidance, and hyperarousal,1 is considered the “flagship” post-trauma
psychiatric disorder, a range of psychiatric outcomes that can be both internalizing (e.g., MDD,
GAD, PTSD) or externalizing (e.g., alcohol and drug use disorders) in nature78 are seen
following traumatic events.69,71,72
MDD in particular is common and highly comorbid with PTSD.69,71,79,80 Early studies
focused on the development of MDD following SLEs, which typically include major life events
such as divorce, unemployment, or being fired from one’s job, in addition to events that are
considered traumas per DSM definition (i.e., “involved actual or threatened death or serious
injury, or a threat to the physical integrity of self or others”).81 Broadly, SLE exposure is
associated with increased risk of disorder or symptoms, and there is also a dose-response
relationship with SLE severity and MDD risk.82 Similar relationships between SLEs and MDD
have been observed in Han Chinese samples.48,83 MDD is also common following trauma
exposure more specifically, with population data demonstrating higher endorsement rates of
MDD for individuals reporting at least one traumatic event (10.1% vs. 4.3%).77 The trauma
literature documents MDD risk following many individual traumas, such as the September 11th
terrorist attacks,84,85 earthquakes,86 and sexual assault.87,88 Further, women may be more likely
than men to develop MDD post-trauma (e.g., 89,90,91). Note, however, that there is some debate as
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to the existence of a “post-traumatic depressive disorder” and whether MDD results from the
trauma itself or from the bereavement/loss experienced.66 Although trauma is broadly associated
with these negative health outcomes (i.e., psychopathology including MDD and PTSD, chronic
health conditions), differential risk is often seen by type of trauma (e.g., 69) and the timing of
trauma(s) (e.g., 92,93).
Trauma types. Categorization of traumatic events is important, as the literature indicates
differences in outcomes across trauma type. Understanding which forms of trauma may be more
deleterious in nature (i.e., more likely to result in negative psychiatric and mental health
outcomes) can help to identify individuals who are at the highest risk, inform prevention and
intervention efforts, and focus research on specific areas that will have an impact. Traumatic
events can be broadly categorized into events that are interpersonal (assaultive) or non-assaultive
in nature.70-72,94 Interpersonal traumas include events such as sexual assault, physical assault, or
kidnapping, which have a strong relational component. In contrast, natural disasters and motor
vehicle accidents are among events considered to be non-assaultive traumas70-72,94 and are more
random events. There are also important, established sex differences that are seen by trauma
type.65,95 Women are more likely to report exposure to interpersonal traumas, particularly those
that are sexual in nature (e.g., rape, sexual molestation, other sexual assault, and childhood
physical abuse or neglect).69,70 In contrast, men are more likely to be exposed to other traumas
such as accidents and non-sexual assault.69,95 This general pattern was also seen within the recent
WMHSC data, where women were more likely to endorse intimate partner/sexual violence (OR
= 2.3). In contrast, men had higher odds of endorsing various other traumas, including
interpersonal violence (which included being beaten up or having witnessed physical fights at
home in this study), causing or witnessing bodily harm, and accidents or injuries.65
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Several published factor analyses support the categorization of traumatic event exposure
into two broad categories. Stein and colleagues94 conducted a principal component analysis of
nine traumas in Canadian twins, finding two factors: “assaultive” (robbery, held captive, beat up,
sexual assault, other life threat) and “non-assaultive” (sudden family death, motor vehicle
accident, fire, natural disaster). In the WMHSC study, the 29 traumatic events examined were
also factor analyzed. Five relevant factors were extracted (plus a sixth that encompassed “other”
events). One factor represented accidental traumas/injuries (corresponding to non-assaultive),
while the remaining factors were all interpersonal in nature (collective violence,
caused/witnessed bodily harm [mostly war/combat-related], interpersonal violence, and intimate
partner/sexual violence).65 Given the large number of events examined within this sample, it is
not surprising that several more specific interpersonal factors emerged which grouped more
similar interpersonal events together. The separation of interpersonal and non-assaultive traumas
may be influenced by genetic and personality factors. Unlike other forms of trauma,
interpersonal traumas have generally been shown to have genetic influences (e.g., assaultive
trauma heritability estimated at 20%;94 35-47% for combat;96 60% for “high-risk” traumas
including rape97). Mechanisms may be through personality factors,98-100 which in turn are
heritable.101 For example, genetic factors contributed to the association between antisocial traits
and exposure to assaultive traumas.100 Thus, one’s genetic predisposition, and subsequent effects
on characteristics such as personality, may influence selection into environments that increase
risk of traumatic event exposure.102 Within the genetics literature, this concept is known as a
gene-environment correlation. In contrast, non-assaultive events tend to be more random
occurrences that are out of one’s own control (e.g., exposure to a fire, flood, or natural disaster),
where gene-environment correlations are likely not at play.103
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Trauma type and psychopathology. Further supporting the importance of categorizing
traumas, there is evidence to suggest that the risk of developing certain psychiatric disorders
differs depending on the type of trauma experienced. It is well established within the PTSD
literature that the risk of developing PTSD is higher and symptoms are more severe following
interpersonal traumas.69,70,104-108 This is generally supported within the more recent WMHSC
data.109 There is also evidence that interpersonal traumas (vs. non-assaultive/accidental traumas)
result in a higher likelihood of MDD diagnosis and higher depressive symptoms.110-114 A recent
study of interpersonal trauma and MDD in Korea found higher rates of interpersonal trauma
(sexual or physical in nature) but not non-assaultive trauma, in individuals with MDD. They also
found higher depressive and PTSD symptoms within those depressed individuals endorsing
interpersonal trauma exposure.113 These relationships may also be true for externalizing disorders
and traits, such as substance use disorders and binge drinking.111,115 Further, it is not just
psychiatric outcomes that are differentially associated with trauma type: a recent review provides
evidence that interpersonal traumas may also be linked to worse physical health as measured via
self-report (e.g., somatization symptoms, physical well-being).116
Trauma timing. Although traumatic experiences can occur across the lifespan, many such
events occur during childhood, which is a particularly sensitive developmental window.92
Around 60% of adults surveyed in the US endorsed at least one adverse childhood experience
(ACE).117-119 Further, a recent review of childhood maltreatment worldwide found specific
prevalences ranging from 13% (CSA, combined across sexes) to 36% (emotional abuse).120
While these may seem like drastically different prevalences, ACEs, like SLEs, typically include
a wide range of negative experiences that can occur during childhood which encompass events
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that are considered to be traumas (e.g., CSA, physical abuse), as well as those that are not (e.g.,
divorce/separation of parents, mental illness of someone in the household).
Childhood trauma and psychopathology. The consequences of ACEs have been
extensively studied over the past few decades, with a review of the literature pointing to
increased risk for psychiatric outcomes, chronic disease, and risky sexual behaviors, and higher
mortality.121 Childhood maltreatment more specifically, including CSA, has associations with
many psychiatric disorders (e.g., MDD, GAD, anorexia, panic disorder, alcohol dependence,
substance use; e.g., 122,123-125). A recent meta-analysis summarizes the state of the literature on
prospective studies of child maltreatment (sexual abuse, physical abuse, neglect) and depression
and anxiety disorders in adults. The authors of this study report that these traumas are
responsible for nearly 400 million cases of depression and anxiety disorders worldwide, with
odds ratios of 2.03 (for any type of maltreatment) and 2.66 (for CSA) in predicting depression
and anxiety disorders.122 However, note that the majority of these studies were conducted in
Western countries. There is a more extensive literature for CSA and MDD outcomes, which
demonstrates that CSA severity (i.e., level of physical contact involved) has a dose-response
relationship with MDD.124,126 These findings provide some evidence that specific characteristics
of the abuse, such as having multiple perpetrators or endorsing intercourse, may differentially
predict MDD risk.127-129 The relationship between CSA and MDD has also been studied in the
Han Chinese population, with similar patterns observed in terms of overall risk, dose-response,
and incident characteristics.130,131 Additionally, there is some evidence to suggest that childhood
events are more potent predictors of future depressive and anxiety symptoms in adults than
traumas that occur more proximally.93 Specific time periods may also confer more risk. In a
recent study, investigators found that age of first exposure to child maltreatment differentially
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predicted MDD and PTSD symptoms.92 Interestingly, individuals who were first exposed to
interpersonal violence between 6-10 years of age had twice the risk for MDD as those who had
their first interpersonal violence exposure as adults. In summary, exposure to trauma during
childhood is prevalent and often interpersonal in nature, resulting in outcomes that persist many
decades following abuse even above and beyond adult trauma load. However, there is a need for
more studies within non-Western populations.
b. Trauma and sleep
Overview of the literature. Another common post-trauma outcome that is related to both
mental and physical health correlates is disturbed sleep. Traumatic events are thought to
disrupt/alter sleep,67,132 with potential mechanisms related to activation of the stress response and
hyperarousal.132 As far back as the 1970s, a relationship between trauma and sleep has been
described in research publications, with the first study using EEG to examine sleep in individuals
who participated in the Yom Kippur War.133 Since then, sleep disturbances and insomnia
symptoms have been reported following a wide variety of specific traumatic events, including
combat exposure,134-138 natural disasters such as earthquakes and tornados,139,140 sexual abuse
(including CSA),141,142 intimate partner violence,143 motor vehicle accidents,144,145 and terrorist
attacks.146 Multiple sleep phenotypes have been used as outcomes across these samples, ranging
from objective measures like polysomnography (less common; outlined in 132) to self-report
sleep disturbances and insomnia diagnoses (focused on here). Despite the variation in traumas
assessed and phenotypes used, the literature supports robust associations between trauma and
sleep. Further, while many traumatic events have been analyzed with sleep outcomes, most
trauma and sleep studies tend to focus on specific traumas and do not explore potential
differential effects of trauma type and/or timing to the extent to which this may have an impact
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on sleep. This is an important consideration, as individuals are often exposed to multiple events
across the lifespan.
Trauma type and sleep. Investigations of trauma type are beginning to emerge within the
trauma and sleep literature. Given that interpersonal traumas are more potent predictors of
internalizing psychopathology (MDD, PTSD)69,70,111,113 and that insomnia is related to these
psychiatric disorders,1 it is possible that similar relationships (i.e., stronger effects for
interpersonal traumas) exist for trauma and sleep. A recent investigation of urban young African
Americans examined seven specific traumatic events that were both interpersonal and nonassaultive in nature, finding that five of the seven events significantly predicted insomnia (ORs
ranging from 1.53-3.27) and that the three interpersonal traumas (sexual trauma, physical assault,
sudden violent death) all predicted more severe insomnia (ORs ranging from 2.39-2.86).147
While this suggests that interpersonal traumas may indeed be predictive of more severe disorder,
it is important to note that results changed upon addition of covariates (which included PTSD),
with no traumas retaining significance in the more severe insomnia category. Further, note that
each traumatic event was examined separately to determine its individual effect on insomnia, not
examined in combination. In another recent study, investigators analyzed the individual and
combined effects of interpersonal and non-assaultive traumas on self-reported sleep in college
students, assessed via a modified version of the Pittsburgh Sleep Quality Index (PSQI).148 When
analyzed hierarchically, only interpersonal trauma had a significant effect on disturbed sleep.
Non-assaultive trauma did not contribute uniquely to the variance in sleep symptoms. These are
some of the first results comparing multiple traumas, and indicate that interpersonal traumas may
have a larger effect on the development of sleep problems.
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Trauma timing and sleep. ACEs in particular have been shown to have deleterious effects
on sleep even decades after the abuse, most notably for women.141 In a recent systematic review,
the authors examined the effect of ACEs on future sleep problems in adults, summarizing 30
studies.141 This literature primarily consists of retrospective studies where individuals report on
prior ACEs and many of the included studies have female-only samples. There is also a range of
sleep phenotypes within the literature, although studies converge on significant associations
between child trauma and sleep. For example, a prospective study of adolescents examined ten
years after the abuse demonstrated that CSA was related to a higher subjective sleep disturbance
score, an association that remained following the addition of both MDD and PTSD symptoms
(which themselves can influence sleep).149 In another study by Greenfield and colleagues,150
individuals endorsing the most severe class of abuse, which included sexual abuse, reported
increased odds of poor subjective sleep measures from the PSQI. More specifically, individuals
were more likely to experience more sleep disturbances, worse sleep quality, and more daytime
dysfunction, in addition to being more likely to utilize sleep medication (all odds ratios > 2). A
recent paper151 added to the literature by examining sleep and CSA in a large twin sample,
finding that for both males and females, CSA increased the odds of experiencing sleep symptoms
by 1.7. Additionally, incident characteristics, including severity, in females endorsing CSA were
examined, but none of these items were differential predictors of worse sleep. Further, there may
be sex differences, with a newer study demonstrating that women are more likely to experience
poor sleep in adulthood following childhood adversity.152 Thus, it is possible that both type and
timing interact. In a recent paper, scientists showed that insomnia symptoms in adolescents were
highest with a history of interpersonal violence (vs. accidents/injuries, social/network events,
other).153 While most studies report associations with sleep, one notable limitation of the child
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trauma and sleep literature is that the majority of these studies have been conducted in North
American or European populations, with no studies in African or East Asian countries including
China.
Trauma, sleep, and psychopathology. An important consideration in interpreting the
trauma and sleep literature is that many studies examine sleep problems along with (or as
symptoms of) comorbid psychopathology. Thus, while it is well established that trauma is related
to sleep disturbances,67 results are often confounded by psychopathology. There is a substantial
literature of longitudinal investigations that establish temporal relationships between sleep and
psychopathology, demonstrating that sleep disturbances both pre- and post-trauma can have an
impact on psychiatric outcomes.41,42,67,140,154-158 For example, Bryant and colleagues156 examined
the relationship between sleep disturbances pre-injury and later psychiatric disorders in a sample
of patients admitted to the hospital. Most disorders (e.g., PTSD, MDD, obsessive compulsive
disorder, substance use) were significantly associated with pre-trauma sleep disturbance, even
after excluding prior psychopathology. Extending results to an Army sample, Gehrman and
colleagues41 looked at associations between pre-deployment insomnia and sleep variables and
the development of psychopathology after deployment. Results indicated that insomnia
symptoms were associated with a higher risk of new-onset MDD, PTSD, and anxiety. Notably,
the effect size of insomnia was similar to that of the trauma (i.e., combat exposure) in all models.
There are also studies of post-trauma symptoms. Wright and colleagues157 looked at insomnia,
MDD, and PTSD at two time points post-deployment, finding that insomnia symptoms at Time 1
predicted PTSD and MDD symptoms at Time 2. More recently, a study of Chinese adolescents
demonstrated that sleep disturbances predicted MDD and PTSD at multiple time points
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following a major earthquake.159 Thus, both pre- and post-trauma sleep symptoms can influence
psychopathology.
Summary and future directions for environmental influences on sleep. There are four
main points to be drawn from this review of the complex trauma, sleep, and psychopathology
literature: 1) trauma exposure is associated with disturbed sleep/insomnia, although many studies
include comorbid psychopathology as an outcome or covariate; 2) disturbed/sleep insomnia is a
predictor of later psychiatric symptoms in individuals exposed to traumatic events; 3) an
emerging literature is investigating contributions of trauma type to insomnia, with early results
suggesting that interpersonal trauma is a more potent predictor; and 4) trauma timing is also
important, with evidence that early trauma influences sleep in adults. However, the extant
literature has a number of limitations that represent important future directions. First, few studies
examine multiple different trauma types together, focusing instead on specific events. Examining
multiple events will allow for a comparison of traumas, improve our understanding of how
events cluster together, and establish important differences in trauma type. Second, there is a
need for more studies that focus specifically on how trauma impacts sleep, apart from
psychopathology. Third, with few studies parsing out effects of both childhood and adult traumas
together on sleep, trauma timing should continue to be examined. Finally, while the childhood
trauma and sleep literature has increased substantially, there is clearly a lack of studies using
non-European populations, such as the Han Chinese, which should be addressed.141 While
trauma exposure is an environmental risk factor that impacts disturbed sleep and insomnia, there
are other etiologic sources, particularly those that are biologic in nature, to consider in
understanding these phenotypes. One such factor is genetics, and there is a long history of
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examining the genetic contributions to insomnia, which will be discussed in the following
section.

III. Genetic components influence both sleep and MDD
a. Behavioral genetics
Family studies. Twin and family studies demonstrate that genetic influences are an
important etiological risk factor for insomnia. Five early family studies of insomnia exist, with
the first dating back to the 1960s.160-164 Higher rates of insomnia in family members of
individuals with the disorder were found across all studies, supporting familial aggregation of
insomnia. Studies did differ in terms of timing of insomnia assessed (childhood vs. adulthood;
two studies looked at childhood sleep patterns) and outcome phenotype examined (insomnia vs.
sleep patterns), but overall results suggest a familial component. A more recent family study165
utilized more sophisticated measures to analyze familial aggregation and heritability, finding that
risk ratios for current and lifetime insomnia were > 2 in first-degree relatives and that heritability
estimates were relatively high, even when controlling for psychopathology (0.48 for current;
0.58 for lifetime). Additionally, a new family study reported a risk ratio of 1.80, consistent with
prior studies.166
Twin studies. The current twin literature for insomnia is much larger than that of family
studies. The twin approach has several notable advantages, including the calculation of specific
estimates of genetic contributions (i.e., heritability), and the ability to parse out shared
environmental components that make individuals similar on a given phenotype. To date, there
are more than 20 twin studies of insomnia and related symptoms (excluding sleep duration), 14
of which were conducted in young adult/adult samples, with the remaining studies coming from
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pediatric samples, and the majority of participants being European or of European-American
descent. Overall, most adult studies report heritability estimates between 20% and 60%.167 The
vast majority of adult twin studies have utilized subjective sleep phenotypes, with the exception
being an early study that used EEG data on sleep latency and wake time.168 It is important to note
that these estimates are consistent despite the wide variety of phenotypic definitions used across
the literature (see Table 2 of Lind and Gehrman (2016)167 for specific estimates). Most twin
studies have used definitions based on individual symptoms or combinations of symptoms, and
these definitions have been heterogeneous with little standardization across studies.167,169
The wide range of heritability estimates found in the literature may be due to
methodological differences across twin studies. For example, many of the higher estimates that
have been found for insomnia sum/composite scores are in younger samples (e.g., Watson and
colleagues170 reported an insomnia heritability of 57% (95% CI: 47% to 63%) with an average
age of 32; Drake and colleagues171 found that the heritability of insomnia was 55% in women
and 43% in men in with an average age of 23). In contrast, studies of older twins have yielded
lower estimates. For example, Hur and colleagues,172 reported an insomnia symptom heritability
of 28% (95% CI: 25% to 31%) with an average age of 50, and the Vietnam Era Twin Study of
Aging found the heritability of a global sleep composite score to be 34% (95% CI: 25% to 42%)
in males with a mean age of 55.173 Given that sleep problems become more prevalent as
individuals age,2 it is possible that there is less variation attributable to genetic effects. This
could be a result of the high prevalence of comorbid health conditions associated with age that
also affect sleep (e.g., arthritis, back pain). Higher heritability has also been reported using
longitudinal data, a design that helps mitigate the effects of measurement error; although note
that higher estimates are expected based on study design. Specifically, while Lind et al.174 found
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that time-specific estimates of insomnia heritability were only around 20%, estimates increased
to 59% (females; 95% CI: 44% to 69%) and 38% (males; 95% CI: 27% to 48%) when both time
points were modeled simultaneously. The degree of insomnia heritability may differ across the
sexes, referred to as a quantitative sex effect, which is consistent with studies of MDD,175 and
highlights the importance of conducting analyses by gender since genes may be more relevant
for insomnia in women.
The twin literature also includes studies that have investigated individual insomnia
symptoms, such as difficulty falling asleep or difficulty staying asleep, instead of or in
combination with insomnia composite scores. In general, these estimates range from 25-45% and
tend to be lower than estimates for insomnia overall.167,171,176 For example, a study of Vietnam
veterans176 found heritabilities of 28% (trouble falling asleep), 42% (trouble staying asleep), and
26% (waking up several times) among individual symptoms. A Finnish twin study of sleep and
mortality reported estimates that were similar but a bit higher, with heritability at 41% (difficulty
initiating sleep; 95% CI: 36% to 46%), and 45% (nocturnal awakening; 95% CI: 41% to 49%).22
Interestingly, Drake and colleagues171 reported similar estimates for DSM insomnia symptoms of
difficulty staying asleep (25% in males and 35% in females) and non-refreshing sleep (34% in
males and 35% in females), but no genetic influences on difficulty falling asleep for both
genders. Heritability estimates from the PSQI, the gold standard self-report measure for sleep
quality, have also converged with the other estimates reported. Two studies in adults have
analyzed the PSQI and its subscales,173,177 finding estimates of 23% (95% CI: 9% to 36%) and
39% (95% CI: 2% to 53%) for the sleep disturbances subscale, which has individuals describe
how often certain events (e.g., trouble falling asleep, waking up, having bad dreams) contribute
to trouble sleeping.178 Overall, the twin literature supports that insomnia, whether measured by a
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composite/total score or by individual symptoms, is moderately influenced by genetic factors.
The highest heritability estimates are seen for insomnia composite scores in younger samples,
which may be related to the fact that sleep disturbances become more common with age.2
The sleep literature is consistent with that of the substantial genetic epidemiologic
literature on MDD in that MDD is also moderately heritable (37-38%).179-181 There is also
evidence that MDD heritability differs across the sexes, with higher estimates in females (4042%) vs. males (29-39%).182,183 Several groups have examined the heritability of individual
MDD symptoms as well, indicating that the sleep symptom more specifically is moderately
heritable (35% and 19%).184,185 Given bidirectional relationships between MDD and insomnia,32
there is a growing twin literature that examines the overlap in genetic and environmental
influences on insomnia and internalizing disorders, particularly MDD (e.g., 186,187). Initial
examinations of etiologic overlap were conducted primarily in samples of children,188-194 with
several studies reporting high estimates of overlap between insomnia phenotypes and MDD (e.g.,
Gehrman and colleagues189 reported complete genetic overlap; Gregory and colleagues193
reported a genetic correlation of 0.64). Emerging longitudinal data in adults supports these
relationships. In a longitudinal examination of overlap between insomnia and common
psychiatric disorders, substantial overlap was found, with 56% (females) and 72% (males) of
insomnia’s latent heritability shared with that of MDD.187 Additionally, a recent young adult
study modeled the genetic and environmental overlap between insomnia and MDD
longitudinally using a correlated factors model, once again finding high genetic correlations
between the two traits (0.73-0.89).186 In sum, family and twin studies have laid the groundwork
for molecular genetic studies of both insomnia and MDD, which aim to identify specific genes
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contributing to these disorders. Further, evidence for shared genetic influences on insomnia and
MDD indicates that this overlap should be considered at the molecular level as well.
b. Molecular genetics
Candidate gene studies. In the section that follows, a brief overview of select candidate
gene studies is presented, followed by a more detailed discussion of the more contemporary
genome-wide designs. The main focus will be on studies conducted on insomnia phenotypes, but
the molecular genetics literature of MDD will be referenced for comparison. In the candidate
gene approach, gene(s) of interest are selected a priori based on biological mechanisms/prior
research and variants within the gene(s) are examined in association with the phenotype of
interest (e.g., insomnia vs. control, quantitative measure of sleep disturbances). Next, statistical
analyses are conducted to determine whether or not the variant of interest occurs more frequently
in individuals with the phenotype (vs. without). Initial candidate gene studies for insomnia and
related phenotypes focused mainly on genes that were plausible based on mechanism. Variants
within circadian rhythm genes, such as CLOCK, PER, and TIMELESS, were examined in early
studies, given that circadian processes are important for sleep. Serotonin, a neurotransmitter that
plays a role in sleep regulation195 and is also widely studied in MDD,196 has also been examined
in sleep. These investigations have included assessments of polymorphisms in the serotonin
transporter (e.g., 5-HTTLPR; e.g., 197,198) as well as in enzymes that degrade serotonin
(monoamine oxidase; MAO) (e.g., 199,200). More recently, new systems that have been studied in
relation to insomnia include dopamine, apolipoprotein, PGC-1α, and the aryl hydrocarbon
receptor.201-204 Overall, the candidate gene literature for insomnia is small compared to
psychiatric phenotypes such as MDD (where around 200 different genes have been analyzed and
multiple meta-analyses conducted205). While the results of some of these insomnia studies show
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significant or suggestive results, results are mixed, particularly for serotonin. Investigations of
serotonin and CLOCK polymorphisms often examine insomnia symptoms in individuals with
MDD or receiving treatment, which makes it challenging to parse out the effects of the variants
on insomnia more specifically.
Limitations of the candidate gene approach. While candidate gene studies utilize a
hypothesis-driven approach that incorporates variants in genes thought to be biologically
relevant, there are several major limitations to consider,206,207 especially given the lack of
replication seen across studies.208 First, the candidate gene approach relies on the appropriate
choice of gene and variants, which is critical yet can be difficult given our minimal
understanding of the biologic etiology of many phenotypes.207 Further, in order to achieve the
best interpretability, variants should be chosen to maximize function (i.e., within coding regions;
related to gene expression, or at least tagging other functional variant(s),206,207,209 but are often
chosen based on ease of genotyping and are limited by our knowledge of the genome.207 Second,
although discrepant results could be due to real differences in study population or phenotype,207
the use of small sample sizes and low power suggest that many results may be invalid (i.e., false
positives, false negatives in replication attempts).210 Within the MDD literature, meta-analyses of
the most commonly studied genes have not converged on strong predictions (even with refined
phenotypes),211 and, despite having enough power to detect these effect sizes in more agnostic
approaches (i.e., GWAS), hypothesized genes are not significant.205 In contrast, it is difficult to
even meta-analyze genes within the insomnia literature, as few studies examine the same variants
and phenotypes are heterogeneous.167 Finally, another important issue is population stratification,
as spurious results could be due to differences in allele frequency across ancestries.206
Quantitative approaches to classifying ancestry can improve this, but were not used in many
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early studies.212 Thus, while the candidate gene literature provides some evidence of a role for
specific genes in these phenotypes, results do not converge and additional approaches are
needed.
Introduction to GWAS of insomnia and MDD. GWAS approaches, which allow for the
simultaneous examination of millions of variants (measured or imputed) across the genome to
identify potential loci contributing to a phenotype, have been used to gain new insight into the
genetic contributions to insomnia. To date, there have only been five published GWAS of
insomnia or related sleep phenotypes213-217 and one replication study.218 Studies that analyze only
sleep duration are excluded from this total. This total is in contrast to other psychiatric
phenotypes like MDD, where a mega-analysis of eight GWAS was published in 2013219 and
multiple additional large GWAS have been published since then (e.g., 220-223). Although the
MDD mega-analysis combined data on over 9,000 cases and 9,000 controls of European
ancestry, no genome-wide significant (GWS) loci were found.219 However, more recent GWAS
of MDD have focused on different phenotypes (recurrent MDD, “broad” depression) and/or
large sample sizes, with more success (e.g., 220-223). Within a sample of Han Chinese women (N
~ 11, 000), two novel GWS loci were found for recurrent MDD: one near SIRT1 and one in
LHPP.220 More recently, a meta-analytic GWAS (N ~ 70,000) conducted on a “broad”
depression phenotype that encompassed both diagnosis and symptoms, was able to identify and
replicate a single nucleotide polymorphism (SNP) with the FHIT gene.222 Finally, in what is the
largest GWAS of MDD to date (over 70,000 cases/200,000 controls), investigators from
23andMe identified novel loci for MDD.223 When this data was meta-analyzed with Psychiatric
Genomics Consortium (PGC) MDD data and combined with an additional 23andMe replication
sample, a total of 17 SNPs in 15 loci reached genome-wide significance for MDD.

23

Specific GWAS of insomnia. In comparison with MDD, there are fewer loci that have
been identified for insomnia and most studies have used much smaller sample sizes; results are
outlined in the following sections. Note that measurement issues remain within this literature, as
only three of the five GWAS include specific “insomnia” phenotypes and the majority of papers
utilize self-report data (with the exception of Spada and colleagues,217 who used objective
phenotypes from actigraphy). The first GWAS of insomnia, published by Ban and colleagues,214
utilized genetic and phenotypic data on 8,719 individuals from a Korean epidemiologic sample
who reported on their insomnia status via self-report. Although no loci reached genome-wide
significance, several top SNPs were determined to be of interest (out of 3354 SNPs with p <
0.005), and had prior associations with psychiatric disorders. ROR1 included the most significant
SNP, and there were multiple other SNPs of marginal significance within this gene, which has
been linked to bipolar disorder.224 PLCB1 was the next-most significant (a total of 17 SNPs in
this gene reached the marginal significance cutoff), and the gene has associations with
schizophrenia.225,226 Next, Byrne and colleagues215 utilized an Australian twin sample (N = 2323)
to conduct a GWAS of an insomnia factor score and other sleep phenotypes (sleep latency, sleep
time, sleep quality, sleep depth, sleep duration). No SNPs passed genome-wide significance for
any phenotypes, including the insomnia factor score. Of interest in this study was a set of SNPs
in linkage disequilibrium (LD) (i.e., recombination occurs between these loci more frequently
than would be predicted by chance227) in the CACNA1C gene, which were nominally significant
in predicting sleep latency. However, these associations did not reach significance in replication
samples either. Of note, another SNP in CACNA1C was of interest for sleep quality. Similar to
the genes suggested by Ban and colleagues,214 above, this gene is associated with both
schizophrenia and bipolar disorder, in addition to MDD.228,229 Parsons and colleagues218 sought
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to replicate the CACNA1C association in a British sample (N = 952) that had PSQI data on sleep
quality, duration and latency. This was successful: the SNP was associated with sleep latency in
the new sample, which provides additional evidence for its relevance in sleep phenotypes.
Despite being a different variant than the one identified in the initial study, this CACNA1C SNP
was also associated with sleep quality in the replication sample, further supporting the role of
this gene in sleep.
Although these initial GWAS studies were not successful in identifying GWS variants for
insomnia, they were able to suggest novel variants that were not previously investigated in
candidate gene studies, with some evidence of replication. Additionally, all SNPs of interest
from these studies seem to be relevant for other psychiatric disorders as well. Newer studies
using different phenotypic approaches and larger sample sizes are adding more genes of interest
to the literature and are finding GWS results. Spada and colleagues217 were the only group to
analyze objective phenotypes, using sleep parameters derived from actigraphy data in a sample
of 956 adults in Germany. Some of these, like sleep quality and sleep latency, correspond to
subjective phenotypes measured in other GWAS. There were significant SNPs in multiple
parameters, including sleep efficiency on weekdays (UFL1, a circadian gene), sleep latency
(DMRT1), and sleep offset (SMYD1). However, these results should be interpreted in light of
several key limitations: 1) there was no correction for the examination of multiple phenotypes;
and 2) a diagnosis of insomnia is made using self-report information on symptoms; to date there
are no clear patterns within objective data from polysomnography or actigraphy.230-232 Another
new study213 identified the RBFOX3 gene as important for self-reported sleep latency in a large
combined sample (N = 4242) of Europeans. The heritability of sleep latency in this sample was
estimated at approximately 20% using SNP-based approaches, reviewed in more depth below.
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Three correlated SNPs within this gene were found to be significant and could be replicated in
additional samples. Gene network analysis was also conducted, and results indicated associations
between RBFOX3 expression and expression of genes involved in calcium channels and gammaamino-butyric acid (GABA) signaling (gene expression and methylation data was also collected
on a subset of individuals). GABA is an inhibitory neurotransmitter that is important for sleep
regulation,233 supporting the plausibility of RBFOX3’s role in sleep latency. RBFOX3 was also
related to other neurotransmitter release (glutamate, serotonin, dopamine), through these
processes. The results of these first four GWAS of insomnia phenotypes, while identifying
different genes and SNPs of interest, do converge in terms of gene function: processes involved
in excitability or sleep reactivity (i.e., quality of sleep in response to a stressful event171) are seen
across these genes.167
Most recently, the largest GWAS of sleep phenotypes to date was published using the
United Kingdom (UK) Biobank data set, which is comprised of health data from over 500,000
volunteers from the UK.216 Data on sleep duration, insomnia symptoms (measured via a single
ordinal item that asked about frequency of difficulty falling and staying asleep, with only the
extremes of “never/rarely” and “usually” used for analysis), and daytime sleepiness were
collected. Insomnia analyses were conducted on 31,767 cases and 29,935 controls. Variants in
five novel genes (including two that may be sex-specific) were identified in this study for
insomnia, and results held when including covariates such as depression. These included MEIS1
(which was also found to be significant when a multi-trait sleep GWAS was conducted using
data on sleep duration, insomnia, and daytime sleepiness), TMEM132E, CYCL1, TGFBI
(females), and WDR27 (males). Interestingly, MEIS1 has been implicated in restless legs
syndrome, another sleep disorder,234 and the same CYCL1 SNP reached nominal significance in a
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GWAS of comorbid alcohol dependence and depression.235 TMEM132E is relevant given its
relationship to psychopathology, as variants near TMEM132E have previously been associated
with bipolar disorder236 and variants in another gene in the same family, TMEM132D, have been
replicated across several GWAS of panic disorder.237,238 Finally, the two sex-specific genes of
interest, TGFB1 and WDR27, have been linked to Type 1 diabetes,239-241 suggesting that immune
processes may be involved in insomnia. Taken together, the results of this newest GWAS
indicate that genes involved in insomnia may be shared not only with other psychiatric disorders
but also with complex traits. However, an important caveat is that the insomnia phenotype was a
single ordinal item and not an established sleep measure or diagnosis.
Summary of molecular literature. Overall, molecular genetic studies of insomnia have
demonstrated mixed results in candidate gene studies, and notably, there have not been any times
in which a GWAS of insomnia has identified a gene that has been studied in a candidate-gene
framework. The early GWAS studies failed to find GWS loci, but are beginning to identify genes
of interest as data are combined, resulting in increases in sample sizes and associated statistical
power. Genes of interest tend to show prior associations with psychopathology.167 This pattern of
gene-finding efforts parallels that of other psychiatric disorders, although the insomnia literature
lags behind (i.e., there are far fewer identified GWS loci for insomnia compared to schizophrenia
and MDD; e.g., 220-223,242). Given this and the small number of published studies to date, it
remains important to continue gene identification as well as replication efforts for insomnia in
different samples. Other than the Korean GWAS,214 all studies were conducted in samples of
European origin, which limits generalizability of findings. Further, while twin studies do
converge on heritability estimates despite diverse phenotypes, consistent phenotyping remains a
problem in gene identification studies, as phenotypic heterogeneity can contribute to lack of
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replication and makes it difficult to synthesize results. To date, no GWAS of insomnia utilize
DSM diagnoses. It will be important for the field to decide on suitable phenotypes and attempt to
conduct genetic analyses appropriately.
Introduction to aggregate molecular approaches. Advances in statistical genetics have
resulted in the development of methods that estimate heritability from available genomic data on
unrelated individuals. One such approach is genome-wide complex trait analysis (GCTA), which
utilizes the estimated genetic relationships between unrelated individuals to estimate the variance
in a trait that is due to the additive effect of SNPs that are available.243 This is done through the
creation of a genetic relatedness matrix (GRM), which includes correlations for all individuals
across all SNPs, which is then regressed on phenotype using a restricted maximum likelihood
(REML) method. This widely popular method has now been used across a variety of complex
traits (e.g., 244-248), although heritability estimates tend to be lower than twin estimates, and
GCTA represents a lower bound.245,249 The method is not without its limitations, particularly
since large sample sizes are needed to have adequate power to detect heritability.250 Analyses of
case-control traits in particular can result in biased estimates since heritability must be
transformed onto a liability scale251 and one recent critique suggests that GCTA is not accurate
even when all assumptions are met, due to problems with the GRM (e.g., noise, over fitting).252
As described within the definition, GCTA can only take into account SNPs that are measured (or
imputed) and other variants that are in LD with them. As this generally encompasses common
SNPs, rarer variants are not represented in GCTA, although they could be contributing to the
disorder. GCTA also assumes additive effects, and thus does not take into account other genetic
effects such as dominance effects, epistasis, or gene-environment interactions (GxE).245,249
Further, there are instances where the genetic architecture of a trait is such that GCTA would not
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detect heritability, despite the trait having large genetic effects. This could occur if there are one
or two significant loci of large effect and then all other variants have small effects (e.g., closer to
Mendelian inheritance). Despite these limitations, GCTA does have several advantages, in that it
is not biased by sample size or to specific effects and conclusions can be made about the trait as
a whole.245 Genetic correlations between traits can also be obtained through GCTA (bivariate),
although there are other methods, such as LD Score regression (LDSC),253 that can estimate
correlations (and heritability) through summary statistics.
There are also additional approaches that leverage molecular data to examine aggregate
genetic risk and overlap across phenotypes, often without needing raw genetic data for all
phenotypes involved. Polygenic risk scores (PRSs), which utilize summary statistics from a
discovery dataset to calculate weighted risk scores that are then applied to individuals in a target
sample, represent one approach. A key difference between GCTA and PRSs, which are both
aggregate approaches, is that PRSs take into account specific SNP effects, weighting
contributions based on effect size from GWAS, while GCTA assumes that effects are random.
PRSs are based on the idea that many traits are polygenic in nature (i.e., many genes of small
effect that do not pass GWS thresholds via conventional GWAS methods contribute to the
trait).245,246,254,255 The assumption is that within the variants that make up a risk score, there are
some with true effects. This approach was initially used to show that genetic risk scores for
schizophrenia predicted bipolar disorder (and vice-versa),254 and since the publication of this first
paper, the method has been applied to many phenotypes (e.g., 247,248). Commonly referred to as
the Purcell method, an important step in this method of creating genetic risk scores is pruning the
list of SNPs based on LD before score creation, as including highly correlated SNPs could bias
the risk scores (although pruning can be done through several approaches256). The Purcell
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method also incorporates p-value thresholds, such that multiple scores are created using SNPs
within different ranges of p-values, ranging from very small to encompassing all SNPs.
New methods for computing PRSs (e.g., LDpred,257 PRSice258) are emerging to address
limitations of the initial method. One main criticism of the Purcell method, described above, is
that important information is lost due to LD pruning. To address this limitation, the program
LDpred incorporates LD information from a reference panel and takes into account LD, and is
thus able to utilize all available SNPs in the score.257 The program also estimates scores
differently, in that it utilizes a Bayesian prior for the genetic architecture of the trait based on an
estimate of the trait’s heritability and proportion of variants (i.e., fraction) that are causally
contributing to the trait to generate scores across different fractions. The method does have its
own limitations, although most of these are related to PRSs in general (e.g., controlling for
ancestry, appropriate LD reference). Like GCTA, PRSs are limited by the SNPs that are
available (i.e., in common across discovery and target samples) and do not generally take into
account non-additive effects, GxE, epistasis, or rare variation.245,249 Sample size is also
important, particularly for the discovery sample, as larger discovery samples will give better
estimates.245,259 Another problem within the PRS literature is the heterogeneity in score
creation,256 making it difficult to compare scores across studies.
Applications and future directions. While these methods have increased our
understanding of genetic contributions to many complex traits, sleep phenotypes are understudied. To date, there are only three studies that have examined SNP-based heritability of
insomnia-related outcomes. Estimates range from 30% for the insomnia symptom of MDD260 to
20% for sleep latency,213 and 21% for insomnia within the UK Biobank GWAS.216 Note that
these estimates were obtained using methods similar to GCTA (i.e., heritability was based on
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SNPs) but not the GCTA software, described above. The estimate obtained for insomnia within
MDD260 is consistent with the twin literature. In contrast, estimates of the two more general
insomnia-related phenotypes are on the lower end when compared to twin estimates of insomnia,
which is consistent with what is seen across the literature for other phenotypes.245,261 Further,
despite evidence for biometric overlap between insomnia and MDD (e.g., 186,187,189), and the
presence of some candidate gene studies that examine genetic contributions to MDD with
insomnia/sleep symptoms (e.g., 199,262-266), few studies examine genetic overlap and/or
incorporate a PRS approach. In the 23andMe MDD GWAS,223 a genetic risk score was created
for MDD (from the 17 identified SNPs) and used to predict a range of other related phenotypes,
including insomnia (assessed via a yes/no question about difficulty “getting to sleep”), where it
was a significant predictor. Within the UK Biobank sample, LDSC was used to examine genetic
correlations between sleep variables and 20 other phenotypes, finding a significant correlation
between insomnia and depression (as well as several metabolic traits).216 Overall, studies that
utilize aggregate molecular approaches for insomnia-related phenotypes are only just beginning
to emerge, and more investigations are warranted, particularly using more refined insomnia
phenotypes. The use of statistical methods described here, in addition to other post-GWAS
approaches, such as gene and pathway analysis, will be important in developing our
understanding of the genetic architecture of insomnia and how it relates to MDD, as this may
have implications for gene-finding efforts.

IV. Aims
Sleep disturbances and insomnia affect the well-being of many individuals worldwide,
making an in-depth understanding of their etiologic influences (both genetic and environmental
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in nature), above and beyond what has been examined in the extant literature, essential for
improving population health. This dissertation aims to address several important and
understudied areas within the sleep literature using the China, Oxford, and VCU Collaborative
Research on Genetic Epidemiology (CONVERGE) dataset, which contains detailed phenotypic
and genetic data on approximately 12,000 Han Chinese women, half with recurrent MDD. Since
few investigators have examined specific effects of trauma type and timing on sleep outcomes
across multiple trauma types while accounting for psychopathology in non-Western populations,
Aim 1 is to determine the relationship between type of trauma exposure (interpersonal vs. nonassaultive) and timing of trauma exposure (childhood vs. adult onset), and sleep disturbances
(Chapter 3). It is hypothesized that interpersonal traumas will be stronger predictors of sleep than
non-assaultive traumas, and that childhood events will be more potent than those that have initial
onset during adulthood. Next, as genetic influences are also important for insomnia, but
molecular studies are still in their infancy, with few examining SNP-based heritability or looking
at sleep in the context of or overlapping with MDD, Aim 2a is to conduct analyses of SNP-based
heritability of disturbed sleep (Chapter 4), and to identify potential genetic variants associated
with sleep phenotypes in CONVERGE (both within and independent of MDD) (Aim 2b, Chapter
5). It is hypothesized that sleep phenotypes will be heritable and that genetic loci of interest will
be identified for these phenotypes. The goal of Aim 2c is to examine molecular overlap between
the different sleep phenotypes as well as between sleep and MDD within this sample by utilizing
two different methods of PRSs (LDpred and the Purcell method) (Chapter 6). It is expected that
PRSs for sleep within MDD will significantly predict sleep in MDD controls (and vice-versa)
and that sleep and MDD risk scores will significantly predict each other. Finally, in an effort to
combine both genetic and environmental influences in order to obtain a more complete etiologic
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model of sleep, the Exploratory Aim (Chapter 7) is to conduct cumulative models of combined
genetic and environmental risk for sleep disturbances using results generated in Aims 1 and 2
(e.g., PRS and trauma variables as predictors of sleep). For this aim, it is expected that both
genetic and environmental risk factors will have significant contributions to sleep disturbances.
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Chapter 2: Methods

I. Sample
The CONVERGE dataset was used for analysis.48 CONVERGE is a large genetically
informative sample comprised of approximately 12,000 Han Chinese women aged 30-60, 50%
with recurrent MDD (cases) and 50% matched screened controls, which was initially ascertained
to conduct detailed genetic and phenotypic analyses of MDD. Genetic data passing all quality
control (QC) standards (described in more detail below) is available for ~88% of the sample
(N=10,502). Data was collected from 59 hospitals from 45 cities in 23 provinces and
municipalities in China via clinical interviews. Exclusion criteria for cases were i) history of
bipolar illness, ii) psychosis outside depressive episodes, iii) drug or alcohol dependence with
onset prior to MDD, iv) developmental disability, and v) blood relative of another case.
CONVERGE included only individuals as cases who presented to psychiatric services for
depression and received treatment. The entry criteria for controls were i) female, ii) current age
40-60 (to reduce the likelihood that these individuals would later develop MDD), iii) no lifetime
history of MDD, and iv) all four grandparents Han Chinese. Controls were excluded if they had a
developmental disability, had a known history of bipolar illness or psychosis, or were a blood
relative of a case.
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II. Measures
Identification of traumatic events. Individuals were asked about 16 SLEs (via yes/no
responses), with each item including a follow up question about the age at the first time this
event occurred. These items were modified from those used within the Virginia Adult Twin
Studies of Psychiatric and Substance Use Disorders (VATSPSUD).175 Ten of these events were
considered to be potentially traumatic events, based on the DSM-5 definition that a trauma must
involve a potential life threat or a threat to the integrity of self/others.1 An additional childhood
trauma variable, CSA, was assessed separately with six items that queried its occurrence and
severity in response to the following question: “Before the age of 16, did any adult, or another
person older than yourself, involve you in any unwanted incidents like…” The six items included
the following question stems: a) Inviting or requesting you to do something sexual; b) Kissing or
hugging you in a sexual way; c) Touching or fondling your private parts; d) Showing their sex
organs to you; e) Making you touch them in a sexual way; f) Attempting or having sexual
intercourse. Response options to these questions included 0 (never), 1 (once), and 2 (more than
once). A broad yes/no CSA variable was created by coding individuals who endorsed at least one
of the six items at least once as 1 and those who did not endorse any of the items as 0 (this is
consistent with prior analyses of CSA124,129,151).
The 11 traumatic events included in subsequent analyses were: 1) death of a spouse,
child, or sibling; 2) serious illness (self); 3) life-threatening accident (self); 4) fire, flood, or
natural disaster (self); 5) witnessed someone being badly injured or killed; 6) rape; 7) physical
attack or assault (self; other than events already indicated); 8) physical abuse as a child (other
than events already indicated), 9) serious neglect as a child; 10) CSA (binary variable); and 11)
threatened with a weapon, held captive, or kidnapped (self; other than events already indicated).
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Assessment of CSA characteristics. Additional CSA items, modified from those used in
the VATSPSUD,175 were also assessed. An ordinal categorical CSA severity variable was
created using this data: (1) no genital contact (sexual invitation, sexual kissing, exposing), (2)
genital contact but no intercourse (fondling and sexual touching), and (3) intercourse. Further,
there were a number of items assessing incident characteristics that were also used for
analysis.129 These included: intercourse vs. other types of abuse (coded as 1 and 0, respectively,
using the CSA severity variable created above), age at time of first abuse (continuous variable),
age of perpetrator (5 categories: under 15 years old, 15-18, 19-24, 25-49, > 50; each analyzed
separately with 1 coding for that age group being endorsed and 0 for non-endorsement), gender
of perpetrator (male [0] vs. female or both sexes [1]), relationship to the perpetrator (relative [1]
vs. non-relative [0]), feeling forced or threatened by the person(s) involved (yes [2] and
somewhat [1] vs. no [0], treated in the regression as a factor with three levels), and how much
the incident affected the victim at the time (on a 7-point scale, with 1 not endorsing being
affected and 7 endorsing that the experience affected you a great deal, recoded to 0-6); if more
than one incident occurred participants were asked to rate the worst one).
MDD assessment. Participants were assessed for recurrent MDD (lifetime) using the
Composite International Diagnostic Interview (CIDI; World Health Organization lifetime
version 2.1; Chinese version) section for the disorder expanded to include a “deep” assessment
of the DSM-IV A criteria for MDD (32 questions for the 9 criteria including culturally sensitive
probes for sad mood and loss of interest). Symptoms were reported for the worst lifetime episode
of MDD, as indicated by the individual.
Sleep assessment.
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General sleep item (GS). All individuals (both MDD cases and MDD controls) were
asked a lifetime question about general sleep patterns, “Do you suffer from sleeplessness?”
within the Neuroticism subscale of the Eysenck Personality Questionnaire,267 which was
translated into Mandarin. This is a binary/yes no item, and is used as the main sleep outcome in
many analyses, as it is the only sleep-related item asked of both MDD cases and MDD controls.
Sleep items within MDD. Two binary sleep items were also asked in the context of worst
MDD episode: “During that worst time (when you were feeling depressed/had lost
interest/lacked energy), did you have trouble sleeping almost every night for two weeks or more
-- either trouble falling asleep, waking in the middle of the night, or waking up too early?” [Item
E8]; “Did you often wake up in the early morning before you wanted to get up and be unable to
get back to sleep?” [Item E8.A].
Composite sleep variables. i. Sleep within depression score (SDS): The two MDD sleep
items, listed above, along with the general sleep item, were summed within MDD cases to obtain
a sleep within depression score, an ordinal variable with levels ranging from 0-3. This variable
was treated as a quasi-continuous variable in genetic analyses (note that it was highly negatively
skewed; see Figure 1 for a histogram showing the distribution of this variable). However, log
transformation did not improve skewness, so the variable was used without transformation. ii.
Adjusted GS: This is a binary sleep variable created for use in genetic analyses that incorporates
all available sleep information for both MDD cases and MDD controls. For MDD controls, it is
the same as the GS, above. For MDD cases, individuals were coded as a ‘1’ if any of the three
sleep items was positively endorsed (i.e., a 1, 2, or 3 on SDS) and a 0 if none of these items were
endorsed (i.e., a 0 on SDS).
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Figure 1: Distribution of sleep within depression (SDS) variable. This histogram displays the
endorsement of the SDS variable, with the count for each category included on top of each bar.

Demographic variables. Standard demographic variables were obtained (e.g., age, level
of education, current job status, social class, and marital status). Within phenotypic analyses,
only age was used as a covariate, as level of education (and other demographic variables relevant
to socioeconomic status) had high missingness.

III. Genetic data
DNA sequencing and imputation. Detailed information on genetic methods can be found
in the original MDD GWAS.220 DNA was collected using saliva samples and extracted using the
Oragene protocol. Samples were sequenced on Illumina Hiseq machines, which were aligned to
Genome Reference Consortium Human Build 37 patch release 5 (GRCh37.p5) with Stampy
(v1.0.17)268 with default parameters. Any reads with base quality < 5 or containing adaptor
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sequencing were removed. Missing genotype data was imputed in two rounds using BEAGLE
version 3.3.2269 using Asian samples from the 1000 Genomes Project Phase1 East Asian
reference panel.270 This resulted in a total of approximately 20.5 million imputed SNPs. The
imputation method was confirmed to be accurate in calling genotypes: 12 samples were resequenced at greater depth (10x), 72 samples were called on a commercial genotyping array, and
all samples were genotyped at 21 random sites using a Sequenom mass spectrometry method
(overall concordance ~98%).220
Population structure. Principal component analysis was conducted to reduce population
stratification within the sample using EIGENSOFT 3.0271 and SMARTPCA.272 Before inclusion
in analysis, SNPs were pruned at r2 > 0.7 to correct for LD.272 Ten intracontinental principal
components (PCs) were constructed using information from 144,929 Autosomal SNPs with
Pr(G) > 0.9 and < 1% missing rate. Only PCs 1 and 2, which represent North-South regional
differences and technical artifacts, were used as covariates in genetic analyses, as these PCs were
used in prior MDD analyses.220
Sample selection. Individuals with an excess number of private variants or an excess
number of heteroplasmic sites in their mitochondrial genome were removed to eliminate
contamination. Individuals were also removed if they had low imputation quality in > 10% of
sites, were first-degree relative of another individual (assessed through identity by state), and/or
had incomplete phenotype information. This resulted in a maximum of 10,502 independent
individuals that could be used for GWAS of sleep phenotypes. Note that this number differs from
the original GWAS of MDD within CONVERGE (N = 10,640),220 as additional related
individuals were removed. Specific Ns for each GCTA and GWAS run are presented Tables 13
and 14, column 2, as this differed for each analysis based on missingness across sleep items.
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Chapter 3: Analyses of trauma type and timing (Aim 1)

I. Data analytic plan
All analyses were conducted using R version 3.3.0.273 All figures (except for Figures 2
and 3) were created using custom code in ggplot2, version 2.2.1.274 Descriptive statistics were
run, and the Psych package version 1.6.9275 was used to obtain tetrachoric correlations across
trauma types.
Factor analyses of trauma type. Several standard techniques for evaluating
dimensionality (i.e., Kaiser rule,276 Scree test,277 parallel analysis;278 all implemented in the
Psych package275) were used to determine how many latent factors might be extracted when
performing exploratory factor analyses (EFAs). EFAs were then run using the Psych package275
to estimate different factor structures for the binary trauma type variables. Following this, the
factor loadings, cross-loadings, and inter-factor correlations for each EFA were evaluated to
provide guidance about specifying and confirmatory factor analysis (CFA) models (i.e., if there
were high cross loadings and/or poorly identified factors, the model was not retained). Next, the
lavaan package version 0.5-22279 was used to carry out CFA to more rigorously test restrictive
factor models within a structural equation model framework. The best-fit CFA model was chosen
based on root mean square error of approximation (RMSEA) and X2.280 Finally, the best-fit
factor solution identified above was used to inform the creation of new trauma type and timing
variables for use in the next step, explained in greater detail within the Results section, below.
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Effects of trauma type and timing on sleeplessness. A series of hierarchical logistic
regression models were run to examine the effects of trauma type and timing on sleeplessness.
For each phenotype, Step 1 examined the effect of demographic covariates (i.e., age, MDD when
necessary) on sleeplessness. In Step 2, child interpersonal and adult interpersonal trauma
variables were included as predictors. In Step 3, child non-assaultive and adult non-assaultive
trauma variables were added to determine whether or not they had unique effects on
sleeplessness above/beyond interpersonal traumas. Model fit statistics (i.e., Akaike Information
Criteria [AIC], which balances parsimony and model misfit281) and Nagelkerke’s pseudo R2
(where possible; calculated by the pscl package version 1.4.9282) were used to compare models.
Following the first set of hierarchical regressions, a second set of stepwise regressions was run to
examine potential interactions between trauma type and timing on sleeplessness. The initial
model in these analyses was the final model from Step 3 (all types of trauma included), and then
interaction terms for child x adult interpersonal trauma and child x adult non-assaultive trauma
were added in sequentially (Steps 2 and 3, respectively).
In order to appropriately address ascertainment bias within the CONVERGE sample,
these regression models were run in three different ways to account for MDD status. First, all
regressions were run in the full sample with MDD as a covariate. Second, a survey-based
approach was utilized using the R package survey,283,284 which assigned different weights to
individuals with and without MDD to model a population prevalence of 8% (i.e., individuals
without MDD were given more weight than individuals with MDD). Third, regressions were run
separately in MDD cases and MDD controls for comparison.
Effects of CSA specifically on sleeplessness. Logistic regressions were run within the full
sample (with MDD and age as covariates) to examine the effect of one particularly potent form
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of child trauma, CSA, on sleep, replicating analyses conducted within the VATSPSUD
sample.151 A binary broad CSA variable was used here to predict sleeplessness in all individuals.
The same analysis was also conducted using the survey method to verify results, but MDD cases
and controls were not examined separately given that individuals with MDD did not differ across
CSA and sleeplessness (i.e., rates of endorsing sleeplessness were similar in those with and
without CSA within this subset of the sample). Next, an examination of CSA severity and
incident characteristics was conducted in the subset of individuals endorsing CSA. Here, CSA
severity, as well as all incident characteristics described earlier in the methods, were used as
predictors of sleeplessness. Survey methods were not used, as a reliable expected population
prevalence of MDD within individuals endorsing CSA would be needed. Given that only 2.7%
of MDD controls endorsed CSA, analyses of incident characteristics were not conducted given
scarcity of cell size for certain variables (e.g., five or fewer individuals endorsing certain
characteristics).

II. Results
Descriptive statistics. The sample consisted of 11,673 Han Chinese women, including
5,864 (~50%) cases with recurrent MDD, and 5,783 (~50%) controls. The mean (SD) age of the
sample was 46.1 (7.6). Approximately 58% of the full sample (N=6,439) endorsed suffering
from sleeplessness. Not surprisingly, endorsement of sleeplessness was significantly lower in
MDD controls (29%) vs. MDD cases (86%) (X2 = 4,000, df = 1, p < 0.0001). Prevalence for
individual trauma types are shown in Table 1 for the full sample, MDD cases, and MDD
controls. Endorsement of most traumatic events was higher in MDD cases than MDD controls,
with the two exceptions being fire, flood, or natural disaster and witnessed someone being badly
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injured or killed, whereas MDD cases did not significantly differ from MDD controls on
endorsement of these events. Table 2 shows correlations across individual trauma types (in the
full sample). The pattern of correlations among trauma types was as expected, with high
correlations between trauma types that were interpersonal in nature (rs ranging from 0.45-0.53,
all p values < 0.01 for rape, physical attack or assault, and threatened, held captive, or
kidnapped), particularly the child trauma specific items (rs ranging from 0.48-0.73, all p values <
0.01 for CSA, childhood physical abuse, and serious neglect, and rs ranging from 0.36-0.50, all p
values < 0.01 across child and other interpersonal traumas). Non-interpersonal events (e.g., fire,
flood, or natural disaster) were less correlated with interpersonal traumas (rs ranging from -0.010.33, not all correlations significant), as well as with each other (rs ranging from 0.10-0.24, all p
values < 0.01). Given that endorsement of interpersonal traumas was low in MDD controls (e.g.,
only 3 individuals (0.1%) endorsed rape and 22 (0.4%) endorsed being threatened, held captive,
kidnapped; see Table 1 below) and correlation patterns were broadly similar when examining
cases and controls separately, factor analyses were run within the full sample.
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Table 1. Prevalences of specific traumatic events by MDD case status
Total
(N, %)
541 (5.0)

MDD Ca
(N, %)
393 (7.3)

MDD Co
(N, %)
148 (2.7)

X2

p-value

120.20

< 0.0001

2. Threatened/held
captive/kidnapped
3. Rape1

109 (1.0)

87 (1.6)

22 (0.4)

39.06

< 0.0001

75 (0.7)

72 (1.3)

3 (0.1)

63.24

< 0.0001

4. Physical abuse (childhood)

300 (2.8)

248 (4.6)

52 (1.0)

133.76

< 0.0001

5. Serious neglect (childhood)

683 (6.3)

572 (10.7)

111 (2.0)

338.99

< 0.0001

6. Childhood sexual abuse

733 (6.8)

588 (11.0)

145 (2.7)

292.47

< 0.0001

7. Life-threatening accident

828 (7.6)

463 (8.6)

365 (6.7)

14.11

0.0002

8. Witness injury/death

868 (8.0)

451 (8.4)

417 (7.6)

2.03

0.1539

9. Fire, flood, or natural
disaster
10. Serious illness

1196 (11.0)

590 (11.0)

606 (11.1)

0.02

0.8793

1160 (10.1)

694 (12.1)

466 (8.1)

52.08

< 0.0001

11. Death of a loved one

2112 (18.4)

1149 (20.1)

963 (16.7)

22.38

< 0.0001

1. Physical attack/assault

Abbreviations: Ca = case; Co = control; MDD = major depressive disorder.
1
This variable was constructed so that it does not overlap with CSA (i.e., if rape was endorsed before the age of 16,
this was counted as CSA).
Note that all chi-squared tests were run on the 2x2 tables using a Yates continuity correction.
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Table 2. Cross-trauma type correlations (full sample)
1

2

1
0.45**

1

0.50**

0.53**

1

4. Physical abuse
(child)
5. Serious
neglect (child)
6. Childhood
sexual abuse
7. Death of a
loved one
8. Serious illness

0.41**

0.50**

0.45**

1

0.41**

0.45**

0.36**

0.73**

1

0.36**

0.43**

0.36**

0.49**

0.48**

1

0.02

0.06*

0.04

0.01

0.05

-0.01

1

0.09

0.16**

0.05

0.12*

0.17**

0.16**

0.13**

1

9. Life-threatening

0.30**

0.33**

0.29**

0.24**

0.25**

0.25**

0.10**

0.22**

1

10. Fire, flood, or 0.19* 0.17** 0.21** 0.17** 0.12** 0.05
natural disaster
11. Witnessed
0.11 0.24** 0.23** 0.27** 0.23** 0.17**
injury/death
*
p < 0.05; **p < 0.01.
Note that correlations are tetrachoric, as all items are binary (yes/no).

0.14**

0.15**

0.24**

1

0.12**

0.14**

0.21**

0.23**

1. Rape
2. Physical
attack/assault
3. Threatened, held

3

4

5

6

7

8

9

10

11

captive, kidnapped

accident
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1

Factor analysis of trauma type. To determine the factor structure of the different trauma
type variables within this sample and provide support for the creation of composite trauma
variables for use in later regression analyses, exploratory and confirmatory factor analyses were
conducted within the full CONVERGE sample (both MDD cases and MDD controls). Parallel
analysis was run to ascertain how many dimensions may be present for the associations among
the different trauma types. A Scree plot showing these parallel analysis results, as well as the
Kaiser rule (line marking eigenvalues equal to 1) is shown in Figure 2. Parallel analysis
suggested the presence of 4 factors, as seen here.

Figure 2: Scree plot and parallel analysis for EFA of trauma type. This figure shows a Scree
plot with the number of factors on the y-axis and the eigen values of the principal factors on the
y-axis. The solid black line represents an eigen value cutoff of 1. As indicated in the legend, the
blue triangles mark the eigen values from the actual data, while the dashed red lines show
simulated and resampled data, representing results of parallel analysis.
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Based on these results, 1-, 2-, 3-, 4-, and 5-factor EFAs were run using the Psych
package275 in R. The EFAs were run using a minimum residual (ordinary least squares) method,
missing data was treated “pairwise”, and tetrachoric correlations were estimated since all trauma
variables were coded as binary. Additionally, a GeominQ (oblique) rotation was implemented
because it was expected that the factors would be correlated (see Table 3 for factor loadings and
Table 4 for factor correlations for all EFAs). Next, CFAs were fit for 1-, 2-, and 3-common
factor model specifications (the 4- and 5-factor solutions were not examined in the CFAs, since
these solutions resulted in some poorly identified factors), using the R package lavaan, which is a
structural equation modeling package.279 Models were developed based on the data driven EFA
results, treating the observed trauma variables as ordered categorical indicators and utilizing a
WLSMV estimator with a theta parameterization. CFA model fitting results indicated that a 3factor solution, with interpersonal (3 items), child interpersonal (3 items), and non-assaultive (5
items) factors, had the best fit to the data, since it had the lowest RMSEA and X2. Model fit
comparisons for the 1-, 2-, and 3- factor CFAs are shown in Table 5. The trauma items that
loaded predominantly on each of the factors, as well as the standardized factor loadings for the 3factor solution and factor correlations are shown in Figure 3.

47

Table 3. Factor loadings from 1-, 2-, 3-, 4-, and 5-factor EFAs

1-factor
2-factor
3-factor

4-factor

5-factor

Rape

Factor

Physical
attack/
assault

Threatened/
held
captive/
kidnapped

Serious
neglect
(child)

Physical
abuse
(child)

Childhood
sexual
abuse

1
1
2
1
2
3
1
2
3
4
1
2
3
4
5

0.67
0.54
0.21
0.80
0.18
0.09
0.58
0.13
0.09
0.02
0.66
-0.01
0.12
0.01
0.00

0.59
0.52
0.15
0.57
0.12
0.00
0.61
0.05
0.02
-0.02
0.03
0.97
0.03
0.01
0.00

0.62
0.62
0.08
0.55
-0.02
-0.02
0.80
-0.01
-0.01
-0.27
0.74
0.04
-0.01
0.02
-0.25

0.76
0.06
0.83
-0.03
0.89
0.02
0.06
0.73
0.04
0.16
-0.02
0.07
0.79
0.00
0.07

0.79
-0.02
0.79
0.16
0.74
-0.01
-0.02
0.96
-0.01
-0.05
0.03
-0.01
0.90
0.03
-0.14

0.61
0.18
0.47
0.26
0.42
-0.01
0.37
0.28
-0.02
0.27
0.37
0.01
0.32
-0.14
0.17

Fire/flood/
natural
disaster

0.25
0.48
-0.17
0.15
-0.08
0.42
0.03
0.04
0.49
-0.25
-0.01
0.06
0.02
0.58
-0.07

Serious
illness

0.21
0.22
0.02
-0.11
0.12
0.41
-0.02
0.01
0.42
0.25
0.01
0.00
0.03
0.29
0.42

Abbreviations: EFA = exploratory factor analysis.
Loadings for each specific factor are in bold.

Table 4. Factor correlations from 1-, 2-, 3-, 4-, and 5-factor EFAs
1*2
1*3
2*3
1*4
2*4
3*4
1*5
-------1-Factor
0.67
------2-Factor
0.57
0.37
0.32
----3-Factor
0.65
0.36
0.30
0.08
0.11
0.03
-4-Factor
0.60
0.64
0.41
0.35
0.20
0.22
0.15
5-Factor
Abbreviations: EFA = exploratory factor analysis.
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2*5
----0.02

3*5
----0.19

4*5
-----0.02

Lifethreatening
accident

0.41
0.55
-0.07
0.25
0.01
0.40
0.31
-0.05
0.39
0.07
0.30
0.05
-0.03
0.29
0.19

Witnessed
someone
injured/
killed

Death of a
loved one

0.34
0.31
0.08
0.07
0.12
0.34
0.02
0.19
0.34
-0.10
0.19
-0.15
0.16
0.32
0.00

0.07
0.22
-0.13
-0.07
-0.04
0.34
-0.05
-0.04
0.32
-0.02
-0.01
-0.02
-0.04
0.29
0.12

Table 5. Model comparisons for CFA
X2
1-Factor Model
276.60
2-Factor Model
175.65
3-Factor Model
91.19

df
44
43
41

p-value
< 0.0001
< 0.0001
< 0.0001

RMSEA (90% CI)
0.022 (0.020-0.025)
0.017 (0.014-0.020)
0.011 (0.008-0.014)

Abbreviations: CFA = confirmatory factor analysis; df = degrees of freedom; RMSEA = root mean square error of
approximation.
Note that the best-fit solution is bolded.
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Figure 3: Results of the best-fit 3-factor CFA solution for trauma type. The identified factors
were interpersonal, child interpersonal, and non-assaultive traumas. The items that comprise each
factor are displayed, with individual loadings shown on the paths. Factor correlations are
presented on double-headed arrows at the top.

Creation of trauma type and timing variables. Using results of the CFA, trauma sum
score variables that incorporated the trauma type structure determined above, in addition to the
age at first onset information available for each trauma, were created. Childhood events were
defined as occurring before the age of 16. Thus, the following four trauma variables were
constructed: 1) child interpersonal; 2) child non-assaultive; 3) adult interpersonal; and 4) adult
non-assaultive. Interpersonal traumas represented across both age groups included rape, physical
attack or assault, and threatened, held captive, or kidnapped. The three child interpersonal items
(from the CFA) were included in the child interpersonal variable only (i.e., CSA, physical abuse,
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serious neglect). The remaining five traumas (death of a spouse, child, or sibling; serious illness;
life-threatening accident; fire, flood, or natural disaster; and witnessed someone badly injured or
killed) were considered to be non-assaultive traumatic events. Given sum score distributions
(most individuals endorsed either 0 or 1 for each event category), each trauma variable was
collapsed into a binary yes/no item, with “yes” indicating that the individual endorsed at least
one event in that category, due to scarcity of cell sizes.
Descriptive statistics for the computed trauma category variables, within the full sample
and separated by MDD case status, are shown in Table 6. Adult non-assaultive traumas were the
most commonly endorsed category. The prevalences of all four variables were significantly
higher in MDD cases (vs. MDD controls). Figure 4 displays the endorsement of sleeplessness
across each trauma category for the full sample, MDD cases only, and MDD controls only.
Significantly more individuals with at least one child interpersonal trauma in the full sample and
MDD control group endorsed sleeplessness, but this did not differ for MDD cases. For all other
trauma categories (child non-assaultive, adult interpersonal, adult non-assaultive), individuals
endorsing at least one event from that trauma category endorsed sleeplessness at a higher rate,
and this was true for all subsets of the sample examined (full, MDD cases, MDD controls), with
the exception of adult interpersonal trauma in MDD controls, which was nominally significant (p
< 0.10). Finally, correlations between trauma and sleeplessness across the sample are presented
in Table 7. There were modest but significant correlations (all p values < 0.01) between all
trauma variables and sleeplessness within the full sample, and these were higher for interpersonal
traumas (0.31 for child, 0.25 for adult) than non-assaultive (0.12 for child, 0.14 for adult)
traumas. For MDD cases, all traumas except for child interpersonal were significantly correlated
with sleeplessness (range 0.07-0.13, p values <0.05, for those that were significant). In contrast,
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all traumas except for adult interpersonal (range 0.13-0.15, all p values < 0.01) were significantly
correlated with sleeplessness in MDD controls.

Table 6. Prevalence of composite trauma variables by MDD case status
Child IP
Child N-A
Adult IP
Adult N-A

Total
(N, %)

MDD Ca
(N, %)

MDD Co
(N, %)

X2

p-value

1268 (11.7)
900 (8.3)
563 (5.2)
3669 (33.9)

1008 (18.8)
483 (9.0)
410 (7.6)
1954 (36.4)

260 (4.8)
417 (7.6)
153 (2.8)
1715 (31.4)

512.78
127.43
6.35
29.65

< 0.0001
< 0.0001
0.0117
< 0.0001

Abbreviations: Ca = case; Co = control; IP = interpersonal trauma; MDD = major depressive disorder; N-A = nonassaultive trauma.
Note that all chi-squared tests were run using a Yates continuity correction. Child IP includes CSA, childhood
physical abuse, severe neglect, physical assault, and threatened held/captive/kidnapped with age of first occurrence
before age 16. Similarly, adult IP includes rape, physical assault, and threatened/held captive/kidnapped with onset
at age 16 or older. Child N-A includes fire, flood, or natural disaster, serious illness, life-threatening accident,
witnessed someone badly injured or killed, and death of a child, spouse, or sibling, endorsed before age 16. Adult NA includes the same traumas as child N-A, but only those that had age of onset at 16 or older.
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+ p < 0.10; * p < 0.05; ** p < 0.01; *** p < 0.001.

Figure 4: Sleep endorsement across trauma type in different subsets of the sample. This
figure shows endorsement of sleeplessness by trauma type (child interpersonal, child nonassaultive, adult interpersonal, adult non-assaultive) for each subset of the sample (full sample,
MDD cases, MDD controls), with percentage shown on the y-axis and N on each bar. Asterisks
indicate significance of chi-squared tests across groups.

Table 7. Tetrachoric correlations between trauma variables and sleeplessness
GS, Full sample
GS, MDD Ca
GS, MDD Co
Child IP
0.31 (0.27-0.34)**
0.00 (-0.07-0.06)
0.16 (0.09-0.23)**
Child N-A
0.12 (0.07-0.17)**
0.09 (0.01-0.18)*
0.13 (0.06-0.19)**
Adult IP
0.25 (0.19-0.30)**
0.13 (0.05-0.21)**
0.09 (-0.01-0.19)
Adult N-A
0.14 (0.11-0.17)**
0.07 (0.13-0.18)**
0.13 (0.08-0.18)**
*p < 0.05; **p < 0.01.
Abbreviations: Ca = case; Co = control; GS = general sleep item; IP = interpersonal trauma; MDD = major
depressive disorder; N-A = non-assaultive trauma.

Hierarchical logistic regression models. Hierarchical logistic regressions were conducted
to examine the effects of child and adult trauma types, and their potential interactions, on
sleeplessness. Analyses were conducted three separate ways in order to best examine effects of
and account for ascertainment bias. First, in the primary model, the full sample was used, with
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MDD status as a covariate. This served as the basis for later genetic analyses within the full
sample to maximize power. Second, a survey approach was used to simulate an MDD prevalence
of 8% and served as a validity check for the first approach, determining whether results were
stable. Finally, analyses were run separately in MDD cases and MDD controls given differences
in ascertainment. This was also done to facilitate the creation of a combined genetic and
environmental model, as PRS analyses presented in Chapter 6 necessitated splitting the sample in
half based on case status. These results will be reviewed in turn.
Full sample, MDD covariate. Results for sleeplessness regressions run in the full sample
are presented in Table 8. Demographic covariates (i.e., age and case status), entered in Step 1,
were both significant predictors of higher odds of reporting suffering from sleeplessness (MDD
OR = 16.39, 95% CI = 14.84-18.14, p < 0.0001; age OR = 1.02, 95% CI = 1.02-1.03, p < 0.0001)
and Nagelkerke’s pseudo R2 was 0.41. In Step 2, both child (OR = 1.30, 95% CI = 1.11-1.54, p =
0.0017) and adult (OR = 1.53, 95% CI = 1.21-1.95, p = 0.0005) interpersonal trauma variables
were significantly associated with higher likelihood of endorsement of sleeplessness. Both age
and MDD remained significant at similar magnitudes to Step 1. The addition of the interpersonal
trauma variables increased the amount of variance in sleeplessness explained in comparison to
Step 1 (new pseudo R2 = 0.44). In Step 3, non-assaultive traumas, both child and adult, were
added into the final model. Both were significant predictors of sleeplessness (OR = 1.44, 95% CI
= 1.21-1.72, p < 0.0001 for child; OR = 1.33, 95% CI = 1.20-1.47, p < 0.0001 for adult). In this
model, both child and adult interpersonal traumas remained significant, with similar ORs, as did
MDD and age (pseudo R2 = 0.45). Model AIC decreased as trauma predictors were added in
Steps 2-3, suggesting a decrease in model misfit and providing support for the inclusion of all
traumas within the final model. The second set of hierarchical regressions aimed at examining
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the potential interactive effect of type and timing began with the final model from above, which
included all trauma categories. Interaction terms for child x adult interpersonal traumas and child
x adult non-assaultive traumas were then added to this model in a step-wise fashion. Neither of
these interaction terms was significant (p = 0.0755 [interpersonal] and p = 0.3347 [nonassaultive] in the final model).

Table 8. Results of hierarchical logistic regressions examining the effects of trauma type and
timing on sleeplessness in the full sample
OR
95% CI
p-value Pseudo R2
AIC
ΔAIC
MDD
16.39 14.84-18.14 < 0.0001
0.41
11109.65
-Step 1:
Demographics
Age
1.02
1.02-1.03
< 0.0001
MDD
15.85 14.29-17.60 < 0.0001
0.44
10769.77 -339.88
Step 2:
Interpersonal
Age
1.03
1.02-1.03
< 0.0001
Child IP
1.30
1.11-1.54
0.0017
Adult IP
1.53
1.21-1.95
0.0005
MDD
15.81 14.25-17.57 < 0.0001
0.45
10722.71 -47.06
Step 3:
NonAge
1.02
1.02-1.03
< 0.0001
assaultive
Child IP
1.23
1.04-1.45
0.0140
Adult IP
1.43
1.13-1.82
0.0034
Child N-A 1.44
1.21-1.72
< 0.0001
Adult N-A 1.33
1.20-1.47
< 0.0001
Abbreviations: AIC = Akaike Information Criterion; IP = interpersonal trauma; MDD = major depressive disorder;
N-A = non-assaultive trauma.
Note: Pseudo R2 is Nagelkerke’s.

Full sample, survey approach. Results for regressions using the survey method (R
package: survey283,284), conducted to examine effects of trauma on sleeplessness in a more
representative sample, are presented in Table 9. Survey weights were computed such that MDD
cases counted for 8% of the sample and MDD controls the remaining 92%. This allowed for a
more population-based estimate without the loss of data that would occur using random sampling
(i.e., take all MDD controls and a random subset of MDD cases). MDD was not used as a
covariate since the population prevalence of MDD was already incorporated into the models.
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Since this is a variation of a generalized linear model, pseudo R2 values cannot be computed.
However, AIC can be calculated using specific algorithms (see survey package documentation)
and is used here to compare models, as was done across all three approaches presented. In Step
1, age was not a significant predictor of sleeplessness. Both child (OR = 2.26, 95% CI = 1.852.75, p < 0.0001) and adult (OR = 1.60, 95% CI = 1.22-2.10, p = 0.0007) interpersonal traumas
were significant predictors of sleeplessness when added in Step 2. Finally, both child (OR =
1.39, 95% CI = 1.15-1.67, p = 0.0006) and adult (OR = 1.35, 95% CI = 1.21-1.51, p < 0.0001)
non-assaultive traumas significantly predicted sleeplessness in Step 3, and child and adult
interpersonal traumas remained significant at similar magnitudes. The AIC decreased in Steps 2
and 3, suggesting that the final model, which contains all trauma categories, results in a decrease
in overall misfit. When interaction terms were added hierarchically, as done above, there were no
significant interactions between child and adult interpersonal or child and adult non-assaultive
traumas (p values of 0.9687 and 0.5880, respectively).

Table 9. Results of hierarchical logistic regressions examining the effects of trauma type and
timing on sleeplessness utilizing a survey-based approach
OR
95% CI
p-value
AIC
ΔAIC
Step 1:
Demographics
Age
1.00
1.00-1.01
0.5138
13963.84
-Age
1.01
1.00-1.02
0.0956
13724.33
-239.51
Step 2:
Interpersonal
Child IP
2.26
1.85-2.75
< 0.0001
Adult IP
1.60
1.22-2.10
0.0007
Age
1.00
1.00-1.01
0.3292
13657.79
-66.54
Step 3:
Non-assaultive
Child IP
2.12
1.73-2.58
< 0.0001
Adult IP
1.50
1.14-1.97
0.0037
Child N-A
1.39
1.15-1.67
0.0006
Adult N-A
1.35
1.21-1.51
< 0.0001
Abbreviations: AIC = Akaike Information Criterion; IP = interpersonal trauma; N-A = non-assaultive trauma.
Note: Pseudo R2 not available due to survey approach.
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Separate case/control analyses. a) Controls. Results for MDD controls only are
presented in Table 10. Age was a significant predictor of sleeplessness in Step 1 (OR = 1.02,
95% CI = 1.01-1.03, p < 0.0001), with a model pseudo R2 of 0.01. In Step 2, child interpersonal
trauma (OR = 1.77, 95% CI = 1.37-2.29, p < 0.0001) significantly predicted sleeplessness, but
adult interpersonal trauma was only nominally significant (OR = 1.35, 95% CI = 0.95-1.89, p =
0.0882). Age remained significant in this model and the pseudo R2 increased to 0.02. In Step 3,
where all traumas were included, both child (OR = 1.45, 95% CI = 1.17-1.79, p = 0.0005) and
adult (OR = 1.32, 95% CI = 1.16-4.33, p < 0.0001) non-assaultive traumas were significant, age
and child interpersonal trauma remained significant, and adult interpersonal trauma was no
longer nominally significant. The pseudo R2 was 0.02 in the final model. Once again, there were
substantial decreases in AIC across models, indicating that the model containing all traumas is
appropriate. No interaction terms were significant when added to this final model (p values =
0.8936 [interpersonal] and 0.8858 [non-assaultive]) and thus are not reported in the tables.

Table 10. Results of hierarchical logistic regressions examining the effects of trauma type and
timing on sleeplessness in MDD controls only
OR
95% CI
p-value Pseudo R2
AIC
ΔAIC
Step 1:
Demographics
Age
1.02
1.01-1.03
< 0.0001
0.01
6496.11
-Age
1.03
1.01-1.04
< 0.0001
0.02
6475.68 -20.43
Step 2:
Interpersonal
Child IP
1.77
1.37-2.29
< 0.0001
Adult IP
1.35
0.95-1.89
0.0882
Age
1.02
1.01-1.03
< 0.0001
0.02
6445.92 -29.76
Step 3:
NonChild IP
1.65
1.27-2.13
0.0002
assaultive
Adult IP
1.27
0.89-1.78
0.1801
Child N-A 1.45
1.17-1.79
0.0005
Adult N-A 1.32
1.16-4.33
< 0.0001
Abbreviations: AIC = Akaike Information Criterion; IP = interpersonal trauma; N-A = non-assaultive trauma.
Note: Pseudo R2 is Nagelkerke’s.
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b) Cases. Results for MDD cases only are presented in Table 11. Age was a significant predictor
of sleeplessness in Step 1 (OR = 1.02, 95% CI = 1.02-1.03, p < 0.0001), with a pseudo R2 of
0.02. In Step 2, adult interpersonal (OR = 1.75, 95% CI = 1.25-2.51, p = 0.0016) but not child
interpersonal trauma was significant, and age continued to predict sleeplessness with a similar
magnitude. Nagelkerke’s pseudo R2 increased to 0.11. When the non-assaultive trauma terms
were added in Step 3, both were significant (OR = 1.41, 95% CI = 1.05-1.94, p = 0.0263 for
child; OR = 1.33, 95% CI = 1.12-1.58, p = 0.0013 for adult). The other variables remained
similar to Step 2 and the pseudo R2 increased to 0.12. AIC decreased across models, similar to
prior regressions, indicating that the final model is more parsimonious and has less misfit than
initial models. Interestingly, when a multiplicative interaction term was added for child x adult
interpersonal trauma, this was significant. This remained significant in the final model where the
child x adult non-assaultive trauma multiplicative interaction (itself non-significant) was added,
with a final effect of OR = 0.43 (95% CI = 0.21-0.87, p = 0.0190, AIC = 4273.61, change in AIC
from model with no interaction = -4.57). This suggests that the combined effect of child
interpersonal and adult interpersonal traumas is less than multiplicative on the odds-ratio scale,
but will not be discussed further since it is scale-dependent and the decrease in model misfit (i.e.,
decrease in AIC) may not be biologically meaningful.
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Table 11. Results of hierarchical logistic regressions examining the effects of trauma type and
timing on sleeplessness in MDD cases only
OR
95% CI
p-value Pseudo R2
AIC
ΔAIC
Step 1:
Demographics
Age
1.02
1.02-1.03 < 0.0001
0.02
4615.54
-Age
1.03
1.02-1.04 < 0.0001
0.11
4290.44 -325.10
Step 2:
Interpersonal
Child IP 1.07
0.88-1.32
0.4905
Adult IP 1.75
1.25-2.51
0.0016
Age
1.02
1.01-1.03 < 0.0001
0.12
4278.18 -12.26
Step 3:
NonChild IP 1.03
0.84-1.27
0.7963
assaultive
Adult IP 1.63
1.17-2.35
0.0059
Child N-A 1.41
1.05-1.94
0.0263
Adult N-A 1.33
1.12-1.58
0.0013
Abbreviations: AIC = Akaike Information Criterion; IP = interpersonal trauma; N-A = non-assaultive trauma.
Note: Pseudo R2 is Nagelkerke’s.

CSA analyses. To examine the effects of one particularly potent form of childhood
trauma, CSA, and incident characteristics associated with it, on sleeplessness, a series of
univariate logistic regressions were conducted. Results of CSA analyses within the full sample,
using the primary method (co-varying for MDD status), are presented in Table 12. MDD and age
were included as covariates in these models. Broad CSA, examined across all individuals, was a
significant predictor of higher odds of endorsing sleeplessness (OR = 1.28, 95% CI = 1.04-1.58,
p = 0.0202) within the full sample. Similar results, although with a larger effect for CSA, were
seen using the survey method (OR = 2.30, 95% CI = 1.77-2.98, p < 0.0001). The subsequent
analyses examining incident characteristics were restricted to only individuals endorsing CSA (N
= 730), as this was a requirement for answering the follow-up questions, and are also shown in
Table 12. CSA severity did not differentially predict sleeplessness, and none of the other incident
characteristics were significant predictors of sleeplessness. Given this, no items were included in
a combined regression. A survey approach was not used here due to the restriction of the sample
to CSA cases only. As endorsement of CSA was much lower in MDD controls than MDD cases
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and there was scarcity of cells across many incident characteristics for MDD controls only,
analyses were not conducted separately.

Table 12. Regression models examining the effects of CSA
and CSA characteristics on sleeplessness in the full sample
with MDD covariate
Item
Childhood sexual
abuse (CSA)
CSA severity
Genital
Intercourse
Intercourse vs. other
forms of CSA
Age at time of abuse
Age of perpetrator
Under 15 years
15-18 years
19-24 years
25-50 years
> 50 years
Gender of perpetrator
Male vs.
female or both
Abuse by a relative
Relative vs. nonrelative or stranger
Forced or threatened
Maybe
Definitely
How affected at the
time

Prevalence
733 (6.8)

Univariate
regression (OR)
1.28 (1.04-1.58)*

287 (39.3)
176 (24.1)
176 (24.1)

0.84 (0.54-1.28)
1.32 (0.78-2.30)
1.45 (0.90-2.41)

12.22 + 5.19

1.01 (0.98-1.05)

91 (12.5)
140 (19.2)
158 (21.6)
316 (43.3)
57 (7.8)

0.79 (0.46-1.40)
1.43 (0.87-2.41)
1.07 (0.68-1.71)
1.00 (0.68-1.47)
0.58 (0.31-1.12)

670 (91.8)

1.09 (0.54-2.10)

227 (31.1)

0.9 (0.63-1.45)

121 (16.6)
102 (14.0)
2.01 + 2.17

0.92 (0.55-1.56)
1.35 (0.74-2.57)
1.05 (0.95-1.15)

*p < 0.05.
Note that the all analyses were run with both age and MDD as covariates.
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III. Discussion
Here, a novel examination of trauma type and timing within a large Han Chinese sample
is presented, and this information is used to examine the relationship between trauma and sleep
in more detail. This is one of the first studies to date to explicitly examine whether sleeplessness
differs across trauma types and to examine the factor structure of trauma type within a Chinese
sample. There are three main findings to be discussed in this section: 1) a three-factor solution
was the best-fit for trauma type, with the three factors representing interpersonal trauma, child
interpersonal trauma, and non-assaultive trauma; 2) hierarchical regressions indicated that all
trauma categories (child interpersonal, adult interpersonal, child non-assaultive, adult nonassaultive) were significant, unique predictors of sleep within this sample, and that effect sizes
were similar across trauma categories, although there were some differences when cases and
controls were modeled separately and when using a population-based approach; and 3) broad
CSA, but not individual incident characteristics, was a significant predictor of sleeplessness
within this sample.
Prevalence of traumatic events. Overall, endorsement of traumatic events within
CONVERGE is lower than what is seen in population samples such as the WMHSC65 and the
NCS.69 However, within the WMHSC data (where men/women were combined), the prevalence
of any traumatic event in China (52.5%) was lower than the overall prevalence worldwide
(70%), and individuals from China were less likely to report traumas across most
events/categories, including those that are interpersonal in nature (i.e., interpersonal violence,
intimate partner/sexual violence). Exceptions included collective violence and man-made
disaster, where ORs did not differ for individuals from China. This should be considered when
making comparisons. Note that death of a loved one was the trauma with the highest
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endorsement in both CONVERGE (18.4% in the full sample) and the WMHSC (31%; higher OR
for women). Particularly striking is the low prevalence of interpersonal traumas within the
CONVERGE sample, even when examined in MDD cases only. For example, being
mugged/threatened with a weapon was endorsed by 14.5% of individuals in WMHSC (not
separated by sex; although being female was protective for endorsement of this event) and 6.8%
of women in the NCS, but only 1.0% of the total sample (and 1.6% of MDD cases) here
endorsed being threatened, held captive, or kidnapped. Further, only 0.7% of CONVERGE
(1.3% of MDD cases) endorsed rape, while reported estimates for rape were 3.2% in the
WMHSC and 9.2% for women in the NCS. In sum, endorsement of traumatic events is low in
CONVERGE. One might expect that rates of interpersonal traumas would be higher given that
half the sample has MDD and SLEs are strongly linked to the disorder (e.g., 82) and the sample is
all female,69,70 but it is possible that under-reporting and cultural differences are at play, similar
to what is hypothesized for lower MDD prevalence (e.g., 45,46,47).
Factor analysis of trauma type. Traumatic events within CONVERGE were factor
analyzed in order to better understand how these events cluster within the population, as this has
not been done yet for a Chinese sample. A 3-factor solution for trauma type, with interpersonal,
child interpersonal, and non-assaultive factors was the best fit, with the interpersonal and child
interpersonal factors highly correlated, as expected (0.76). These results are similar to other
factor analyses of trauma type in different samples that show a separation of interpersonal and
non-assaultive traumas. For example, Stein and colleagues94 found a 2-factor solution from a
principal component analysis of nine traumas in a veteran twin sample (comprised of both males
and females), with Factor 1 representing “assaultive” events (e.g., robbery; sexual assault) and
Factor 2 representing “non-assaultive events (e.g., motor vehicle accident; tornado, flood,
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earthquake). Note that none of these traumas were specific to childhood. Benjet and colleagues65
had access to a much wider range of traumatic events within the WMHSC data (29 in total) than
available in CONVERGE (and Stein et al.94) and EFAs were conducted using data on both sexes.
Five distinct factors (with a sixth that encompassed other events) were found: exposure to
collective violence (e.g., civilian in war zone, refugee); causing/witnessing bodily harm to others
(e.g., combat); interpersonal violence (e.g., beaten up; this factor includes events in childhood);
intimate partner or sexual violence (e.g., rape); accidents and injuries (e.g., natural disasters).
The factor solution presented here is similar to the interpersonal violence, intimate partner or
sexual violence, and accidents and injuries factors, with some exceptions as to what items loaded
where (e.g., traumatic event to loved one loaded on the intimate partner or sexual violence factor
in Benjet et al.,65 while similar items from CONVERGE, such as death of a loved one, loaded
onto the non-assaultive factor).
These results are unique in that a separate factor for child interpersonal traumas was
identified in the context of other traumatic events that occur mostly during adulthood, indicating
that these childhood events in particular cluster together. Prior studies of childhood adversities
demonstrate that events are related and often co-occur, with individuals exposed to one event
more likely to be exposed to others.285-288 In several studies of population data, sexual abuse,
physical abuse, and neglect all loaded strongly onto one factor representing “maladaptive family
functioning” along with several other child adversity variables,285,287,288 supporting shared
etiology and aligning with the results demonstrated here. Another recent study of 18 childhood
events (defined as occurring before age 18) considered to be “traumatic or extremely stressful”
also found that CSA, physical abuse, and neglect/poverty loaded onto one factor, along with
emotional abuse, bullying, and domestic violence.93 Thus, childhood traumas (and their resultant
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sequelae) are likely a product of the overall environment that occurs in childhood (factors
influencing this can be related to the specific child, parent, family as a whole, community, and
even society289) and thus often do not occur in isolation.
Further, this child trauma factor was highly correlated with the interpersonal trauma
factor. This is consistent with prior studies of revictimization, which suggest that individuals
exposed to sexual abuse in childhood are more likely to experience sexual assault as adolescents
or adults.290-294 A wide range of approaches have been used to investigate correlates of
revictimization, examining predictors such as prior psychopathology (e.g., PTSD, alcohol use)
and risky sexual behavior, among other intrapersonal factors (e.g., 290). Personality may also
contribute. Several studies show that childhood abuse is related to higher neuroticism and
openness,295,296 and openness could result in higher risk-taking behavior, thus selecting
individuals into situations that could increase the likelihood of sexual assault. This could be a
result of gene-environment correlation, as personality dimensions have been shown to be
heritable.101 Revictimization may also have a genetic influence in that both childhood abuse and
rape/sexual assault could share similar genetic underpinnings, which is in line with the literature
suggesting that interpersonal traumas are heritable.94,96,97 Mechanisms could also be acting
through the environment. There is a wealth of literature suggesting that early exposure to
traumatic events (i.e., during sensitive periods) has lasting effects on the stress response system,
resulting in sensitization and changes in how the individual responds to future stressors (e.g., 297299

). A limitation of these results is that age for traumas other than CSA, childhood physical

abuse, and serious neglect was not used within the factor analysis. Overall, factor analyses
demonstrate that the structure of traumatic events is similar in the Chinese population, despite
low endorsement of many events, and highlight the significance of both type and timing (i.e.,
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separate child interpersonal factor). Based on factor analytic results, both trauma type and timing
were incorporated into final trauma type categories such that effects of timing on each type of
event were considered.
Hierarchical regressions, trauma and sleeplessness. Results of hierarchical logistic
regressions indicated that all trauma types (child interpersonal, adult interpersonal, child nonassaultive, adult non-assaultive) had unique effects on the endorsement of sleeplessness, and that
the relative potency of each event category (i.e., through comparison of ORs and 95% CIs) was
similar, with exposure to at least one traumatic event in that category resulting in higher risk for
sleeplessness. Results remained similar when a survey approach was used to simulate a
population prevalence of 8% for MDD (i.e., control individuals were weighted so that they
encompassed 92% of the sample and cases were weighted to encompass 8% in order to more
closely model a population sample, as done in CONVERGE genetic analyses,300 instead of using
MDD as a covariate), although there was potency found for child interpersonal trauma as related
to sleeplessness using this method. Further, there were some differences observed when analyses
were run separately in cases and controls, discussed below. In general, these results were
contrary to initial hypotheses, where it was expected that interpersonal traumas would be
stronger predictors than non-assaultive traumas and that child traumas would be more potent
than adult traumas. This may differ depending on subset of the sample used, which highlights the
importance of appropriate sample selection. The different approaches will be discussed in turn.
Within analyses of the full sample (including MDD covariate), all traumatic event
categories (child interpersonal, child non-assaultive, adult interpersonal, adult non-assaultive)
were significant predictors of sleeplessness at similar magnitudes. This is in contrast to the small
body of trauma and sleep literature where interpersonal traumas have been shown to be more
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potent predictors of sleep disturbances than accidental traumas.147,148 In a recent paper examining
trauma and sleep in college students, it was shown that although accidental traumas were
significant predictors of sleep individually, they were no longer significant when included in a
model with interpersonal traumas.148 Interpersonal events also predicted more severe insomnia
within an urban sample147 and a study of childhood adversity and insomnia in adolescence found
that exposure to interpersonal violence (e.g., rape) resulted in the highest risk for insomnia.153
The lack of differential predictions seen here could be due several different factors. First,
ascertainment may be contributing, as this sample is not representative of the more general
Chinese population and the MDD covariate does not necessarily account for differences.
Additionally, while one might expect that the age range of the study (30-60) would result in
more variation in sleep responses since the endorsement of sleep problems increases with age,166
high rates of endorsement for sleep within MDD could be masking effects. Second, the
sleeplessness item may not be an appropriate proxy for insomnia. It could be that these
relationships are only seen at a more clinically significant level of sleep disturbances. Third, as
discussed earlier, population prevalences of traumatic events were lower across the sample, as
were correlations between trauma and sleep, which could be contributing to smaller effects seen
here, especially if acting in combination with the non-specific sleep item used here. Despite the
lack of specificity for trauma type, note that effect sizes for each trauma category were relatively
modest (ORs ranged from 1.23 – 1.44 in the final model) in comparison to the large effect of
MDD specifically (OR = 15.81 in the final model) on sleeplessness, yet trauma exposure was
still significantly associated with higher odds of experiencing sleeplessness. MDD within this
sample is likely more severe than that of other samples examining trauma and sleep and taking
into account psychopathology (e.g., 153).
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Additionally, child interpersonal traumas more specifically did not have larger effects on
sleep than other traumas within these analyses, which is in contrast to the extant literature for
sleep and MDD (e.g., 92,93,153). Two papers using detailed analyses of type and timing showed
that childhood traumas/stressors resulted in higher risk for depression and anxiety when
compared to adult traumas, highlighting the importance of both type and timing.92,93 Further, a
recent study by Wang and colleagues153 examined trauma types and insomnia risk across
development (early childhood, middle childhood, adolescence), finding higher risk for insomnia
in individuals exposed to interpersonal violence during early childhood or adolescence (but not
middle childhood), although these results are difficult to interpret and cannot be extended to
adults. Findings could be due to ascertainment, particularly since there were no differences
across child interpersonal trauma and sleep for MDD cases, or an effect could be masked by
more proximal traumatic events accounting for the effects of earlier traumas. There were also no
significant interactions between child and adult interpersonal and child and adult non-assaultive
traumas. While initial hypotheses were based on the idea that individuals with child interpersonal
trauma might be more likely to endorse adult interpersonal traumas (i.e., revictimization) and
that this would then have more of an effect on sleep than endorsing one of these categories alone,
this was not the case here. In the study by Chu et al.,93 described above, interactions between
early life stressors and adult stressors were also tested, and were not significant predictors of
depression or anxiety. Thus, while many traumatic events do co-occur, their effects on sleep may
be distinct.
In contrast to analyses within the full sample, presented above, results from the survey
method demonstrated that child interpersonal trauma did have a larger effect than the other
trauma types (OR = 2.12, 95% CI= 1.73-2.58) on sleeplessness, although adult interpersonal
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trauma had the same magnitude as the others (all traumas were significant). This approach
minimized the contributions of MDD cases and modeled a population sample where MDD cases
and MDD controls were appropriately weighted. These results provide some support for larger
effects of child interpersonal trauma on sleep and align more closely with the literature presented
above (e.g., 147,148). The lack of difference in magnitude for adult interpersonal trauma suggests
that larger effects of interpersonal trauma on sleep seen in the literature may be driven by
exposure to child interpersonal traumas only. Indeed, prior studies showing larger effects for
interpersonal traumas on sleep did not focus on timing, and thus variables for events such as
sexual assault could encompass events that occurred in childhood.147,148 Given that
revictimization is common for sexual assault, it could be that this initial event has a stronger,
more persistent effect on disturbed sleep than subsequent traumas. Moreover, these results
highlight the importance of sample ascertainment in drawing conclusions and provide some
insight into the contradictory findings presented earlier. Based on this, it is likely that results
seen in the full sample are due to ascertainment biases that cannot be corrected for by including
MDD status.
There were also differences for interpersonal traumas when cases and controls were
analyzed separately. Adult interpersonal trauma was not a significant predictor of sleeplessness
in MDD controls. While this may seem contrary to prior results, the prevalence of the adult
interpersonal trauma variable was even lower within this subset of the sample (See Table 4) and
endorsement of the sleep item did not significantly differ by trauma endorsement. Thus, it is
possible that there is not enough power to detect effects of interpersonal traumas within this
subset of the sample, given low endorsement. Further, although the prevalence of sleep
disturbances within MDD controls broadly aligns with population estimates (although it is higher
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than some of what has been reported in China,2,4,6) it is possible that due to selecting specifically
for control individuals without recurrent MDD (and also without substance use and psychosis),
the sample does not represent insomnia risk in the general Han Chinese population. This could
result in underestimates of trauma prevalence, which could in turn be why effects on sleep are
not seen. On the other hand, it could also be that adult interpersonal traumas are not significantly
related to sleep when including other types of traumas, particularly when child interpersonal
traumas are included as well (see discussion in the prior paragraph regarding lack of differential
effects). Finally, as discussed earlier, the lack of specificity of the sleep item is also important to
consider.
For individuals with MDD, child interpersonal trauma was not a significant predictor of
sleeplessness. The endorsement of child interpersonal trauma did not differ based on
sleeplessness (refer to Figure 4), which is reflected in the regression results. This subset of the
sample is highly selected, such that all individuals have recurrent MDD and the majority
endorses sleeplessness, and thus there is not much variation here. Further, prevalence rates for
child interpersonal traumas are much higher in MDD cases than MDD controls. Thus, it is
probable that the lack of a significant finding is due to ascertainment rather than lack of effect, as
many studies across the literature report significant effects of child interpersonal traumas (e.g.,
CSA) on sleep,141,142 and some indicate that childhood interpersonal trauma is a more potent
predictor than all other traumas in predicting depression and anxiety (e.g., 93). However, in a
recent study, investigators found that childhood trauma was significantly associated with
cognitive dimensions of depression only, not other dimensions, which included insomnia.301
Within MDD cases, however, all other forms of trauma examined (adult interpersonal, child nonassaultive, and adult non-assaultive) were significant predictors of sleeplessness, aligning with
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earlier results and prior literature (i.e., that individuals endorsing any form of trauma vs. none
endorse more sleep disturbances),153, although there were no differences in terms of magnitude
of effect across these events. Thus, trauma endorsement, more broadly, is associated with more
sleeplessness in MDD cases, but it is difficult to understand the contributions of childhood
interpersonal trauma due to ascertainment.
In sum, examinations of trauma and sleeplessness showed associations between the
phenotypes within this large Han Chinese sample. Most trauma types were important at similar
magnitudes across all analyses run, with several exceptions: 1) child interpersonal trauma did not
predict sleeplessness in MDD cases; 2) adult interpersonal trauma did not predict sleeplessness
in MDD controls; and 3) child interpersonal trauma may have a larger effect on sleeplessness
than other traumas for individuals in a more general population (modeled via the survey
approach). Evidence for the potency of child interpersonal trauma in predicting sleeplessness
supports a more detailed examination of CSA.
CSA analyses. While it is well established that CSA has an effect on sleep in adults
decades after the abuse,141,142 this is the first study to examine the effects of this particularly
potent traumatic event on sleep in a Han Chinese population, as earlier studies have primarily
used European and European American samples. Similar to prior analyses of child interpersonal
trauma, broad CSA was a significant predictor of sleeplessness. The odds ratio of 1.28 (95% CI
= 1.04-1.58; co-varying for MDD status) for CSA predicting sleep here is similar to, although a
bit less than, what was found for CSA predicting insomnia symptoms in female twins within the
VATSPSUD sample (OR = 1.67, 95% CI = 1.35-2.06),151 despite sample differences. Note that
both samples were assessed for broad CSA using identical questions, but that CONVERGE has a
much lower CSA prevalence (6.8%) than the female twin sample used from VATSPSUD
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(30.1%),151 even when restricting to MDD cases only (11.0%). The samples also differed in
terms of sleep assessment (binary item assessing sleeplessness vs. quasi-continuous insomnia
symptom variable). The OR for CSA predicting sleeplessness in CONVERGE did increase to
2.30 (95% CI = 1.77-2.98) when the survey approach was used to model population prevalence,
suggesting that the effect may in fact be larger in a more population-based sample that is not
oversampled for MDD. This is closer to ORs for CSA predicting MDD in CONVERGE,130,131
and provides some evidence that a particularly potent child interpersonal trauma like CSA may
have a larger effect on sleep then other, more recent traumas, which is in line with the literature
outlined above.93 Overall, these results support that findings across CSA and sleep are robust and
do extend to the Han Chinese population, despite lower endorsement.
Upon examination of incident characteristics within individuals endorsing CSA in
CONVERGE, none of these items (or CSA severity) were significant predictors of sleeplessness.
Within the MDD literature, a dose-response relationship with CSA severity is documented (e.g.,
124,126

) and shown to replicate in CONVERGE.130,131 However, so far this has not been shown for

insomnia; it was not identified within VATSPSUD.151 Some argue that CSA severity is related to
both emotional and physical factors, and that these physical factors alone are not enough to
explain severity.302 Further, studies of incident characteristics in relation to sleep outcomes are
mixed,149,151,303,304 with some showing differential predictions. There is also variation within the
MDD literature, where this has been studied in more detail, with some evidence that certain
characteristics may be associated with greater risk for MDD following CSA (e.g., 128,303), while
others do not demonstrate differential impacts (e.g., 125). It could be that differential effects of
CSA severity and/or incident characteristics on sleep do exist, but cannot be detected here
because they are mediated through MDD/MDD symptoms. The severity of the abuse could be
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reflected in the development of early MDD, which could in turn result in more sleep disturbances
(see 305 for analyses of psychopathology mediating the relationship between broad CSA and
sleep). Additional analyses would be needed to further explore this and would require a sample
that is not oversampled for recurrent MDD.
Limitations. All results should be interpreted in light of five main limitations. First, there
is ascertainment bias, as the CONVERGE sample has been selected such that half of the women
have recurrent MDD, while the other half do not. As a result, the endorsement of sleeplessness
was much higher in MDD cases (86%) than in MDD controls (28%). This was addressed by
running trauma and sleep analyses using three different approaches, although there were also
differences that occurred in the endorsement of traumatic events (almost all higher in MDD
cases, but lower than population samples65,69) and across both trauma and sleep (MDD cases
with and without child interpersonal traumas endorsed sleeplessness at similar rates; MDD
controls with and without adult interpersonal traumas endorsed sleeplessness at similar rates),
which make it difficult to draw conclusions. Further, the MDD controls did not have a history of
psychosis, bipolar disorder, or substance use, which may not reflect the general population and
recurrent MDD may represent a more severe subset of individuals with the disorder. Second,
although there is detailed information on trauma type and timing and trauma assessment was
conducted through clinical interview, this information was collected retrospectively and the exact
temporal order of all lifetime traumas was unknown (e.g., if an event has occurred more than
once, only the age at first onset is known). There could also be reporting bias, given the
retrospective nature of assessment (i.e., reporting age of onset), and there may be underreporting, particularly for sensitive childhood events (e.g., CSA).306 The trauma list is not
exhaustive, and all events may not truly be DSM-IV Criterion A traumas, as this was not
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assessed. Third, and perhaps most importantly, the assessment of sleep within this sample was
not ideal, with only one subjective binary sleep item available on all individuals, assessed at the
lifetime level, which was not part of a verified sleep scale. However, assessments of disturbed
sleep tend to have high face validity.169 It is also recognized that endorsement of this general
sleep item may reflect other underlying sleep disorders, such as circadian rhythm disorders.
Fourth, analyses presented here are correlational and causal conclusions cannot be drawn.
Finally, generalizability is limited, as the sample is comprised solely of Han Chinese women.
There are several strengths worth noting. First, few studies specifically examining trauma
type and timing and sleep exist, making this investigation novel. Second, the detailed assessment
of traumatic events permitted the examination of factor structure and thus the specific influences
of type and timing within this sample. Third, the Han Chinese are an understudied population
with regard to analysis of trauma types and the relationship between CSA and sleep. Fourth, the
use of an all female sample is appropriate given that the prevalence of interpersonal traumas,69,70
sleep disturbances,2,13 and MDD44,49,50 are all higher in women. Fifth, since controls in
CONVERGE were ascertained to minimize the likelihood of developing recurrent MDD in the
future, the general sleep item endorsed in MDD controls is unlikely to be confounded by
experiencing sleep disturbances within MDD (or psychopathology such as substance use,
psychosis, or bipolar disorder).
Conclusions and Future Directions. Traumatic events separate into interpersonal and
non-assaultive types in a large, Han Chinese sample, and child interpersonal items (physical
abuse, neglect, CSA) in particular may represent a unique factor. This is largely consistent with
the prior literature, despite lower prevalences.65,69 However, regression analyses of trauma type
and timing predicting sleeplessness did not find differential effects for separate types of traumas,
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which is in contrast to the prior literature for sleep and psychopathology (e.g., 69,105,106,113,147,148).
However, results may differ in a more population-based sample, as there was some evidence
through survey-based methods (and examining MDD controls only) that child interpersonal
events in particular may exert stronger effects on sleep. Finally, a relationship between CSA and
sleep was replicated within this sample, but there was no evidence for specific effects of severity
or incident characteristics. Taken together, these results indicate that although certain trauma
types (i.e., interpersonal) are more potent predictors of internalizing disorders, effects on sleep
may vary depending on sample ascertainment (i.e., oversampling for MDD results in higher
endorsement of both trauma and sleep problems). Nevertheless, findings across CSA and sleep
do appear to extend to diverse populations and highlight the importance of assessing sleep
disturbances in individuals with CSA histories. More work is needed to examine relationships
between trauma type and timing and sleep in population samples with less ascertainment bias,
better sleep phenotypes, and trauma assessments with additional temporal information, and a
focus on child interpersonal trauma in particular may be warranted. This line of research has the
potential to identify individuals who may be at higher risk for experiencing poor sleep following
trauma and target interventions accordingly, and may also help prevent the development of
psychopathology.
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Chapter 4: Estimating heritability of sleep phenotypes through GCTA

I. Data analytic plan
The software program GCTA, which estimates the heritability of a trait based on the
additive effect of SNPs present within available genome-wide data, was used to obtain
heritability estimates. This method creates a GRM based on SNPs for all pairs of individuals in
the sample. The GRM is then used to predict phenotypic relatedness using a REML approach,
resulting in an estimate of the variance in the phenotype of interest that is due to SNPs.243 For
binary traits, the variance can be transformed to a liability scale by indicating the expected
population prevalence.307 Here, GCTA version 1.24.7 was used to create the GRM and obtain
heritability estimates. The GRM was constructed from 4.7 million hard-called SNPs that had a
genotype probability > 0.9, missing rate < 1%, MAF > 1%, and Hardy-Weinberg p value > 10-6
(see 300 for more details). Two north-south ancestry PCs (PC1 and PC2) out of 10 total were used
as covariates in all analyses (as done in prior genetic analyses of this sample220,300), and an MDD
covariate was used as appropriate (i.e., for analyses including both MDD cases and MDD
controls). The SDS variable was analyzed as a quantitative trait (quasi-continuous variable),
while all other sleep phenotypes were analyzed as binary variables, with the estimated population
prevalence of the trait included in all analyses to transform the estimates onto the liability scale
(see Table 13 for prevalence estimates used across variables).
Case-control power analyses were run in the GCTA-GREML power calculator,
http://cnsgenomics.com/shiny/gctaPower/). There was over 80% power to detect heritability for
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the SDS,250 and 100% power to detect heritability for combined MDD cases and MDD controls.
However, for separate analyses in MDD cases and MDD controls, power calculations indicated
only 52% power for the GS in MDD cases and 74% for the GS in MDD controls. Power
estimates were even lower (<30%) for the Adjusted GS and Item E8, given high endorsement
within the sample.

II. Results
To determine the SNP-based heritability of sleep phenotypes and to prioritize the
variables in subsequent GWAS analyses (Aim 2b), GCTA of all sleep phenotypes were
conducted. Results are shown in Table 13. The first four rows show estimates for sleep variables
that exist only in MDD cases, starting with the quasi-continuous trait (SDS), followed by binary
sleep variables. None of these GCTA analyses yielded heritability estimates of sleep variables
that were significant, with large standard errors and all p-values > 0.05. Similar results were seen
in the fifth row for the GS in MDD controls. The final four rows show results within the
combined sample of both MDD cases and MDD controls, utilizing the GS and the Adjusted GS
(which contained additional sleep information for MDD cases). When there was no adjustment
for MDD case status, both versions of the GS were heritable (8% for GS and 14% for Adjusted
GS, p-values < 0.05), as can be seen in lines 7 and 9 of Table 13, respectively. Including the
MDD covariate resulted in decreases in both estimates (~0 for GS and 1% for Adjusted GS),
with neither estimate remaining significant. Although there was not support for SNP-based
heritability for any of the sleep variables examined in CONVERGE, the SDS in MDD cases
(quantitative trait and thus higher power than case/control analyses with a large number of cases)
and the Adjusted GS (with MDD covariate) in the full sample (which incorporates the most
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information across all individuals) are discussed in detail in subsequent GWAS analyses.

Table 13. Estimates of SNP-based heritability for sleep phenotypes generated from GCTA*
Covariates1 Specified
Sample
N
H2
SE
p-value
disease
prevalence (scaled to
(Ca/Co)
prevalence)

prevalence

SDS

2

5069

PCs

MDD Cases only
---

0.00

0.06

0.50

2.58 (0.79)

GS

5116

PCs

0.85

0.86

0.00

0.13

0.50

PCs

0.85

0.96

0.00

0.41

0.50

PCs

0.85

0.92

0.02

0.21

0.46

PCs

MDD Controls only
0.30
0.29

0.00

0.10

0.50

PCs

Full sample
0.35
0.58

0.08

0.04

0.02

(4375/741)

Adjusted GS

5244
(5039/205)

Item E8

5221
(4813/408)

GS

4885
(1404/3481)

GS

10001
(5779/4222)

GS with
MDD
Adjusted GS

10001
(5779/4222)

10129

PCs,
MDD
PCs

0.35

0.58

0.00

0.04

0.50

0.35

0.64

0.14

0.05

<0.001

PCs,
MDD

0.35

0.64

0.01

0.04

0.41

(6443/3686)

Adjusted GS,
with MDD

10129
(6443/3686)

Abbreviations: Ca = sleep case; Co = sleep control; GCTA = genome-wide complex trait analysis; GS = general
sleep item; H2 = heritability; MDD = major depressive disorder; PC = principal component; SDS = sleep within
depression; SE = standard error; SNP = single nucleotide polymorphism.
*
Note that GCTA was also run on the original MDD variable to ensure that code worked properly.
1
Although age was a significant predictor of sleep variables in phenotypic analyses, it accounted for a small
proportion of variance, particularly within controls, so it was not included within genetic analyses presented here.
When age was included as a covariate in the analyses in rows 1-5 presented above, estimates remained similar. For
combined case/control samples, age and case status are confounded due to ascertainment within CONVERGE, so it
was not included for the full sample either.
2
This variable was treated as a quantitative trait so no prevalence was specified.
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III. Discussion
To determine the extent to which sleep phenotypes utilized with CONVERGE are under
genetic influence, and subsequently determine the SNP-based heritability of these traits, GCTA
was conducted on sleep variables, both in the full sample and separately in MDD cases and
MDD controls. Overall, heritability estimates were not significant, with estimated variance due
to additive genetic effects close to zero for the SDS (quantitative trait) in MDD cases, GS in
MDD cases, and GS in MDD controls (see Table 13) and only 2% for the main insomnia item
from MDD assessment (Item E8) in MDD cases. None of these estimates were significantly
different from 0. In contrast, a significant heritability estimate (8%) was obtained when MDD
cases and controls were combined together for the GS, but this effect was no longer significant
when accounting for MDD status, suggesting that the variance detected was due to MDD.
Similar results were obtained with the Adjusted GS variable, which incorporated all available
sleep information for MDD cases, although the initial estimate was higher (14%). This estimate
also became non-significant when MDD status was included as a covariate.
Taken together, these results suggest that sleep phenotypes within the CONVERGE
sample are not heritable, which contradicts the extant literature for insomnia. The twin literature
indicates that insomnia phenotypes are moderately heritable, with the lower bound of published
estimates at around 20% and the highest estimates close to 60%.167 Several published GWAS of
insomnia have included SNP-based heritability estimates within their results, and these are
broadly consistent with, but on the lower end of, twin estimates: The UK Biobank GWAS of
sleep phenotypes216 reported that their binary insomnia phenotype had a heritability of 21%
(using BOLT-REML variance components analysis308), and the sleep latency GWAS by Amin
and colleagues213 reported an estimate of 20% for sleep latency, estimated through GenAbel.309
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The heritability estimate obtained within CONVERGE when combining MDD cases and MDD
controls for the adjusted sleep variable (~14%) is closest to these estimates, although this is
heavily influenced by ascertainment and MDD status, and thus all genetic variance is accounted
for by MDD. Estimates within MDD cases and MDD controls separately were robust to the
effects of age and were reported without age covariates. Differences in the phenotype from
CONVERGE, as well as ascertainment within the sample, could be contributing to the
inconsistency with the current literature, and will be discussed in greater detail below.
Another paper specifically investigated the SNP-based heritability of MDD symptoms,
which included insomnia-related items.260 Principal component analysis was conducted on the 17
items that made up the Hamilton Rating Scale for Depression (HRSD) to determine how the
specific items sorted into clusters. Interestingly, insomnia was among the most heritable
symptom clusters, with an estimate of 30%, surpassing heritability for anxiety (5%) and core
MDD symptoms (14%), but equal to that of appetite. This heritability is very similar to the twin
estimates for sleep within depression (19-35%; 184,185). Given the detailed phenotyping for MDD
that occurred within CONVERGE, replication should have been possible within this sample for
sleep variables within depression, especially given the larger sample size (over 5,000 when
restricted to MDD cases, compared to under 2,000 in Pearson et al.260), but this was not the case.
The HRSD asked three insomnia items specific to MDD, while CONVERGE only included two
MDD-specific insomnia items (the third item used in the SDS was a general item). There are
other differences between the sample presented here and that used within the Pearson study that
may be contributing to these divergent findings. Pearson and colleagues260 utilized a sample of
treatment-seeking individuals of European ancestry who were diagnosed with MDD per DSMIV criteria. The study reported a much wider age range than CONVERGE (18-75 years old vs.
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30-60 years old) and included both genders (~60% female, vs. 100%). Given that both
insomnia174 and MDD175 have been shown to have higher heritability in women, this should
increase the likelihood of detecting heritability in CONVERGE. However, note that there are no
twin estimates of MDD symptom heritability in Asian samples, so it is assumed that estimates
parallel those in the existing literature, which could be incorrect. Further, since individuals
within CONVERGE were selected for recurrent MDD, it could also be that endorsement of the
sleep items in this sample (~90%) were too high and there was not enough variation to obtain
estimates.
Power. In addition to placing these findings in the context of the extant literature, there
are several major points to consider in interpreting these GCTA results, including 1) power; 2)
phenotype; and 3) method. First, the ability to detect significant heritability estimates for these
phenotypes within the CONVERGE sample is dependent on power, which for GCTA is, in turn,
dependent on sample size and the prevalence of the trait. Power may be influencing some of the
results seen here, especially given the high endorsement of sleep variables within the sample. For
the quasi-quantitative SDS trait, there was over 80% power,250 which should have been adequate
to detect the expected heritability of approximately 30%. However, note that the variable is
highly negatively skewed (and thus not normally distributed even after log transformation; refer
to Figure 1 for distribution), and this could result in a biased estimate.251 When both cases and
controls were combined for the GS item, there was also adequate power (~100%) given the large
sample size (over 10,000). These estimates were significantly different from 0 without an MDD
covariate, but decreased when MDD was included. However, power is definitely a concern when
looking at sleep variables separately in MDD cases and MDD controls, where the sample size is
half as large as for the combined analyses. For all of these binary sleep items, power was below
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80%, and in some cases even below 30%. This suggests that heritability may not be identified for
these traits due to low power, which is related to the population prevalence and high
endorsement within this sample.
Phenotype. Second, there are problems with the sleep phenotypes used that could be
contributing to the lack of genetic influences. The only item available for both MDD cases and
MDD controls is the GS, which consists of one binary item that asks, “Do you suffer from
sleeplessness?” This particular question is not part of DSM criteria for insomnia1 nor does it
come from an established insomnia (e.g., Insomnia Severity Index310) or sleep quality (PSQI178)
scale. However, note that there is variability in terms of insomnia phenotypes used across the
two samples213,216 that have estimated SNP heritability so far. The UK Biobank utilized one
ordinal (3-level) insomnia item that was collapsed into a binary yes/no variable (i.e.,
endorsement of “never/rarely” indicated a control; “usually” were cases; “sometimes” were
excluded).216 This question encompassed both trouble falling asleep and waking up at night,
which are two of the main DSM insomnia symptoms.1 In contrast, Amin and colleagues213
utilized a quantitative sleep latency phenotype, which measured time to fall asleep, in minutes,
which may reflect the difficulty falling asleep component of insomnia (i.e., individuals with
difficulty falling asleep would report a longer sleep latency). Note that neither of these studies
used an insomnia diagnosis. The general sleep phenotype used here, although binary and not
from a standardized measure, is consistent with prior analyses given that it measures an insomnia
symptom (trouble sleeping), not disorder. Further, within the subset of MDD controls, it is
certain that these individuals do not have recurrent MDD and will likely not develop it in the
future (i.e., genetic risk is minimized). Given bidirectional relationships between sleep and
psychopathology,32,34,38 it is useful to know that for these individuals, the endorsement of this
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sleep item is not confounded by MDD. This means that any genetic contributions detected are
sleep-specific. However, this could also be a disadvantage in that sleep in these individuals is not
representative of the general population (i.e., they could be “super controls”), and thus could
partially explain the lack of insomnia heritability for MDD controls seen here.
In comparison, in MDD cases, sleep is appropriately assessed within the context of
MDD, as CONVERGE was ascertained for studying the genetic contributions to MDD and items
come from diagnostic criteria.48 Note that individuals were given the option to endorse
hypersomnia as well as insomnia, although insomnia is the focus here (in general, estimates did
not differ with hypersomnia included as a covariate). The endorsement of these sleep items is
high within CONVERGE, with 92% of individuals with MDD who were included in GCTA
endorsing the main MDD sleep item (Item E8; difficulty falling or staying asleep). Further, 87%
of these individuals endorsed early morning awakenings. These estimates are definitely high but
not surprising, given associations that have been shown between insomnia and depression
severity (e.g., 36,37). Since this is a sample with recurrent MDD, it is reasonable that insomnia
symptoms are very prevalent. The literature points to sleep as a core symptom of MDD35 and up
to 90% of individuals with MDD report experiencing a sleep symptom.32 Further, in a recent
South Korean sample, endorsement of insomnia items within MDD was 93%.37 A quasiquantitative trait for sleep within depression (SDS) in MDD cases was also analyzed, created by
summing up responses on the main MDD sleep item (Item E8), early morning awakenings (Item
E8.A), and the general sleep item, which also had high endorsement in MDD cases (86%). This
was based on results from a prior paper that showed that three insomnia symptoms (difficulty
falling asleep, difficulty staying asleep, and early morning awakenings) loaded highly onto a
single factor in a phenotypic factor analysis, although the three items used in this paper were
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asked on a 1-5 Likert scale.174 Thus, it is possible that the SDS sum score variable used here is
not adequately measuring sleep within the sample, and as noted earlier, the variable is skewed.
The skewness of the variable and high endorsement (and thus low variation) could lead to biased
estimates of heritability.
Method. Overall, estimates of SNP-based heritability have been lower than twin estimates
across a range of phenotypes, both psychiatric and non-psychiatric in nature.245,311-314 While
promising, this method has been unable to resolve all of the so-called “missing heritability” (a
concept also discussed in the context of the total variance explained by known GWS
loci).251,315,316 GCTA assumes an additive effect for all variants (and does not incorporate effect
sizes) when estimating heritability.243,245 While additivity is an assumption also made in the twin
literature (unless dominance is modeled), it does not encompass all possible types of genetic
contributions to the trait, such as dominance effects and epistasis (gene-gene interactions).317
Some researchers have proposed that heritability is not “missing,” but is instead “phantom”
heritability that results from the overestimation of the total variance, since GxE and gene-gene
interactions, among other genetic effects, are not measured.316 Generally, GCTA estimates
narrow-sense heritability and estimates are considered to be a lower bound for the true
heritability, given that all genetic variation is not encompassed.245,249 GCTA is also limited by
the available SNPs in the study sample, which includes those that are measured or imputed, as
the estimate can only be influenced by these SNPs and variants that are in LD with them.245,249
As a result, GCTA captures effects of mostly common variants, since rarer variants are not in LD
with what is measured or imputed.318 Within the analyses presented here, no variants with minor
allele frequency (MAF) < 1% were included in GCTA, although note that the majority of
common variation has been measured, given that genetic data collected here is sequence-based.

82

Based on this, variants that are not included in GCTA (i.e., rarer variants) could be contributing
to missing heritability251, however this is not likely to account for the majority of the missing
heritability.
Further, there are some assumptions of GCTA related to case-control phenotypes that
warrant discussion. GCTA was initially designed for quantitative traits319 and then adapted for
use in case-control methods.307 For a binary trait, heritability estimates are dependent on sample
size, prevalence of the trait in the population, proportion of cases, true heritability, and number
of SNPs.251 Thus any of these variables could affect the estimate. The approaches are similar, but
in the case-control method, the initial scale is 0,1 (not liability, as seen for quantitative traits),
ascertainment results in many more cases than would be seen in a population sample, and
estimates are more sensitive to artifacts.307 To address this first point, it is assumed that there is
an underlying latent liability for case-control traits, as indicated by the liability threshold model
(i.e., the latent trait is continuous/normally distributed and once individuals reach a certain
threshold they can be considered cases). To calculate the SNP-based heritability for a binary
trait, GCTA takes the phenotype, coded as 0/1, uses REML to calculate the observed heritability,
and then converts it to the liability scale based on population prevalence k.243 While this is
technically unbiased, there are several assumptions of REML that are violated in the case of a
binary trait. First, the underlying distributions of variables are not normal (genes, environment,
liability). For the case of liability in particular, case-control ascertainment generally collects
more cases than one would expect in the general population, resulting in a non-normal
distribution. GCTA does correct for this, transforming using information on population
prevalence,243 but Golan and colleagues251 argue that this may not be sufficient. Second, REML
assumes that genetic and environment influences are uncorrelated, yet the case-control design
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itself can introduce an “induced” GxE, which is problematic.251 Additionally, Golan et al.251 also
argue that including covariates into a case-control design (i.e., by adding fixed-effects) can
further bias the estimates. These assumptions and their violations, which have the greatest effects
when the N is large and population prevalence is low and are believed to result in biased (i.e.,
underestimated) estimates, should be taken into consideration. The most relevant of these
limitations to the CONVERGE sample include 1) bias if the ascertainment correction is not
appropriate; and 2) bias introduced by the case-control design, which could be introducing GxE.
Additionally, there is a recent paper that argues that GCTA results in biased estimates for
quantitative traits, even without violations of assumptions, due to noise and over-fitting of the
GRM.252
Summary. In sum, SNP-based heritability for sleep items within CONVERGE was not
detected using GCTA, which in contrast to the prior literature.213,216 Future directions (aside from
utilizing a sample with better sleep phenotypes and less ascertainment bias) include utilizing
other programs to estimate heritability and see if predictions improve. For example, LDSC
incorporates LD information to provide heritability estimates that are not biased by the LD
between markers and causal variants,253 which is one criticism of GCTA that its creators
acknowledge.319 The lack of heritability indicates that results of subsequent genetic analyses
should be interpreted with caution. If significant estimates were obtained, sleep phenotypes
would be able to be compared better to those within the literature. Further, there would be more
justification in proceeding with gene-finding efforts and PRSs within this sample and the
subsequent interpretation of these results could be done with more certainty.
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Chapter 5: Identification of variants contributing to sleep phenotypes through GWAS
(Aim 2b)

I. Data analytic plan
GWAS were conducted in Plink, version 1.07,320 using dosage data and run by
chromosome. All sleep phenotypes were treated as binary (case/control), except for the SDS
variable, which was analyzed as a quantitative trait. Covariates included two ancestry PCs (used
within the original MDD GWAS and GCTA papers220,300) and MDD case status, where
appropriate (i.e., full sample). Included SNPs were filtered such that all had a Hardy-Weinberg
p-value > 1x10-7, INFO > 0.9, and MAF > 0.01 and < 0.99. This resulted in a total of
approximately 6.1 million SNPs retained for subsequent analysis (see Table 15 for exact
numbers). Manhattan and Q-Q plots were constructed using custom code in ggplot2274 in R,
adapted from scripts used within the Molecular and Statistical Genetics course at VCU, HGEN
603. The genomic inflation factor, lambda, was also calculated using custom code in R. The
p.adjust function in the R package stats (specifying “fdr” and default values) was used to
calculate false discovery rate [FDR]-based q-values for all SNPs that passed QC, and only SNPs
with q-values < 0.5 were further examined via annotation. Notably, an FDR of 0.5 is very liberal,
as this means that approximately half of the values below this cut-off are false positives. A more
stringent FDR (e.g., 0.05, 5% false positives) would be scientifically and statistically ideal in
order for results to be believable (i.e., to have confidence that the variant(s) of interest may
actually be influencing the phenotype and is/are not just false positives), and to justify more
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detailed examination of specific genes. However, given the goal of balancing rigorous science
with choosing an FDR that would realistically provide the ability for training and experience in
further probing of top variants, this level was put forward.
Annotation of these top SNPs was conducted using the UCSC genome browser321 hg19
geneKey, 20151017, adapted from code used in the Spit for Science genetic analysis pipeline.
For initial examination, SNPs were grouped into clusters such that a cluster contained SNPs that
were on the same chromosome and located within 10 kb of each other. Following this, clusters
were then created such that SNPs < 75 kb from each other were collapsed. The gene key, above,
was used to determine if each cluster included specific annotated gene(s). The clusters were also
examined for other nearby genes (i.e., genes located 50 kb upstream or downstream from the
cluster start/end). LocusZoom,322 a regional association plotting program available online, was
used to visualize genes of interest (i.e., that contained variants with a minimum p-value < 10-6).
The hg19 genome build with 1000 genomes Mar 2012 ASN LD reference was used to create all
LocusZoom plots. –log10P values for all SNPs +/- 200 kb from the specified gene of interest
were plotted, along with their LD correlations in relation to the index SNP (defined here as the
SNP with the lowest p-value). Finally, replication of GWS SNPs (or SNPs indicated to be of
interest due to nominally significant p-values in the original studies) from the five prior GWAS
of insomnia-related phenotypes was conducted, examining the effects of 7 (out of 15 total)
previously identified SNPs within the summary statistics of the Adjusted GS with MDD
covariate in CONVERGE. This phenotype was chosen for replication, as it is more similar to
general insomnia than the SDS variable. Effect allele, effect size, and p-values were compared
across the original insomnia GWAS and CONVERGE.
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Power calculations for the two main GWAS phenotypes (SDS in MDD cases and
Adjusted GS with MDD covariate in the full sample) are shown in Table 14. For the SDS (quasiquantitative trait), power was calculated across different estimates of variance explained using
custom code in R. There was adequate power (i.e., > 80%; see first half of Table 14) to detect
individual variant(s) that explain > 0.8% of the variance in the trait, but not for variants with
smaller effects. For the Adjusted GS with MDD covariate (binary), power was calculated across
several MAFs and genotype relative risks using the Genetic Association Study Power Calculator,
http://csg.sph.umich.edu/abecasis/cats/gas_power_calculator/index.html; see second half of
Table 14. Here, power was adequate to detect variants with genotype relative risk > 1.15 and
MAF > 0.25 (prevalence was set at 35%).

Table 14. Power to detect variants in GWAS across main sleep phenotypes
SDS, MDD cases only
Adjusted GS, MDD covariate
(Quantitative trait, N = 5073)
(Binary trait, N = 6,450 Ca, 3,704 Co)
Variance explained
Genotype relative risk
MAF
0.001
0.005
0.008
0.01
1.05
1.10
1.15
1.20
0.05
0.7%
33.9%
82.1%
95.3%
0%
0.1%
2.0%
17.2%
0.25
0.7%
33.9%
82.1%
95.3%
0.1%
13.6%
82.3%
99.8%
0.5
0.7%
33.9%
82.1%
95.3%
0.2%
25.7%
92.5%
100%
Abbreviations: Ca = case; Co = control; GS = general sleep item; MAF = minor allele frequency; MDD = major
depressive disorder; SDS = sleep within depression variable.

II. Results
GWAS of main phenotypes. In order to determine if specific genetic variants contributed
to risk for sleep traits within CONVERGE, GWAS were conducted with PC1 and PC2, as well
as MDD where appropriate, as covariates. Association analyses focus on the SDS in MDD cases
and Adjusted GS with MDD covariate within the full sample, given discussion following the
pattern of GCTA findings. An overview of results is presented in Table 15, including covariates
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used, sample size, number of SNPs passing quality control (QC) filters, genomic inflation factor,
minimum p-value obtained, and number of SNPs with FDR < 0.5. Association results for the
main phenotypes are presented in the top 2 rows. Manhattan plots and Q-Q plots are presented
for these variables (SDS, Figures 5 and 6; Adjusted GS with MDD covariate, Figures 7 and 8)
and will be discussed. No p-values reached genome-wide significance (5x10-8) for either of the
two phenotypes, although there was a p–value range (between –log10P value of 4 and 6) in the QQ plot of the SDS that contained more values than expected by chance. Several p–values passed
the threshold of nominal significance (-log10P > 6) for this trait. Both lambda values were just
below 1 (0.998 for both), indicating that overall, the distributions of p–values are slightly under
inflated (i.e., more larger p-values than would be expected by chance). FDR q-values were used
to identify SNPs and regions of interest for the SDS that passed the a priori threshold (< 0.5).
There were 312 SNPs with q-values < 0.5 (i.e., less than 50% chance that the SNP is a false
positive) for the SDS, thus warranting further examination. No SNPs passed q < 0.5 for the
Adjusted GS with MDD covariate.
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Table 15. Sample sizes and summary of GWAS results for all phenotypes run
Minimum
Covariates?
GWAS N
SNPs
Genomic
p-value
passing QC inflation (λ)
filter
Main phenotypes
SDS1
PCs
5073
6,105,870
0.998
3.72E-07
Adjusted
PCs, MDD
10154
6,111,327
0.998
2.28E-06
(6450 Ca,
GS, All

SNPs with
FDR < 0.5

312
0

3704 Co)

Other phenotypes
4906
6,112,139

GS, MDD
controls

PCs

1.000

5.75E-07

0

GS, MDD
cases

PCs

5120

6,106,412

1.005

1.97E-06

0

(4376, Ca,
744 Co)
5248
(5041 Ca,
207 Co)

Adjusted
GS, MDD
cases
Item E8,
MDD
cases
GS, All

PCs

6,105,541

0.993

3.27E-07

0

5225

6,104,655

1.010

1.30E-06

0

6,111,579

1.015

2.67E-06

0

6,111,327

1.025

7.08E-07

489

(1409 Ca,
3497 Co)

PCs

(4815 Ca,
410 Co)

PCs

10026
(5785 Ca,
4241 Co)

Adjusted
GS, All

PCs

10154
(6450 Ca,
3704 Co)

Abbreviations: Ca = sleep case; Co = sleep control; FDR = false discovery rate; GS = general sleep item; GWAS =
genome-wide association study; MDD = major depressive disorder; PC = principal component; QC = quality
control; SDS = sleep within depression; SNP = single nucleotide polymorphism.
1
This variable was treated as a quantitative trait.
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Figure 5: Manhattan plot for SDS in MDD cases. This figure plots the –log10(p) values of
associations for the SDS by chromosome. The red line represents genome-wide significance (p =
5x10E-08), while the blue line indicates nominal significance (p = 10-6).

Figure 6: Q-Q plot for SDS in MDD cases. The expected distribution of p-values is shown on
the x-axis, while the observed distribution of p-values from GWAS of the SDS is shown on the
y-axis. All p-values are represented as –log10(P). The dashed lines represent 95% confidence
intervals.
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Figure 7: Manhattan plot for Adjusted GS in full sample, MDD covariate. This figure plots
the –log10(p) values of associations for the Adjusted GS with MDD covariate by chromosome.
The red line represents genome-wide significance (p = 5x10E-08), while the blue line indicates
nominal significance (p = 10-6).

Figure 8: Q-Q plot for Adjusted GS in full sample, MDD covariate. The expected
distribution of p-values is shown on the x-axis, while the observed distribution of p-values from
GWAS of the Adjusted GS with MDD covariate is shown on the y-axis. All p-values are
represented as –log10(P). The dashed lines represent 95% confidence intervals.
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Top SNPs for SDS. Table 16 displays 33 clusters of SNPs with q < 0.5 (SNPs that are part
of a cluster are located on the same chromosome and within 75 kb of each other) for the SDS,
annotated with UCSC hg19 data. Chromosome, position start and end, number of SNPs included
in the cluster, minimum p-value and minimum q-value from that cluster, associated genes, and
local genes are all located in this table. Genes with a minimum p-value less than 10-6 include
Potassium Two Pore Domain Channel Subfamily K Member 9 (KCNK9) on Chromosome 8 (16
SNPs) and Aldehyde Dehydrogenase 1 Family Member A2 (ALDH1A2) on Chromosome 15 (54
SNPs). LocusZoom plots322 that show KCNK9 and ALDH1A2, with 200 kb flanking either side
of the gene, are presented in Figures 9 and 10, respectively. The SNP with the smallest p-value
(as indicated in Table 15) is used as the index SNP in both plots. These plots show that for each
gene of interest, there are a number of SNPs that are in high LD with the top SNP.
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Table 16. Annotated clusters of top SNPs for SDS phenotype, ordered by chromosome and
position
Chr Start BP
End BP
# of
Min P
Min
Genes
Local genes
SNPs
Q
ST6GALNAC3
None
1
76922551
76943605
11
1.16E-05
0.42
None
LMX1A
1
165166002 165170408
2
2.07E-05
0.46
None
None
2
36195077
36199327
3
1.51E-05
0.42
None
KCMF1,
2
85289866
85315647
4
3.40E-06
0.38
3

112018435 112047314

13

8.48E-06

0.42

BC041484

3

193670290 193684988

7

7.20E-06

0.42

LOC647323

4
5

84599815
87981557

84599815
87981557

1
1

2.06E-05
8.58E-06

0.46
0.42

None
None

5
6
6
7

165108213 165108213
168889305 168918704
170339330 170349370
968785
968785

1
5
43
1

1.31E-05
9.12E-06
1.60E-06
2.49E-05

0.42
0.42
0.38
0.49

None
SMOC2
None
ADAP1

7
7
8
8

18777804
75426938
2994124
23200605

18782969
75426938
2994124
23224711

4
1
1
10

1.74E-05
2.20E-05
1.89E-05
1.53E-06

0.45
0.47
0.45
0.38

HDAC9
None
CSMD1
LOC100507156
, LOXL2

8
8
9
9
9
10
11
12

77437702
77483797
140590172 140615287
28263705
28263705
82121130
82170990
85332673
85359511
72887202
72887202
93104594
93138334
31285810
31298362

24
16
1
4
27
1
3
9

6.30E-06
3.72E-07
1.78E-05
1.36E-05
8.11E-06
1.21E-05
1.97E-05
2.42E-06

0.42
0.38
0.45
0.42
0.42
0.42
0.45
0.38

None
KCNK9
LINGO2
None
None
None
CCDC67
OVOS2

12

54578882

54584028

12

8.01E-06

0.42

SMUG1

13
13
14
15

38967904
89020561
82510563
58209736

38997952
89057520
82510563
58353510

12
29
1
54

1.14E-05
1.19E-05
8.33E-06
3.95E-07

0.42
0.42
0.42
0.38

None
None
None
ALDH1A2
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TCF7L1
BC041484,
CD200,
SLC9C1
DPPA2P3,
LOC647323
None
LINC00461,
MEF2C, MIR9-2
None
None
None
ADAP1,
COX19, GET4
None
CCL24, CCL26
None
BC128546,
ENTPD4,
LOC100507156,
LOXL2,
R3HCC1
ZFHX4-AS1
None
None
TLE4
None
None
None
DDX11,
DKFZp434C06
31, OVOS2
AX747003,
CBX5,
MIR3198-2,
SMUG1
UFM1
None
None
None

Chr

Start BP

End BP
60017791
74671931

# of
SNPs
1
5

15
15

60017791
74613097

X
X

2273319
15830587

Min P
1.79E-05
1.56E-05

Min
Q
0.45
0.44

2273482
15891711

3
2

2.38E-05
1.63E-05

0.49
0.45

Genes

Local genes

None
BC013681,
CCDC33,
CYP11A1,
LOC729739

BNIP2
BC013681,
CCDC33,
CYP11A1,
LOC729739,
SEMA7A
None
None

None
None

Abbreviations: BP = base position; Chr = chromosome number; Min = minimum.
Rows that contain nominally significant p-values (p < 10-6) are in bold.
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Figure 9: LocusZoom plot for SDS gene of interest KCNK9. Associations for SNPs
within/surrounding the gene of interest KCNK9 (+/- 200 kb) from the SDS GWAS are shown
here. rs4736083, the SNP with the smallest p-value, was used as the index SNP. The x-axis
shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors, with
red being highest and blue being lowest.
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Figure 10: LocusZoom plot for SDS gene of interest ALDH1A2. Associations for SNPs
within/surrounding the gene of interest ALDH1A2 (+/- 200 kb) from the SDS GWAS are shown
here. rs35016264, the SNP with the smallest p-value, was used as the index SNP. The x-axis
shows the position of each SNP, while the y-axis reflects the p-value, transformed to –log10(p).
Magnitude of LD for each SNP with the index SNP (r2) is represented by different colors, with
red being highest and blue being lowest.
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Attempted replication of previously identified GWAS loci for insomnia within results for
Adjusted GS. Table 17 lists SNPs that were found to be GWS (or of interest) in prior GWAS of
insomnia phenotypes and are also available within the filtered CONVERGE summary statistics
for the Adjusted GS with MDD covariate in the full sample. Information on the SNP (including
the initial phenotype where association was found, rs number, chromosome, BP, and alleles) is
shown in the first five columns. Next, summary statistics for the SNP from the original sample
are shown (N, effect allele frequency, INFO, effect [OR/beta], 95% CI/SE, and p-value) in
columns 6-11. Finally, the same information from the Adjusted GS with MDD covariate
summary statistics is shown in the final six columns. Most SNPs had different MAFs and
directions of effect than in the original samples and were not significant. However, rs2302729
(see row 4), was nominally significant in CONVERGE (OR = 1.12, p = 0.01).
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Table 17. Summary of replication attempts for existing insomnia-related GWAS results within the Adjusted GS, MDD covariate
Original sample

CONVERGE
Adjusted GS, MDD covariate

Phenotype

SNP

CHR

BP

Alleles

N

EAF

INFO

Insomnia216

rs5922858

X

82971008

G/T

58676

0.85

0.99

OR/
Beta
1.12

Insomnia
(females)216
Sleep
latency215
Sleep
quality215
Insomnia214

rs3792900

5

135393754

C/T*

58702

0.47

0.99

1.10

rs7304986

12

2438105

C/T*

2323

0.01

NR

0.49

95%
CI/SE
1.071.16
1.071.14
0.11

P

N

EAF

INFO

OR

SE

P

1.3E-8

10154

0.70

1.00

1.01

0.04

0.90

2.2E-8

10154

0.44

0.97

1.00

0.04

0.91

1.4E-6

10154

0.98

0.98

1.02

0.16

0.89

rs2302729

12

2783972

T/C

2323

0.17

NR

0.17

0.04

4.4E-6

10154

0.35

0.98

1.12

0.04

0.01

rs11208305

1

64088067

C/G*

8719

0.34

NR

1.60

NR

5.6E-6

10154

0.97

1.01

1.05

0.11

0.68

Insomnia214

rs718712

20

8714008

A/G*

8719

0.32

NR

0.82

NR

8.5E-6

10154

0.67

0.99

1.00

0.04

0.92

88404547
Sleep
rs2919869
2
G/A*
956
0.26
NR
0.27
0.05
3.5E-8 10154 0.21
1.00
0.95 0.05
offset217
Abbreviations: BP = base position; EAF = effect allele frequency; GS = general sleep item; MDD = major depressive disorder; SNP = single nucleotide
polymorphism.
*Effect allele is not the same in CONVERGE.
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GWAS of additional phenotypes. Results of GWAS for six additional sleep phenotypes
are also presented in Table 15 (see “Other phenotypes” heading). Manhattan and Q-Q plots for
these variables are shown in Figures 11-22, below, for reference. Approximately 6.1 million
SNPs were included in each analysis, and there was no genomic inflation (λ ranged from 1.001.025). No SNPs reached genome-wide significance in any of these six phenotypes, and only one
analysis resulted in any SNPs that had an FDR < 0.5 (Adjusted GS without MDD covariate, a
region of interest in the Q-Q can be seen in Figure 23; however, these results are confounded
with MDD).
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Figure 11: Manhattan plot for GS in MDD controls. This figure plots the –log10(p) values of
associations for the GS in MDD controls by chromosome. The red line represents genome-wide
significance (p = 5x10E-08), while the blue line indicates nominal significance (p = 10-6).

Figure 12: Q-Q plot for GS in MDD controls. The expected distribution of p-values is shown
on the x-axis, while the observed distribution of p-values from GWAS of the GS in MDD
controls is shown on the y-axis. All p-values are represented as –log10(p). The dashed lines
represent 95% confidence intervals.
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Figure 13: Manhattan plot for GS in MDD cases. This figure plots the –log10(p) values of
associations for the GS in MDD cases by chromosome. The red line represents genome-wide
significance (p = 5x10E-08), while the blue line indicates nominal significance (p = 10-6).

Figure 14: Q-Q plot for GS in MDD cases. The expected distribution of p-values is shown on
the x-axis, while the observed distribution of p-values from GWAS of the GS in MDD cases is
shown on the y-axis. All p-values are represented as –log10(p). The dashed lines represent 95%
confidence intervals.
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Figure 15: Manhattan plot for Adjusted GS in MDD cases. This figure plots the –log10(p)
values of associations for the Adjusted GS in MDD cases by chromosome. The red line
represents genome-wide significance (p = 5x10E-08), while the blue line indicates nominal
significance (p = 10-6).

Figure 16: Q-Q plot for Adjusted GS in MDD cases. The expected distribution of p-values is
shown on the x-axis, while the observed distribution of p-values from GWAS of the Adjusted GS
in MDD cases is shown on the y-axis. All p-values are represented as –log10(p). The dashed
lines represent 95% confidence intervals.
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Figure 17: Manhattan plot for Item E8 in MDD cases. This figure plots the –log10(p) values
of associations for the Item E8 in MDD cases by chromosome. The red line represents genomewide significance (p = 5x10E-08), while the blue line indicates nominal significance (p = 10-6).

Figure 18: Q-Q plot for Item E8 in MDD cases. The expected distribution of p-values is
shown on the x-axis, while the observed distribution of p-values from GWAS of Item E8 in
MDD cases is shown on the y-axis. All p-values are represented as –log10(p). The dashed lines
represent 95% confidence intervals.

103

Figure 19: Manhattan plot for GS in full sample, no MDD covariate. This figure plots the –
log10(p) values of associations for the GS in the full sample with no MDD covariate by
chromosome. The red line represents genome-wide significance (p = 5x10E-08), while the blue
line indicates nominal significance (p = 10-6).

Figure 20: Q-Q plot for GS in full sample, no MDD covariate. The expected distribution of pvalues is shown on the x-axis, while the observed distribution of p-values from GWAS of the GS
in the full sample with no MDD covariate is shown on the y-axis. All p-values are represented as
–log10(p). The dashed lines represent 95% confidence intervals.
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Figure 21: Manhattan plot for Adjusted GS in full sample, no MDD covariate. This figure
plots the –log10(p) values of associations for the Adjusted GS in the full sample with no MDD
covariate by chromosome. The red line represents genome-wide significance (p = 5x10E-08),
while the blue line indicates nominal significance (p = 10-6).

Figure 22: Q-Q plot for Adjusted GS in full sample, no MDD covariate. The expected
distribution of p-values is shown on the x-axis, while the observed distribution of p-values from
GWAS of the Adjusted GS in the full sample with no MDD covariate is shown on the y-axis. All
p-values are represented as –log10(p). The dashed lines represent 95% confidence intervals.
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III. Discussion
GWAS were conducted to determine if any specific genetic variants contribute to sleep
disturbances within depression in MDD cases, as well as sleeplessness in general. Findings
should be interpreted with the caveat that SNP-based heritability estimates of these phenotypes
were not significantly different from zero, as discussed in the prior chapter. This discussion will
focus on results for the SDS phenotype (quantitative trait), as well as the Adjusted GS with
MDD covariate, with other phenotypes discussed briefly since there were no GWS results or
SNPs with q-values < 0.5 in these additional variables. Overall, there were also no variants that
reached genome-wide significance in the SDS or Adjusted GS with MDD as a covariate and Q-Q
plots showed under inflation generally (lambda < 1.0). However, as indicated in the results
above, there was an area of interest within the SDS phenotype where there were more p-values
than expected by chance (between –log10P of 4 and 6). Although the most significant p-values
were not within this region, SNPs in this region could be in LD with top SNPs, which suggests
that some of these variants could be of interest for sleep within depression. The genome-wide
significance cut-off of 5x10-8 represents a conservative approach to limiting the number of false
positives, and is based on the concept of family-wise error rate (FWER). A FWER reflects the
probability of having any false positive across the millions of associations tested. In contrast,
other methods for controlling for false positives, such as the FDR, permit the individual to set the
percentage of false positive results that are acceptable. Although a higher rate of Type 1 errors is
permissible through the FDR method, power is maximized.323 As discussed above, a very liberal
FDR was adopted (< 0.5) to provide the opportunity for training on further examination of
GWAS findings.
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Results of interest for SDS. The 312 SNPs that had q-values < 0.5 for the SDS were
further annotated and examined. As discussed in the results, there were two genes, KCNK9 and
ALDH1A2, with minimum p-values < 10-6. However, these should be interpreted with caution
given that FDR < 0.5 is liberal. Additional support (e.g., significance in gene-based tests,
identification in a larger sample of sleep within depression with a better phenotype) would be
needed in order to confirm the role of these genes in sleep within MDD. As mentioned in the
Results, the Locus Zoom plots showed multiple SNPs in high LD with the most significant SNP
in each of these genes, thus representing potential genes that may contribute to sleep
disturbances in individuals with MDD. The minimum q-value within these results was 0.38.
KCNK9, which contains two SNPs and begins a maximum of 22.9 kb downstream from the
remaining thirteen SNPs within that cluster (this includes rs4736083, which has the smallest pvalue [p = 3.72E-07]), encodes a pH-dependent potassium channel.324,325 The gene is imprinted
such that the maternal allele is usually expressed, and a mutation within this gene results in BirkBarel mental retardation dysmorphism syndrome, which is characterized by mental retardation,
hypotonia, hyperactivity, and facial dysmorphism.326 KCNK9 has also been implicated in cancer
(through overexpression/amplification327-329), as well as in metabolic traits like hypertension and
body mass index (e.g., 330,331). Interestingly, knockout mouse models show that the gene may be
involved in sleep, demonstrating slower transitions from wake to sleep and more fragmented
REM sleep,332 in addition to increased activity during the dark period333 in knock out animals.
ALDH1A2 contained the most SNPs with q < 0.5, including rs35016264, which had the next
smallest p-value. This gene codes for the enzyme that catalyzes the synthesis of retinoic acid, a
signaling molecule that is important for embryonic development.334 Like KCNK9, there are also
associations between ALDH1A2 and cancer (e.g., 335,336). Further, there is some evidence that this
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gene may be involved in psychiatric disorders. A haplotype containing two ALDH1A2 SNPs
(neither of which were included in the top hits in this sample) was found to be protective for
schizophrenia in a Han Chinese sample337 and methylation near ALDH1A2 was associated
(negatively) with intoxication/loss of control, suggesting a role in alcohol problems.338
Sleep within depression literature. There are no GWAS to date that have examined sleep
within MDD, making this investigation novel. However, there is a small candidate gene literature
looking at sleep in the context of MDD. Gass and colleagues262 examined adenosine-related
genes in the context of depression with and without sleep symptoms, finding that SLC29A3 was
associated with depression with early morning awakenings although this finding did not remain
significant following Bonferroni correction. There were also some associations with depression
including these sleep variables in men (with SLC28A1), but these were not significant after
applying a correction for multiple testing. Another analysis by the same group examined 18
circadian genes with these same phenotypes, finding that TIMELESS was associated with
depression with fatigue and depression with early morning awakenings in both men and women
(although there was some gender specificity), and replicated this association with seasonal
symptoms.266 Another study found that MDD with late insomnia was associated with variants in
pre-miR-182, which targets CLOCK.264 Finally, there are some investigations of polymorphisms
in several genes (CLOCK, MAO-A) and sleep in individuals with depression, although results are
mixed, with only some studies identifying significant genetic effects.199,265,339 Note that none of
these candidate genes correspond to the genes of interest from the SDS GWAS, although this is
not surprising given issues with power, phenotype, and ascertainment within the CONVERGE
dataset and the fact that insomnia candidate genes do not replicate in insomnia GWAS either.167
It is interesting to note, however, that the top gene in the SDS results, KCNK9, codes for an ion
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channel, and only around 1% of protein coding genes are ion channels.340 CACNA1C, identified
by Byrne and colleagues215 for sleep latency, as well as ABCC9, implicated in sleep
duration218,341 are also involved in ion channels, providing further evidence for an excitatory
mechanism for insomnia/poor sleep.167
Adjusted GS and additional phenotypes. While there were no loci potentially associated
with the GS in the full sample (or any of the additional GWAS of the GS in MDD controls or full
sample), other GWAS of insomnia have identified genes of interest. Note that analyses presented
here represent the first GWAS of an insomnia phenotype in a Han Chinese sample, although the
first insomnia GWAS was in a Korean sample.214 Only one of the prior studies utilized a larger
sample size than was available in CONVERGE.216 A more detailed overview of the insomnia
GWAS findings to date can be found in Chapter 1, Section IIIa, Molecular Genetics. A brief
overview of results will be presented here. The first two GWAS of insomnia phenotypes did not
identify GWS hits but were able to identify several genes of interest,214,215 one of which could be
replicated.218 The three remaining studies identified a total of nine loci that reached genome-wide
significance, all using different phenotypes (described below in the Phenotype
limitation).213,216,217 When summarizing prior GWAS of insomnia, it is important to consider that
none of these studies identified GWS variants in the same genes and minimal replication has
occurred. Identified SNPs from these earlier insomnia GWAS were examined in CONVERGE
results for the Adjusted GS with MDD covariate, where available (refer to Table 17 for results).
Most SNPs did not replicate, but rs2302729, which was nominally associated with sleep latency
(Beta = 0.20, p = 4.63E-06) in women in the GWAS by Byrne and colleagues215 (2013), was also
nominally related within the CONVERGE sample (OR = 1.12, p = 0.01).
Power. There are several major limitations to consider that could explain the inability to
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identify GWS hits for sleeplessness and sleep within MDD. These include power, phenotype,
and method, paralleling what was discussed in the prior chapter for GCTA. For GWAS,
important determinants of power include sample size, effect size, and MAF. As sample size
increases, so does the ability to detect less common variants and/or those with smaller effects.
Phenotype is also important for power, as rarer traits that are stable and have high heritability
will require smaller Ns to detect common effects.342 As described in the data analytic plan, there
was adequate power (> 80%) to detect variants with ORs > 1.15 and MAFs > 0.25, but not for
smaller genotype relative risks and MAFs, within analyses of the Adjusted GS with MDD
covariate. The inclusion of covariates (here, two ancestry PCs and MDD) may decrease the
power in case-control analyses, but should not be an issue here given the large sample size.343
However, note that most of the variance within this trait is likely accounted for by the MDD
covariate, as seen in GCTA, potentially explaining the lack of GWS results. For the SDS,
analyses were well-powered to detect individual variants that explain > 0.8% of the variance in
sleep within MDD, but not for variants with smaller effects. Further, as discussed previously, the
variable was highly skewed. The majority of individuals endorsed higher values (i.e., 2-3). In
order to maximize the power to identify genetic variants contributing to sleep within MDD, a
new sample with balanced ascertainment with regard to sleep variables would be needed.
Specifically selecting for individuals with MDD who do not endorse sleep problems, as well as
those who endorse multiple sleep problems would be a way to increase variation and maximize
the power, as selecting from extremes improves power for a quantitative trait.342
Phenotype. Phenotypic issues for GWAS are similar to those described in detail for
GCTA (see Chapter 4, Section III, Phenotype), and will be expanded upon here to compare with
the extant GWAS literature. To recap, the fact that the GS consists of a single sleep item that
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does not come from DSM criteria or a standard sleep scale is problematic. However, phenotypic
heterogeneity is a concern across the five insomnia GWAS conducted to date, which used
different phenotypes. Ban and colleagues214 utilized a binary self-report insomnia phenotype,
while Byrne and colleagues,215 who did create an insomnia factor, found main results of interest
for self-reported sleep latency and quality. The three GWAS identifying GWS loci used
phenotypes ranging from one subjective insomnia item,216 to a quantitative phenotype of sleep
latency213 and objective actigraphy parameters.217 Thus, while the insomnia phenotype used here
is not ideal, neither are those utilized within the literature, as none reflect full diagnostic criteria
or a standardized sleep measure (although sleep latency and quality are components of scales
such as the PSQI). For the SDS variable, the GS and sleep items in MDD were summed to create
a quasi-quantitative trait. As no GWAS of sleep in MDD have been done, phenotypes cannot be
compared as done for GWAS. Interestingly, several of the candidate gene studies of sleep within
MDD compared depressed individuals with sleep problems to controls,262,266 while others
examined sleep only within those who were depressed.263,265,339
Method. While the GWAS approach allows for the examination of many variants without
specific pre-determined hypotheses, there are five important limitations to consider. First,
GWAS analyzes common variants. Rarer variants (MAF < 0.01) were filtered out in the results
presented here. This is common across GWAS, as rare variants are imputed with less
certainty.342,344 With improvements in sequencing approaches and imputation, analyzing variants
of lower frequency is becoming possible. Since CONVERGE is comprised of whole-genome
sequence data, it does contain rarer (and rare) variants. However, the power to detect effects of
these lower frequency variants is likely less than that for common variants, particularly with
smaller sample sizes (i.e., less than 6,000) across most phenotypes here. Specific types of
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analyses exist for examination of rare variants in aggregate,345 which could be a future direction.
Second, identified GWS variants have not been shown to account for a large proportion of the
hypothesized heritability across many psychiatric traits (e.g., 220,251,315,316). Overall, effect sizes
are small and missing heritability remains a problem, as discussed within the GCTA section
(Chapter 4, Section I, Method). Third, like GCTA, GWAS does not account for non-additive
genetic effects or interactions, such as epistasis and GxE. Fourth, results can be influenced by
population stratification (i.e., results are spurious/false positives) if ancestry components are not
properly controlled for. This is likely not a problem here, since CONVERGE is Han Chinese and
ancestry PCs were used as covariates across all genetic analyses. Finally, GWAS examines
variants individually, and thus does not account for the potential polygenic nature of the trait of
interest. As there is evidence that many psychiatric disorders, such as MDD, are polygenic in
nature,219,245,246,254,255 it may be more useful to examine the effects of variants in aggregate using
a PRS approach, which is different than GCTA in that it takes into account effect sizes of
variants in creating risk scores,245 as will be discussed in the next chapter.
Summary. Overall, no GWS variants contributing to these sleep phenotypes independent
of MDD were identified, although there were two potential genes of interest for the SDS
(KCNK9, ALDH1A2). Significant results for sleep in MDD would be particularly novel, given
that no GWAS have examined this phenotype, and could provide insight into the heterogeneity
of symptoms experienced within this disorder. Identified variants could be considered “modifier
variants”, influencing the symptom presentation of the disorder.346 Had significant variants been
identified, the next step would be replication in independent sample(s) using similar sleep
phenotypes. Following replication, functional analyses on the specific gene/SNP of interest
would be useful to determine how the findings fit into known biology. For example, in the sleep
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latency GWAS that identified RBFOX3, functional analyses of co-expression showed a role for
the gene in neurotransmitter release (including GABA, an important inhibitory neurotransmitter
for sleep/wake regulation), highlighting a potential mechanism by which RBFOX3 variants could
affect variation in sleep latency.213 Further, given hypothetically significant results, running
additional bioinformatics analyses (e.g., gene-based enrichment, pathway analysis) on the results
would then be warranted to increase understanding of related processes and functions. For
example, pathway analysis (e.g., using Ingenuity Pathway Analysis software,
http://www.ingenuity.com) involves utilizing GWAS summary statistics to determine if specific
pathways are over-represented within results from the phenotype of interest.
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Chapter 6: Examining genetic overlap between sleep in MDD and sleep in general, as well
as sleep and MDD, using PRSs (Aim 2c)

I. Data analytic plan
Two methods for generating PRSs were used and compared. First, LDpred,257 a software
program written in Python that generates risk scores from GWAS summary statistics, was used.
LDpred utilizes Bayesian priors on the genetic architecture of the trait of interest (calculated
from heritability [as estimated by the program] and fraction of causal variants) and LD
information from a reference sample, to estimate PRSs at different fractions (i.e., models of
inheritance). In the seminal paper, the authors demonstrated that this method results in PRSs that
account for greater proportions of variance in the phenotype of interest, when compared to prior
PRS methods.257 The LDpred software was downloaded from
http://bitbucket.org/bjarni_vilhjalmsson/ldpred and Python version 2.6.6347 was used for all
steps. A subset of hard-called genotypes from CONVERGE (converted from dosage files using
PLINK) were used as the target sample in LDpred. In order to be included in the hard-called
subset, INFO had to be at least 0.99. Every genotype call for each SNP and person had to include
one genotype probability of at least 0.9, or that SNP was set to missing for that person. LDpred
filters on MAF < 0.01 and removes ambiguous SNPs (i.e., SNPs where the two potential alleles
are complementary to each other, such as A/T; when this occurs it is difficult to know if the
strand needs to be flipped, and thus the individual’s genotype at that location may be unclear).
The CONVERGE sample was used as its own LD reference, and the LD radius (i.e., “the number
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of SNPs…[to]…adjust for on each side of a given SNP”; see page 579 of Vilhjalmsson et al.257)
used across all analyses was 1157 (calculated as instructed in LDpred; total number of SNPs
from initial step/3000). Default fractions (i.e., percentage of variants contributing causally to the
trait of interest) were used to model genetic architecture (0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1,
infinitesimal).
Scores were created using summary statistics from GWAS above of the SDS (MDD
cases), Item E8 (MDD cases), GS (MDD cases), and GS (MDD controls). The use of MDD cases
and MDD controls separately is referred to here as the “natural split,” which permitted the
examination of overlap between sleep in MDD cases and sleep in MDD controls. Additionally,
the sample was randomly split in half in order to look at genetic overlap between sleeplessness
and MDD (referred to here as the “random split” approach). Half of individuals were assigned to
an MDD GWAS, while the other half were assigned to sleep GWAS (GS and Adjusted GS, with
MDD covariate), and scores were created using these summary statistics. Following their
creation, scores were used to predict sleep phenotypes in the opposite half of the sample (i.e.,
scores created from the GS in MDD controls were used to predict sleep variables in MDD cases
[SDS, GS, Item E8] and vice-versa in the natural split; scores from MDD were used to predict
sleep [GS, Adjusted GS] and vice-versa in the random split). This was done using logistic
regressions (glm for binary, polr for ordinal) conducted in R, with Nagelkerke’s pseudo R2 (as
determined by the pscl package282) and p-values used to evaluate the model prediction.
Covariates included two PCs (PC1 and PC2) in all analyses, and MDD in the random split
approach when sleep was the outcome.
The second method used was the Purcell method.254 This method uses Plink to create
weighted risk scores from summary statistics following pruning of variants in LD. In order to
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facilitate comparisons between Plink and LDpred scores, hard called genotypes were also used
for Plink, ambiguous SNPs were removed from the summary statistics, and SNPs were required
to have MAF < 0.01. For the Purcell method, risk scores were generated in Plink version 1.07,320
using a tutorial from the Psychiatric Genetics department at QIMR Berghofer as a guide for data
management.348 Once a complete list of available SNPs was compiled, pruning was performed in
Plink to remove SNPs that were in high LD with each other (pairwise r2 > 0.3, 50 BP window).
Following, risk scores were created from the pruned SNPs across a range of p-value thresholds
(0.001, 0.01, 0.1, 0.5, 1.0; modeled off of a risk score paper examining seasonality).246 The
number of SNPs that went into each Plink score is shown in Tables 16 and 18. The same logistic
regression analyses as above were conducted using the Plink scores (sleep in MDD cases to
predict sleep in MDD controls and vice-versa; MDD to sleep and vice-versa). Once all analyses
were conducted across both methods, a Benjamini-Hockberg FDR was applied separately for pvalues generated from the natural split (MDD case/control) and random split (MDD/sleep)
analyses to determine what method/phenotype/threshold passed multiple testing correction, and
thus could be carried forward into a combined analysis with trauma variables, examined earlier.

II. Results
Natural split. To determine whether there was genetic overlap between sleep in MDD
cases and sleep in MDD controls, PRSs were constructed both using LDpred and the Purcell
method across three sleep variables in MDD cases (GS [sleeplessness], Item E8 [difficulty
falling or staying asleep within MDD], and SDS [sleep within depression; quasi-quantitative
trait]) and one in MDD controls (GS [sleeplessness]) using GWAS results from Chapter 5. The
number of SNPs that went into Plink scores at each threshold is shown in Table 18. Results are
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displayed in Table 19 (across all phenotypes and methods), and Figures 23 (LDpred) and 24
(Plink). Information provided in Table 19 includes method (LDpred or Plink), discovery
phenotype, target phenotype, threshold or fraction used, effect of risk score, p-value for the
effect, total variance explained by the model (Nagelkerke’s pseudo R2), change in variance from
a base model containing only PCs (ΔR2, %), and q-value (from Benjamini-Hockberg FDR, used
to correct for multiple testing). The figures provide a visual representation of how the variance
explained differs across thresholds and phenotypes for each method, and p-values for the PRS
effect are presented above each bar. Overall, none of the predictions were significant using
LDpred scores, with analyses using the GS in MDD cases/GS in MDD controls demonstrating
the smallest change in variance (nearly 0). However, for the SDS in MDD cases (see Figure 23,
top right graph), genetic risk scores were nominally significant predictors of the GS in MDD
controls (p values ranging from 0.04 [Inf] to 0.081 [0.001]), resulting in a ~0.1% increase in R2.
For predictions done in Plink (see Figure 24), there were nominally significant results across
higher thresholds (p < 0.1, p < 0.5, p = 1) for the GS in MDD cases predicting GS in MDD
controls (and vice versa), resulting in a change in variance ranging from 0.10-0.15%. Predictions
for Item E8 in MDD cases predicting GS in MDD controls were also nominally significant
across most thresholds (ΔR2 = ~0.1%). Finally, genetic risk scores were significant (and passed
multiple testing correction) when the SDS in MDD cases was used to predict GS in MDD
controls and vice-versa at higher thresholds (p < 0.1, p < 0.5, p = 1; ΔR2 = 0.2-0.3%)
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Table 18. Number of SNPs that are part of each Plink PRS score; natural split
Threshold
SDS Cases
E8 Cases
GS Cases
GS Controls
p <0.001
156
159
130
187
p <0.01
1696
1623
1631
1686
p <0.1
16964
16841
16958
17017
p <0.5
85031
85476
85388
85594
p <=1
170579
170517
170568
170804
Abbreviations: E8 = depression item E8; GS = general sleep item; SDS = sleep within depression
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Table 19. Results of PRSs for sleep in MDD cases predicting sleep in MDD controls (and viceversa), conducted in both LDpred and Plink

Method

Discov.

Target

Thresh.
or
Fraction

LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred

SDS Ca
SDS Ca
SDS Ca
SDS Ca
SDS Ca
SDS Ca
SDS Ca
SDS Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co

GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
SDS Cad
SDS Cad
SDS Cad
SDS Cad
SDS Cad
SDS Cad
SDS Cad
SDS Cad
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
GS Ca
GS Ca

Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1

a

OR (95% CI)
LDpred
1.07 (1.00-1.14)
1.06 (0.99-1.13)
1.06 (0.99-1.13)
1.06 (0.99-1.13)
1.06 (0.99-1.12)
1.06 (0.99-1.13)
1.06 (0.99-1.13)
1.06 (0.99-1.13)
1.06 (1.00-1.13)
1.04 (0.98-1.11)
1.04 (0.98-1.11)
1.04 (0.98-1.11)
1.04 (0.98-1.11)
1.04 (0.98-1.11)
1.04 (0.98-1.11)
1.04 (0.98-1.11)
1.01 (0.95-1.07)
1.00 (0.94-1.07)
1.00 (0.94-1.07)
1.00 (0.94-1.07)
1.00 (0.94-1.06)
1.00 (0.94-1.07)
1.00 (0.94-1.07)
1.00 (0.94-1.07)
1.06 (0.99-1.12)
1.05 (0.99-1.11)
1.05 (0.99-1.11)
1.05 (0.99-1.11)
1.05 (0.99-1.12)
1.05 (0.99-1.11)
1.05 (0.99-1.11)
1.05 (0.99-1.12)
1.10 (1.00-1.22)
1.07 (0.97-1.18)
1.07 (0.97-1.18)
1.07 (0.97-1.18)
1.07 (0.97-1.18)
1.07 (0.97-1.18)
1.07 (0.97-1.18)
1.07 (0.97-1.18)
1.01 (0.93-1.09)
1.00 (0.93-1.09)
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R2
(%)b

ΔR2
(%)

0.842
0.812
0.812
0.811
0.808
0.812
0.811
0.811
0.815
0.766
0.767
0.767
0.770
0.767
0.767
0.768
0.721
0.720
0.720
0.720
0.719
0.720
0.720
0.719
0.138
0.119
0.119
0.120
0.124
0.119
0.119
0.121
0.193
0.109
0.109
0.110
0.110
0.109
0.109
0.109
0.220
0.219

0.1222
0.0924
0.0924
0.0920
0.0884
0.0924
0.0921
0.0915
0.0953
0.0471
0.0471
0.0474
0.0505
0.0471
0.0472
0.0483
0.0014
0.0002
0.0002
0.0001
0.0000
0.0002
0.0002
0.0001
0.0749
0.0560
0.0560
0.0567
0.0606
0.0560
0.0562
0.0578
0.1598
0.0761
0.0761
0.0766
0.0775
0.0761
0.0765
0.0765
0.0023
0.0005

pvalue
0.040
0.075
0.074
0.075
0.081
0.074
0.075
0.076
0.070
0.203
0.203
0.201
0.187
0.203
0.202
0.197
0.829
0.940
0.940
0.948
0.984
0.940
0.943
0.964
0.078
0.128
0.128
0.126
0.113
0.128
0.127
0.122
0.060
0.195
0.195
0.193
0.191
0.195
0.194
0.194
0.797
0.904

qvaluec
0.281
0.281
0.281
0.281
0.281
0.281
0.281
0.281
0.281
0.304
0.304
0.304
0.304
0.304
0.304
0.304
0.972
0.972
0.972
0.972
0.984
0.972
0.972
0.976
0.281
0.285
0.285
0.285
0.285
0.285
0.285
0.285
0.281
0.304
0.304
0.304
0.304
0.304
0.304
0.304
0.972
0.972

Method

Discov.

Target

Thresh.
or
Fraction

LDpred
LDpred
LDpred
LDpred
LDpred
LDpred

GS Co
GS Co
GS Co
GS Co
GS Co
GS Co

GS Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca

0.3
0.1
0.03
0.01
0.003
0.001

Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink

SDS Ca
SDS Ca
SDS Ca
SDS Ca
SDS Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co

GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
GS Co
SDS Cad
SDS Cad
SDS Cad
SDS Cad
SDS Cad
E8 Ca
E8 Ca
E8 Ca
E8 Ca
E8 Ca
GS Ca
GS Ca
GS Ca
GS Ca
GS Ca

a

OR (95% CI)
LDpred
1.00 (0.93-1.09)
1.01 (0.93-1.09)
1.01 (0.93-1.09)
1.00 (0.93-1.09)
1.00 (0.93-1.09)
1.01 (0.93-1.09)
Plink
0.99 (0.93-1.05)
1.02 (0.96-1.09)
1.09 (1.03-1.16)
1.11 (1.04-1.18)
1.11 (1.04-1.18)
1.06 (1.00-1.13)
1.04 (0.98-1.11)
1.06 (0.99-1.12)
1.05 (0.99-1.12)
1.05 (0.99-1.12)
0.98 (0.92-1.04)
1.00 (0.94-1.07)
1.05 (0.98-1.11)
1.06 (0.99-1.12)
1.07 (1.00-1.13)
0.96 (0.90-1.02)
1.03 (0.97-1.10)
1.10 (1.04-1.17)
1.10 (1.04-1.17)
1.10 (1.03-1.17)
0.95 (0.86-1.05)
1.04 (0.94-1.15)
1.05 (0.95-1.16)
1.09 (0.98-1.20)
1.08 (0.98-1.20)
0.97 (0.90-1.05)
1.02 (0.94-1.10)
1.08 (1.00-1.17)
1.08 (1.00-1.16)
1.07 (0.99-1.16)

R2
(%)b

ΔR2
(%)

0.219
0.219
0.219
0.219
0.219
0.219

0.0005
0.0005
0.0007
0.0005
0.0005
0.0006

pvalue
0.905
0.900
0.886
0.904
0.904
0.893

qvaluec

0.972
0.972
0.972
0.972
0.972
0.972

0.725 0.0060 0.648
0.843
p < 0.001
0.733 0.0133 0.498
0.658
p < 0.01
0.948
0.2289
0.005
0.065
p < 0.1
1.028 0.3081 0.001
0.035
p < 0.5
1.010 0.2910 0.002
0.035
p <= 1
0.830
0.1109
0.051
0.281
p < 0.001
0.767 0.0475 0.201
0.304
p < 0.01
0.806 0.0868 0.084
0.281
p < 0.1
0.793 0.0735 0.112
0.285
p < 0.5
0.797 0.0774 0.103
0.285
p <= 1
0.733 0.0139 0.488
0.657
p < 0.001
0.720
0.0004
0.902
0.972
p < 0.01
0.781 0.0617 0.145
0.304
p < 0.1
0.806 0.0867 0.084
0.281
p < 0.5
0.835 0.1155 0.046
0.281
p <= 1
0.116 0.0525 0.141
0.304
p < 0.001
0.089 0.0257 0.302
0.444
p < 0.01
0.305
0.2421
0.002
0.035
p < 0.1
0.299 0.2362 0.002
0.035
p < 0.5
0.277 0.2135 0.003
0.046
p <= 1
0.077
0.0436
0.327
0.472
p < 0.001
0.057 0.0240 0.467
0.638
p < 0.01
0.074 0.0415 0.338
0.479
p < 0.1
0.154 0.1206 0.102
0.285
p < 0.5
0.142 0.1088 0.121
0.285
p <= 1
0.240 0.0223 0.423
0.589
p < 0.001
0.224 0.0062 0.673
0.861
p < 0.01
0.360 0.1422 0.043
0.281
p < 0.1
0.335 0.1165 0.067
0.281
p < 0.5
0.320 0.1017 0.086
0.281
p <= 1
Abbreviations: Ca = cases; Co = controls; Discov. = discovery sample; E8 = depression item E8; GS = general sleep
item; Inf = infinitesimal model; SDS = sleep within depression; Thresh. = p–value threshold.
a
All scores have been standardized such that the odds ratio can be interpreted as the increase in the likelihood of
endorsing sleeplessness for a 1 SD increase in PRS; bR2 = Nagelkerke’s pseudo R2; cBenjamini-Hockberg FDR was
used; dWhen analyzing the SDS as an ordinal outcome, PC2 violated the proportional odds test. Given this, a linear
model that treats the phenotype as quasi-continuous was also run. Results were similar in both models, so the ordinal
regression is shown here for consistency.
Bold text is used to indicate results passing multiple testing correction (q < 0.10).
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Figure 23: Results of PRS analyses for sleep in MDD cases predicting sleep in MDD controls (and vice-versa), using LDpred
software. Graphs for risk scores created from sleep variables in MDD cases predicting sleeplessness in MDD controls are shown in
the top row, while graphs for the reverse, risk scores created from sleeplessness in MDD controls predicting sleep variables in MDD
cases, are shown in the bottom row. Within each individual graph, the fraction of variants modeled as contributing to the trait of
interest is shown on the y-axis (see legend) and the change in Nagelkerke’s pseudo R2 (in percent) from a base model containing only
principal component covariates is shown on the x-axis. The p-value of each PRS effect is shown on top of each individual bar.
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Figure 24: Results of PRS analyses for sleep in MDD cases predicting sleep in MDD controls (and vice-versa), using the Purcell
method in Plink. Graphs for risk scores created from sleep variables in MDD cases predicting sleeplessness in MDD controls are
shown in the top row, while graphs for the reverse, risk scores created from sleeplessness in MDD controls predicting sleep variables
in MDD cases, are shown in the bottom row. Within each individual graph, the p-value threshold used is shown on the y-axis (see
legend) and the change in Nagelkerke’s pseudo R2 (in percent) from a base model containing only principal component covariates is
shown on the x-axis. The p-value of each PRS effect is shown on top of each individual bar.
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Random split. To examine overlap between sleeplessness and MDD, PRSs were created
for MDD, GS, and Adjusted GS (incorporating additional information on sleep for MDD cases)
within random halves of the sample (i.e., randomly assigned to GWAS so that individuals
included in the MDD and GS/Adjusted GS samples did not overlap), also utilizing both methods.
Similar to the natural split, described above, Table 20 shows the number of SNPs that went into
Plink scores at each threshold. Table 21 provides information on method, phenotypes, effect/pvalue, and variance at each threshold. Note that FDR q-values are not shown since none of the
predictions were significant or nominally significant. Results converged across the two methods,
with no risk scores emerging as significant predictors (for MDD predicting either GS and viceversa), and very small ΔR2 values were obtained (see Table 21 and Figures 25 and 26; all ΔR2 <
0.04%). Note that for all analyses with MDD predicting GS, an MDD covariate was used (in
addition to PCs), since many of the individuals utilized within the sleep GWAS were MDD
cases. Finally, Figure 27 provides a comparison of the percent variance explained across samples
and methods, displaying the maximum variance explained by risk scores for the natural split and
random split analyses using LDpred and Plink. As can be seen in the figure, the maximum
variance explained by Plink scores was higher than that of LDpred scores for the natural split,
but both methods were similar for the random split. More variance was explained in natural split
than random split analyses.

Table 20. Number of SNPs that are part of each Plink PRS score; random split.
Threshold
MDD
GS
Adj. GS
p <0.001
181
186
156
p <0.01
1920
1672
1732
p <0.1
17701
17197
17016
p <0.5
86523
85384
85750
p <=1
170659
170634
170578
Abbreviations: GS = general sleep item; Adj. GS = Adjusted GS item, such that all sleep items were incorporated
for cases; MDD = major depressive disorder.

123

Table 21. Results of PRSs for MDD predicting sleep (and vice-versa; random split halves),
conducted in both LDpred and Plink

Method

Discov.

Target

Threshold
or
Fraction

LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred
LDpred

MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
GS
GS
GS
GS
GS
GS
GS
GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS

GS
GS
GS
GS
GS
GS
GS
GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD

Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001
Inf
1
0.3
0.1
0.03
0.01
0.003
0.001

Plink
Plink
Plink
Plink
Plink
Plink
Plink

MDD
MDD
MDD
MDD
MDD
MDD
MDD

GS
GS
GS
GS
GS
Adj. GS
Adj. GS

p < 0.001
p < 0.01
p < 0.1
p < 0.5
p <= 1
p < 0.001
p < 0.01

a

OR (95% CI)
LDpred
1.04 (1.97-1.12)
1.00 (0.93-1.07)
1.00 (0.93-1.07)
1.00 (0.93-1.07)
0.99 (0.92-1.06)
1.00 (0.93-1.07)
1.00 (0.93-1.07)
1.00 (0.93-1.07)
1.01 (0.93-1.10)
0.96 (0.88-1.04)
0.96 (0.88-1.04)
0.96 (0.88-1.04)
0.95 (0.87-1.03)
0.96 (0.88-1.04)
0.96 (0.88-1.04)
0.96 (0.88-1.04)
1.04 (0.98-1.09)
1.00 (0.95-1.06)
1.00 (0.95-1.06)
1.00 (0.95-1.06)
1.00 (0.95-1.06)
1.00 (0.95-1.06)
1.00 (0.95-1.06)
1.00 (0.95-1.06)
1.01 (0.96-1.07)
0.97 (0.92-1.03)
0.97 (0.92-1.03)
0.97 (0.92-1.03)
0.97 (0.92-1.03)
0.97 (0.92-1.03)
0.97 (0.92-1.03)
0.97 (0.92-1.03)
Plink
0.95 (0.89-1.02)
0.99 (0.92-1.06)
1.03 (0.96-1.11)
1.01 (0.95-1.09)
1.02 (0.95-1.10)
0.95 (0.87-1.03)
0.97 (0.89-1.05)
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R (%)

ΔR2
(%)

pvalue

41.59
41.56
41.56
41.56
41.57
41.56
41.56
41.56
60.56
60.57
60.57
60.57
60.58
60.57
60.57
60.57
0.734
0.694
0.694
0.694
0.694
0.694
0.694
0.694
0.697
0.720
0.720
0.720
0.720
0.720
0.720
0.720

0.0272
0.0000
0.0000
0.0000
0.0021
0.0000
0.0000
0.0001
0.0017
0.0132
0.0132
0.0144
0.0249
0.0132
0.0135
0.0164
0.0400
0.0001
0.0001
0.0001
0.0001
0.0001
0.0001
0.0001
0.0032
0.0262
0.0262
0.0262
0.0262
0.0262
0.0262
0.0262

0.226
0.980
0.981
0.992
0.736
0.981
0.988
0.945
0.738
0.349
0.349
0.328
0.198
0.348
0.344
0.297
0.208
0.948
0.948
0.948
0.939
0.948
0.948
0.945
0.722
0.309
0.309
0.309
0.309
0.309
0.309
0.309

41.60
41.57
41.58
41.57
41.57
60.58
60.57

0.0350
0.0011
0.0152
0.0031
0.0066
0.0262
0.0095

0.170
0.804
0.366
0.682
0.551
0.187
0.426

2

b

Method

Discov.

Target

Threshold
or
Fraction

Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink
Plink

MDD
MDD
MDD
GS
GS
GS
GS
GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS
Adj. GS

Adj. GS
Adj. GS
Adj. GS
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD
MDD

p < 0.1
p < 0.5
p <= 1
p < 0.001
p < 0.01
p < 0.1
p < 0.5
p <= 1
p < 0.001
p < 0.01
p < 0.1
p < 0.5
p <= 1

a

OR (95% CI)
Plink
0.99 (0.91-1.08)
1.01 (0.93-1.10)
1.02 (0.94-1.10)
0.98 (0.93-1.03)
1.01 (0.95-1.06
1.03 (0.97-1.08)
1.00 (0.95-1.06)
1.01 (0.95-1.06)
1.03 (0.98-1.09)
0.99 (0.94-1.05)
1.02 (0.96-1.07)
1.00 (0.95-1.06)
1.00 (0.95-1.06)

R (%)

ΔR2
(%)

pvalue

60.56
60.56
60.56
0.709
0.696
0.715
0.694
0.696
0.725
0.696
0.704
0.694
0.695

0.0005
0.0006
0.0021
0.0151
0.0016
0.0209
0.0000
0.0021
0.0316
0.0016
0.0100
0.0004
0.0006

0.849
0.844
0.707
0.439
0.798
0.363
0.967
0.772
0.264
0.800
0.530
0.906
0.876

2

b

Abbreviations: Ca = cases; Co = controls; GS = general sleep item; Adj. GS = Adjusted GS item, such that all sleep
items were incorporated for cases; Inf = infinitesimal model; MDD = major depressive disorder.
a
All scores have been standardized such that the odds ratio can be interpreted as the increase in the likelihood of
endorsing sleeplessness for a 1 SD increase in PRS; bR2 = Nagelkerke’s pseudo R2.
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Figure 25: Results of PRS analyses for MDD predicting sleeplessness (and vice-versa)
through random sampling, using LDpred. Graphs for risk scores created from MDD
predicting sleeplessness are shown in the top row, while graphs for the reverse, risk scores
created from sleeplessness predicting MDD, are shown in the bottom row. Within each
individual graph, the fraction of variants modeled as contributing to the trait of interest is shown
on the y-axis (see legend) and the change in Nagelkerke’s pseudo R2 (in percent) from a base
model containing only principal component covariates is shown on the x-axis. The p-value of
each PRS effect is shown on top of each individual bar.
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Figure 26: Results PRS analyses for MDD predicting sleeplessness (and vice-versa) through
random sampling, using the Purcell method in Plink. Graphs for risk scores created from
MDD predicting sleeplessness are shown in the top row, while graphs for the reverse, risk scores
created from sleeplessness predicting MDD, are shown in the bottom row. Within each
individual graph, the p-value threshold used is shown on the y-axis (see legend) and the change
in Nagelkerke’s pseudo R2 (in percent) from a base model containing only principal component
covariates is shown on the x-axis. The p-value of each PRS effect is shown on top of each
individual bar.
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Figure 27: Summary of variance explained by PRSs in CONVERGE. The maximum change
in variance explained by each PRS method across both splits of the sample is shown here. The xaxis shows the method (Plink or LDpred) and sample split (natural or random), while the y-axis
show the maximum change in Nagelkerke’s pseudo R2 (in percent). The percent change is also
written on the individual bars.

Discussion
Despite the lack of demonstrated SNP-based heritability and no significant GWAS hits
within this sample, it is likely that the genetic architecture of insomnia is polygenic in nature,
such that many variants of small effect (and thus not detectable/reaching genome-wide
significance in GWAS at current sample sizes)245,254 contribute to the variance in sleep traits
when examined in aggregate. Taking into account polygenicity, PRS methods utilize summary
statistics from GWAS of a trait of interest (discovery sample) and use this information to create
weighted risk scores in a target sample (where genetic information is available), which are then
used to predict another (or the same) phenotype. PRSs assume that in summing up effects of
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many variants, some true effects are included. As the number of SNPs included grows, the
increase in noise produced by adding more SNPs is balanced by the likelihood that some of these
SNPs will have real effects.245,254 The analyses presented here are novel, as few PRS studies of
sleep phenotypes exist. Significant predictions were found within the natural split analyses (sleep
in MDD cases predicting sleeplessness in MDD controls), which also demonstrated a larger
maximum change in variance (by an order of magnitude) than in random split analyses
(examining overlap between sleeplessness and MDD). Further, Plink scores explained nearly
twice the variance as LDpred scores within the natural split analyses, although estimates were
similar across methods within the random split. Results from each sample split, as well as a
comparison of methods, will be discussed in turn.
Sleep in MDD cases and MDD controls, natural split. Results provide some evidence
that the genetic influences on sleep within MDD (particularly via the SDS variable) significantly
predict sleeplessness in MDD controls, resulting in an increase in variance of ~0.3% from the
baseline model, using risk scores created in Plink. This prediction also occurred in the reverse,
with the GS in MDD controls predicting the SDS in MDD cases as well (~0.2% increase in
variance). For both of the Plink analyses, the significant p-value thresholds were those that
encompassed more variants (p < 0.1, p < 0.5, all SNPs), the effects indicated an increase in risk
for sleeplessness (OR > 1), and the p-values from these thresholds remained significant
following an FDR correction that accounted for 78 tests run (three phenotype combinations, two
directions, thirteen thresholds across two methods). Additionally, LDpred scores for the SDS in
MDD cases predicting GS in MDD controls were nominally significant (before correction),
supporting Plink findings for the SDS. There was also suggestive evidence in Plink for other
sleep within MDD variables (i.e., some p-values that did not pass multiple testing correction but
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were at least nominally significant; this occurred for the GS in both directions and Item E8
predicting GS in MDD controls). The amount of variance explained in the Plink models with the
SDS (0.2-0.3%) is lower than what has been reported in the literature using bipolar disorder and
schizophrenia (~1-3%).254 However, it is similar to what Byrne and colleagues246 found when
using bipolar disorder scores to predict seasonality (0.4%; although note that they found higher
predictions for schizophrenia, up to 3%, and no prediction for MDD) and roughly twice what
Maciejewksi et al.248 recently identified for MDD predicting suicidal ideation (0.1-0.16%). The
fact that significant predictions were present for thresholds incorporating more p values
highlights the polygenic nature of these phenotypes, and is consistent with prior literature
indicating that this seems to be the case for psychiatric phenotypes (when compared to other
complex traits like cardiovascular disease).245,256
This is the first examination of molecular genetic overlap between sleep in depressed and
non-depressed individuals, making these findings novel. As discussed in detail within the
introduction, twin studies have looked at heritability of insomnia symptoms within the context of
MDD (e.g., 184,185), as well as genetic overlap between insomnia and MDD (e.g., 186,187), finding
similar estimates to insomnia in general and a high degree of overlap. Further, at the molecular
level, candidate gene studies have attempted to identify genes related to sleep symptoms in MDD
(e.g., 262,266). However, here, it was uniquely possible to answer the question of whether or not
the same genes contribute to an insomnia phenotype in non-depressed vs. depressed individuals.
Sleep within depression and sleeplessness in women without MDD have a shared genetic
etiology, according to analyses presented here. While the amount of variance explained by the
genetic risk scores may seem small (0.2-0.3%), it should be noted that for MDD, risk scores have
only been able to explain a maximum of 1% of the variance (e.g., 219,220). As phenotype remains
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an issue throughout all genetic analyses presented here, it is possible that more variance could be
explained with an improved phenotype.
Sleeplessness and MDD; random split. PRS analyses were also conducted to examine
overlap between sleeplessness and MDD. Within these analyses, there was no support for genetic
overlap between sleeplessness and MDD in either direction, with MDD case status appropriately
controlled for. Results were consistent across Plink and LDpred. These results differ from the
extant literature, given that biometric studies demonstrate large (i.e., over 50%186-188) genetic
overlap between insomnia and MDD in adults, which suggests that there may be few insomniaspecific genes that are not also involved in MDD187 and thus significant predictions would be
expected. Results are in contrast to two existing studies that have utilized molecular data to
examine genetic overlap between insomnia and MDD, although only one incorporated a PRS
method. First, in a recent GWAS of MDD223 in the large 23andMe dataset, the authors created a
risk score from 17 MDD SNPs identified as GWS within the sample and used this to predict
insomnia, finding a significant effect. Note that the sample size here was large, with predictions
made in nearly 250,000 individuals that were either insomnia cases or controls. In addition to the
sizeable N, this PRS approach was different in that the risk score was constructed using GWS
SNPs only. It is possible that using GWS SNPs reduced the amount of noise within the score,
resulting in improved prediction over the use of SNPs across a range of p-value thresholds, as
done here. However, a recent overview of heterogeneity in the PRS literature found that using
GWS SNPs (vs. no correction/pruning/clumping) resulted in the smallest amount of variance
explained across four traits of interest, which included MDD.256 Second, within their GWAS of
insomnia in the UK Biobank, Lane and colleagues216 examined the relationship between
insomnia and MDD using LDSC, identifying a significant genetic correlation of 0.3. LDSC
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utilizes all available SNPs and accounts for the LD between them, so the aggregate effects of
many variants were used in determining the correlation here (i.e., many more variants used than
in the Hyde et al. PRSs). Note that this is lower than most genetic correlations between insomnia
and MDD reported in the twin literature for adults (most are over 50%).186-188 Thus, while there
is some molecular evidence for overlap between insomnia and MDD, this is an underdeveloped
literature where more analyses are clearly needed.
There are several factors that could be contributing to the lack of predictions seen here.
First, while MDD was well-phenotyped within the sample, sleep was not. As touched on in the
prior sections of the discussion, the binary item measuring sleeplessness is not the ideal measure
of insomnia. Second, in order to examine this overlap within CONVERGE, the sample had to be
randomly split in half. This resulted in sample sizes of ~5,000 for both phenotypes. While 5,000
individuals should be more than enough for the target sample, a larger discovery sample is
desirable for best predictions.245,259 Ideally, access to an outside genetically informed sample for
insomnia, preferably within an Asian population, would provide the best way to assess genetic
overlap between insomnia and MDD using CONVERGE. This would address the phenotypic
issues within insomnia and maximize the use of MDD data. With appropriate insomnia data,
significant cross-predictions would be expected for insomnia and MDD, in addition to a robust
genetic correlation.
Comparison of methods. As discussed earlier, significant predictions were only found
within Plink analyses of phenotypes in the natural split (sleep in MDD cases/sleeplessness in
MDD controls), and here, Plink scores explained approximately twice the variance as LDpred
scores. The maximum change in variance explained by risk scores was much larger within the
natural split analyses than in random split analyses, where there were no significant results. The
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larger amount of variance explained by Plink (and lack of significant results in LDpred) was
surprising, given that the initial paper describing LDpred demonstrated that scores generated by
this program performed better than other scores (e.g., Plink) in risk prediction.257 LDpred was
designed to address the loss of information that occurs due to LD pruning during the Purcell
method, with the idea that including more SNPs (while still properly accounting for LD) will
improve prediction. Thus, among the differences between these two methods, a key point to
consider is the number of SNPs included in each set of scores. For the scores constructed using
LDpred, over 3 million SNPs were included, since the software uses all available SNPs (that are
in common between target and discovery samples) and accounts for the LD between them using
information from a reference panel (in this case, the same sample).257 In contrast, fewer SNPs
were included in Plink scores, as pruning was performed prior to score creation and different sets
of p-value thresholds were used. The number of SNPs included ranged from several hundred
(smallest threshold, p < 0.001) to around 160,000 (all SNPs) (see Tables 18 and 20 for additional
details on number of SNPs per specific Plink score). Note that in general, prediction improved at
higher thresholds in Plink; this suggests that a larger number of variants are contributing to risk,
as discussed before.254 A similar pattern was seen across the LDpred results for phenotypes
where scores accounted for some variance (i.e., Item E8 and SDS); the largest amounts of change
in variance explained (and lowest p-values; see Figure 25) were within the infinitesimal models
(i.e., where an infinite number of causal variants are contributing to risk in the phenotype; note,
however that p-value thresholds cannot be directly compared to fractions of causal variants,
although as the fractions increase, more variants are thought to contribute to the trait, just as
higher p-value thresholds contain more SNPs). Another major methodological difference
between Plink and LDpred is that LDpred utilizes the heritability of the trait based on SNPs
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(from the input summary statistics) in its calculation of risk scores, which could be an issue since
initial GCTAs showed low to no heritability. In several instances, the sample size had to be
increased in order to obtain an LDpred estimate, which is likely contributing to the smaller
amount of variance explained by LDpred scores. Finally, LDpred assumes that a point normal
prior is appropriate for modeling the genetic architecture of the trait of interest, which could be
incorrect depending on the true genetic architecture of the trait.257
Limitations of PRSs. There are several limitations to discuss in the context of PRS
methods. The first is that larger discovery samples give better predictions and thus have more
power.245,246,254,259 Many of the initial (and current) analyses utilize large consortium data as the
discovery sample.246,247,254 In comparison, the discovery sample sizes utilized here (~5,000 since
the sample was split in half) are of modest size. Second, PRS methods are not standardized and
individual studies do not often report the exact methods used. Across the literature, studies
utilizing the Purcell method have addressed LD in different ways. Most do either pruning or
clumping (using a variety of parameters) within Plink, although some choose not to adjust at all.
Additionally, p-value thresholds used to bin SNPs also vary based on study. A recent publication
outlined the issue of heterogeneity in PRS methods, running different variations of Purcell PRSs
for several traits (height, weight, educational attainment, and depression; over 400 analyses in
total) within a large publicly available dataset.256 Among the researchers’ conclusions was that
while scores created using GWS SNPs were worse, no specific method of pruning/clumping
resulted in the highest variance. In fact, many of these scores at the same thresholds had low
correlations with each other. Based on this, the authors actually recommend the use of no LD
pruning or clumping so that results are replicable.256 Third, PRS methods cannot capture all
genetic influences on a trait, as rare variation, GxE, or gene-gene interactions are not included.
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Fourth, methods assume that larger effects carry more weight, which may not necessarily be the
case (see cholesterol as an example, where a variant explains a small portion of variance in the
trait of interest but has a large effect on enzyme metabolism; e.g., 349). Lastly, the PRS methods
used here are not all-encompassing, as new software continues to develop (e.g., PRSice) and
approaches are fine-tuned.
Summary. Overall, results provide some evidence that sleep within MDD can predict
sleep within MDD controls, which had not been examined prior to this study. However, there is
no support for overlap between sleeplessness and MDD within the sample. Results should be
interpreted with the caveat that GCTAs of sleep items did not demonstrate heritability and no
significant hits were identified through GWAS. Given robust genetic correlations seen in prior
twin studies, additional examination of molecular genetic overlap between sleep and MDD is
needed, using samples with better phenotypes.
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Chapter 7: Combined phenotypic and genetic analyses (Exploratory Aim)

I. Data analytic plan
To examine the contributions of both genetic and environmental risk factors to
sleeplessness, a combined model was conducted. Based on the overall results from the
phenotypic and PRS analyses, the final trauma regression for MDD controls from Chapter 3
(Table 10, Step 3; contains age and four trauma variables) was the basis for this combined model
that added the significant PRS (created from the SDS) from Chapter 6 (Table 19). Three scores
for the SDS in MDD cases predicting sleeplessness in MDD controls passed multiple testing
correction (Plink method with thresholds p < 0.1, p < 0.5, all SNPs), but the score from the
threshold of p < 0.5 was chosen for the final model since it explained the largest proportion of
variance. The final model (age, all trauma variables, PCs, PRS) was compared to the initial
phenotypic model (age, all trauma variables) through the change in Nagelkerke’s pseudo R2,
change in AIC, and analysis of variance (ANOVA). The effect of PRSs alone was determined by
comparing a model with age, traumas, and PCs to the final model listed above. All regressions
were conducted in R, using the same methods as described in Chapters 3 and 6.

II. Results
As shown in Table 22, effect sizes remained similar to the initial model, with age and all
traumas, except for adult interpersonal, significant. PC2, but not PC1, was a significant predictor
of sleeplessness, as seen in prior PRS models. The PRS was a significant predictor of
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sleeplessness in the final combined model as well, such that a one standard deviation increase in
PRS results in a 10% increase in risk (OR of 1.10, 95% CI = 1.03-1.17, p = 0.0037). The pseudo
R2 increased to 0.0332 (from 0.02441; change of 0.009) and model AIC decreased by 24.62
(5811.191 to 5786.57). Comparison of models through ANOVA indicated that adding the PRS
and PCs resulted in a significant change (X2 = 30.62, p < 0.0001) suggesting that adding the PRS
does improve model fit/decrease model misfit. The change in variance explained by PRSs alone
(above and beyond an intermediate model including age, traumas, and PCs, AIC = 5793.02;
model not shown) was 0.002 (from 0.0308 to 0.0332), with a significant change also identified
through ANOVA (X2 = 30.62, p = 0.0037).

Table 22. Results of final combined model examining the effects of both genetic and
environmental influences on sleeplessness in MDD controls (using the top PRS created from the
SDS in MDD cases)
OR
(95% CI)
p-value
Model R2
Model AIC
Age
1.03 (1.01-1.04)
< 0.0001
0.0332
5786.57
PC1
0.96 (0.90-1.02)
0.2053
PC2
1.16 (1.09-1.23)
< 0.0001
Child IP
1.63 (1.24-2.14)
0.0004
Adult IP
1.25 (0.87-1.80)
0.2221
Child NA
1.41 (1.12-1.75)
0.0026
Adult NA
1.30 (1.14-1.48)
0.0001
PRS
1.10 (1.03-1.17)
0.0037
Abbreviations: AIC = Akaike Information Criterion; IP = interpersonal trauma; MDD = major depressive disorder;
NA = non-assaultive trauma; PC = principal component; PRS = polygenic risk score; SDS = sleep within
depression.
Notes: Nagelkerke’s pseudo R2 is reported. PC1, PC2, and PRS have all been standardized to facilitate
interpretation.
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Note that this is slightly different from Table 10, as the model was restricted to individuals with
genetic data in order to allow for model comparison.
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III. Discussion
Overall, results for this combined model demonstrate that both genetic (via PRS) and
environmental (i.e., traumatic event exposure) influences are significant predictors of
sleeplessness in MDD controls within the CONVERGE sample and account for unique variance.
These analyses are novel in that they are the first to integrate molecular genetic risk scores (i.e.,
PRS) and environmental risk factors in relation to sleep phenotypes. Here, a genetic risk score
created in Plink from GWAS results of the sleep within depression (SDS) variable and
containing SNPs with p < 0.5 after pruning predicts sleeplessness in MDD controls, above and
beyond the effects of traumatic events (child interpersonal, adult interpersonal, child nonassaultive, adult non-assaultive). Within this final model, effects of all trauma variables (and the
PRS) are consistent with prior models. Note that while the PRS was significant and the model fit
improved with the inclusion of the genetic data, with an increase in variance of 0.9%, the risk
scores themselves only explained an additional 0.2% of the variance in sleeplessness, similar to
what was observed in PRS analyses described in Chapter 6.
Despite these novel results, there are several caveats to note upon interpretation. First, the
amount of variance in sleeplessness that is explained by the genetic risk score is small. Thus,
even though the PRS reflects the effects of thousands of SNPs across the genome, explanatory
power is limited. This suggests that there are other important factors contributing to sleeplessness
that are not captured here. Second, while it is straightforward to interpret the meaning of an odds
ratio for trauma type (e.g., experiencing at least one interpersonal traumatic event results in a
30% increase in risk of endorsing sleeplessness), interpretation of genetic risk scores becomes
more complicated, as the PRS is a summation of the aggregate effects of all included SNPs. The
PRS used here has been standardized, such that a one standard deviation increase in the PRS
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predicts a 10% increase in risk of endorsing sleeplessness within this sample, but exactly what
this means on a more molecular level is unclear, as this does not implicate specific variants or
combinations of variants. Third, the model presented here was limited to MDD controls only.
Risk scores within this dissertation were created in split halves of the sample (MDD cases only
or MDD controls only) to avoid overlap between individuals, and thus could only be combined
with trauma variables for those same individuals. For a more complete model of combined
genetic and environmental risk for sleeplessness in this data, a risk score for insomnia created
from an external phenotype would be needed so that the full sample could be used. Finally, the
same sample limitations discussed in prior phenotypic and genetic sections (i.e., phenotype and
ascertainment) should also be considered in relation to the final model presented here,
particularly since a combined model is only shown for MDD controls.
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Chapter 8: Overall discussion and future directions

This dissertation explored both genetic and environmental contributions to sleep
phenotypes. To recap, phenotypic analyses showed that the factor structure of trauma type was
consistent with prior literature, different trauma types are related to sleeplessness at similar
magnitudes (although childhood interpersonal traumas may be more potent), and the relationship
between CSA and sleep was replicated in Han Chinese women. Next, genetic analyses of sleep
phenotypes (both general and within the context of MDD) did not indicate that there were robust
genetic contributions to sleeplessness or sleep within MDD, which was in contrast to the extant
literature (e.g., 213,216). There were several suggestive GWAS findings for sleep within MDD (in
KCNK9 and ALDH1A2) and some evidence for genetic overlap between sleep in MDD and
sleeplessness in general from PRS analyses. However, these results should be interpreted with
caution given that the GCTA estimates of heritability did not differ significantly from zero.
Finally, genetic risk remained a significant predictor of sleeplessness in MDD controls when
combined into a model with trauma types, indicating that both genetic and environmental risk
factors contribute to sleeplessness. As outlined in earlier chapters, there are several key
limitations, which remain an issue across all sets of analyses and represent areas of future
direction for subsequent investigations of insomnia.
First, appropriate phenotypes are critical. Sleep phenotypes used within all analyses
presented here were limited. The only sleep item available across both MDD cases and MDD
controls was the binary GS item, reflecting “sleeplessness.” To reiterate prior discussions, this
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item is not from a formal insomnia definition (i.e., DSM or ICD) nor is it from a standardized
scale for measuring sleep quality or insomnia. Further, endorsement was high within MDD cases
(86%), resulting in less variation than would be expected in a general sample. This high
endorsement was problematic across all analyses. Sleep items within MDD, although from
diagnostic criteria, were also endorsed at high rates given MDD severity (i.e., recurrent MDD)
within the sample. The sum score created for sleep in MDD (SDS) was highly negatively
skewed, since it summed up responses across three widely endorsed items, and it is possible that
this score does not reflect a unique phenotype. Taken together, these phenotypic issues are likely
contributing to results presented here. However, the state of the insomnia literature as a whole is
also limited. Epidemiologic studies of insomnia use definitions that vary in timing and severity
(e.g., 2,3) and extant insomnia GWAS use mostly self-report phenotypes (see discussion in
Chapter 5 for more details) as opposed to clinical DSM based diagnoses. Thus, the measurement
of insomnia has not been ideal and this represents an important area to address, particularly for
genetic studies. While large consortia that combine data are becoming the standard for genetic
studies, there is not currently a consortium for insomnia. As stated earlier, fewer GWAS of
insomnia phenotypes exist (compared to other psychiatric disorders like MDD and
schizophrenia), and phenotypic heterogeneity will need to be resolved to some extent in order to
make such a large-scale collaboration a viable option.
Second, ascertainment was a major problem within CONVERGE, as the sample was
designed for genetic analyses of MDD. Reduced phenotypic heterogeneity across MDD
(recurrent, homogeneous sample) resulted in the identification of MDD-relevant loci,220 but was
clearly a disadvantage in the analyses of insomnia presented here. The full sample did not
represent a population sample for insomnia, and combining individuals from both cases and
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controls resulted in little to no heritability once the effect of MDD was regressed out. Further, the
ascertainment of cases resulted in individuals with recurrent MDD, which relates to the high
prevalence of sleep variables seen here, given that insomnia is a key symptom of the disorder
and may reflect severity (e.g., 36,37). Controls, although they did not have recurrent MDD nor
were they likely to develop it, may be “super controls” and thus not reflective of the population
either. Ascertainment issues were highlighted within phenotypic analyses as well, as some
traumas were non-significant predictors of sleep when restricted to specific subsets of the sample
(i.e., adult interpersonal trauma was not significant in MDD controls, child interpersonal trauma
was not significant in MDD cases). Modeling a population prevalence of MDD of 8% indicated
that child interpersonal traumas might be more potent predictors of sleep, a finding that was not
seen using other methods. Study designs with appropriately matched cases and controls for
insomnia (or depressed individuals with and without sleep problems for studying insomnia
within MDD), as opposed to samples of convenience or samples used to study other phenotypes,
will be essential for studying genetic influences on insomnia and the contributions of trauma to
sleep disturbances. Moreover, the ideal sample for genetic analysis may not be ideal for
phenotypic analyses, particularly if trying to understand a specific population.
Related to ascertainment is phenotypic heterogeneity, which may be a key contributor to
missing heritability.245 For example, heritability estimates may be higher in clinical samples vs.
population based245 (this is seen in the twin literature for psychiatric disorders like schizophrenia;
e.g., 350-353). Heterogeneity as it relates to clinical subtypes may also be important.245 Within
insomnia, this could reflect differences in the genetic contributions to sleep-onset vs.
maintenance subtypes of the disorder. This has not been explored at the molecular level, as
genetic studies of insomnia generally use composite phenotypes or questions that incorporate
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both onset and maintenance. Within the twin literature, some studies do examine different
symptoms separately,167 but detailed comparisons have not been made and some twin studies
have even found no heritability for some symptoms (e.g., 171). Examining subtypes may make it
easier to detect important variants, as effect sizes are likely larger in these more specific
samples.245 It also is possible that the incorporation of other intermediate phenotypes may aid in
understanding the genetic architecture of insomnia. For example, the concept of sleep reactivity
(change in sleep in response to a stressor), which has been identified as a robust risk factor for
insomnia,354,355 may also have shared genetic influences with the disorder171. Difficulties in using
other phenotypes like this is that they may also influence other disorders like MDD,245 as is the
case for sleep reactivity,356 which could make it difficult to isolate insomnia-specific effects
(although note that twin studies suggest there may not be many insomnia-specific genes [e.g.,
186,187

], making the examination of other phenotypes a good strategy).
Third, large sample size and the number of cases and controls is also important for

genetic analyses (sample sizes were adequate for phenotypic analyses, with the exception of
some CSA-specific analyses). Although the overall sample size in CONVERGE was large, the
study was not designed as a case-control study for insomnia, resulting in an imbalance in cases
and controls for sleeplessness when the full sample was used (i.e., 86 % of MDD cases endorsed
sleeplessness, see Section III, Discussion in Chapters 4 and 5). Further, samples sizes were
modest for GWAS (~5,000) when split into MDD cases and MDD controls, and endorsement for
sleep within depression remained problematic. In general, as sample size increases, so does the
power to detect significant variants, particularly those of smaller effect sizes. Large GWAS of
other phenotypes, such as schizophrenia, have identified more loci as the numbers of cases and
controls have increased (e.g., for schizophrenia, there were seven GWS loci in a sample of
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~9,000 cases and 19,000 controls, the first PGC,357 increasing to 108 loci identified using
~37,000 cases and 108,000 controls in the most recent PGC analysis).242 The most recent GWAS
of sleep phenotypes, which included insomnia assessment in ~60,000 individuals, was able to
identify five top loci for the trait.216 This provides support for the notion that adding more
individuals will help gene identification efforts for insomnia as well, given that its genetic
architecture is likely polygenic.
Once large, well-phenotyped samples for insomnia exist, this will also permit further
examination of overlap with other psychiatric and non-psychiatric traits and increase our
understanding of shared molecular underpinnings, which should in turn add to knowledge of the
disorder. One strategy is that used within the UK Biobank insomnia GWAS,216 where LDSC was
used to look at genetic correlations between sleep and other phenotypes. However, replications
are needed using different approaches, particularly PRSs, since no studies to date, excluding this
dissertation, have created insomnia-related PRSs. A focus on overlap with other psychiatric
disorders in particular is warranted, given biometric studies of shared genetic contributions (e.g.,
186,187

). Although overlap was examined here (with some evidence for overlap between sleep in

MDD and sleep in general but none for sleeplessness and MDD), sample limitations discussed
earlier (with regard to phenotype and ascertainment) make it difficult to interpret results. Risk
scores created from other established phenotypes (i.e., from PGC consortia) should also be used
to examine overlap with insomnia, as a good discovery sample results in greater power to detect
shared genetic effects, and target samples do not need to be as large.245,259 The CONVERGE
MDD results could be used in this way, but an appropriate insomnia GWAS (e.g., from
combined data, if possible) would also be needed. Examination of GWS hits (or scores created

144

from GWS hits, similar to what was done in the 23andMe MDD GWAS223) for related
phenotypes may also prove useful.
Further, as our understanding of genetic contributions to insomnia increases, the
inclusion of both genetic and environmental influences in an etiologic model (e.g., as done in the
exploratory aim here) will be important, as the ultimate goal is to utilize this information to
inform prevention and intervention efforts for insomnia. A recent overview of the literature
suggests that incorporating well-characterized environmental factors and considering phenomena
such as GxE is important from a public health perspective, as it may improve understanding of
genetic effects and their underlying mechanisms.358 Although this sounds simple in theory, there
are multiple reviews that outline the difficulty in incorporating large-scale genetic information
for psychiatric traits into useful interventions.358-360 Unlike the fields of cancer and
pharmacogenomics, the genetic architecture of the traits being studied (e.g., insomnia, most
psychiatric traits) is not well understood.358 For phenotypes with identified variants of larger
effect, examining risk conferred by these variants has clinical relevance, but this is not the case
for psychiatric traits like insomnia and MDD. Additionally, determining exactly how to utilize
genetic data is difficult. Currently, PRSs have the most potential in terms of prediction (i.e., it
may be that individuals with certain combinations of risk alleles are more likely to develop the
disorder or respond to a certain treatment or medication), given what is known about the
polygenic nature of psychiatric traits.245,358 However, the aggregate nature of the method, its
assumption of additive effects, and its restriction to common variants represent important
limitations to consider in utilizing PRSs. As statistical genetic approaches continue to develop,
they will inform the field’s understanding of how to best integrate genetic and phenotypic
results, and it may be that PRSs are not ideal. Knowledge of genomics is constantly changing,
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and statistical innovations are coming online that can be used in studying insomnia. For example,
the field of epigenetics has gained popularity in recent years, given that these DNA
modifications are (at least partially) a result of environment, which may be particularly relevant
for insomnia.361 Other non-additive contributions, such as gene-gene interactions, may be
relevant once more research has been done. One area that has been promising for insomnia is
gene expression, where studies have found differences in genes expressed within insomnia
following specific insomnia treatments (e.g., 362,363)
Final conclusions. This dissertation aimed to understand the genetic and environmental
influences on sleep disturbances, both within and outside of MDD, in an understudied
population. There were several novel findings in both phenotypic (i.e., verification of trauma
structure in Han Chinese, replication of the effect of CSA on sleep in a Chinese population) and
genetic (i.e., identification of several suggestive genes based off of the liberal q-value threshold
that could be relevant for sleep within MDD, demonstration of shared genetic influences between
sleep within MDD and sleeplessness in general) analyses and a final model incorporated both
trauma and aggregate genetic risk. However, limitations of the sleep phenotypes and sample
ascertainment greatly limited the ability to answer the proposed questions, bringing up concerns
that are relevant to the insomnia literature as a whole. Many questions remain unanswered,
particularly in understanding insomnia in the context of MDD and the extent to which molecular
genetic influences overlap between insomnia and MDD. This underscores the need for additional
studies of well-defined insomnia phenotypes that examine the differential effects of traumatic
event exposure, additional environmental variables (e.g., overall physical health/exercise), and
comorbid psychiatric conditions, in addition to incorporating genomic data, in order to advance
our understanding of this prevalent health concern.
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